

*Arthritis Research & Therapy* Vol 6 Suppl 1, 2004  
 Meeting abstracts  
**24th European Workshop for Rheumatology Research**  
 Berlin, Germany  
 26–29 February 2004

Received: 16 January 2004 Published: 25 February 2004  
 These abstracts are online at <http://arthritis-research.com/supplements/6/S1>  
 © 2004 BioMed Central Ltd (Print ISSN 1478-6354; Online ISSN 1478-6362)

## Autoantibodies and autoantigens

1

### Differential antibody recognition of the 349–364aa B-cell epitope of human La/SSB protein and its phosphorylated analogue

AG Terzoglou, JG Routsias, HM Moutsopoulos, AG Tzioufas

Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece

*Arthritis Res Ther* 2004 **6**(Suppl 1):1 (DOI 10.1186/ar1043)

**Background** La/SSB is a phosphoprotein that associates with various small RNA molecules. It has been found that the primary phosphorylation site of the molecule during various physiological processes is in Ser366.

**Objectives** To determine whether the phosphorylation state of Ser366 could affect the antigenicity and the recognition of the protein by antibodies from patients with primary Sjögren's syndrome (pSS).

**Methods** Peptides 349–368aa and phos349–368aa (with the Ser366 residue phosphorylated) were synthesized. Sera with anti-La specificity from 30 patients with pSS and sera from 19 normal individuals were examined against the two synthetic peptides in ELISA. The antibody specificity against the epitopes was tested with homologous and heterologous inhibition assays.

**Results** Of pSS sera 23% reacted against the 349–368aa peptide. Sera binding to unphosphorylated peptide reacted also with phos349–368aa. Although the same sera gave a positive reaction against both peptides, the optical density values received from antibodies to phos349–368aa were higher, indicating a higher concentration or stronger affinity. When phos349–368aa was used as soluble inhibitor, in homologous inhibition the reactivity was almost completely abolished (92%). In contrast, when the unphosphorylated peptide was used as inhibitor, the reactivity of sera against phos349–368aa was only partially reduced (35%), indicating that sera from these patients possess two distinct groups of antibodies: one against the unphosphorylated and one against the phosphorylated epitope.

**Conclusion** The phosphorylation of the serine366 residue resulted in a significant increase in antibody binding on epitope 349–368aa of La/SSB. These observations might explain the increased antigenicity of La/SSB autoantigen in various pathological situations in which phosphorylation may occur.

2

### Surface-bound immune complexes containing antibodies to collagen type II induce production of TNF- $\alpha$ , IL-1 $\beta$ and IL-8 from monocytes via Fc $\gamma$ RII

M Mullazehi<sup>1</sup>, L Mathsson<sup>1</sup>, J Lampa<sup>2</sup>, J Rönnelid<sup>1,2</sup>

<sup>1</sup>Department of Clinical Immunology, Uppsala University, Uppsala, Sweden; <sup>2</sup>Department of Rheumatology, Karolinska Institute, Stockholm, Sweden

*Arthritis Res Ther* 2004 **6**(Suppl 1):2 (DOI 10.1186/ar1044)


**Background** Antibodies to collagen type II (anti-CII) are found in a subpopulation of rheumatoid arthritis (RA) patients. In joint inflammation CII

epitopes are exposed to anti-CII, with possible formation of surface-bound immune complexes (IC). We investigated whether surface-bound CII anti-CII IC can induce cytokine production from mononuclear cells and the mechanisms behind this.

**Methods** ELISA plates were coated with native human CII and blocked with human serum albumin, after which sera with varying concentrations of anti-CII were added. Serum-free mononuclear cell cultures from healthy blood donors were then added, and after 20 hours cytokine levels in supernatants were measured using ELISA. Parallel wells without cell cultures were developed as anti-CII ELISAs. Sixty-five RA patients and 10 control individuals were investigated cross-sectionally, and 17 patients with anti-CII followed longitudinally for 1–5 years. Fc $\gamma$ RII and Fc $\gamma$ RIII were blocked with specific antibodies. Cell depletion/enrichment studies were performed to define responder cells. High sensitivity CRP measurement was performed with nephelometry.

**Results** Surface-bound IC containing CII induce TNF- $\alpha$ , IL-1 $\beta$  and IL-8 from mononuclear cells via Fc $\gamma$ RII. Cytokine production correlated highly with anti-CII levels in the cross-sectional investigation. Five out of the six longitudinally followed patients with highest anti-CII levels also showed parallel changes in anti-CII OD, cytokine induction and CRP. Depletion/enrichment studies showed monocytes to be the responding cells.

**Figure 1**



**Conclusion** Surface-bound anti-CII IC can form in inflamed joints. Such IC can induce proinflammatory cytokines such as TNF- $\alpha$ , IL-1 $\beta$  and IL-8 from monocytes via Fc $\gamma$ RII. Most serially followed patients with high anti-CII levels showed parallel changes in anti-CII, induced cytokines and CRP. This may imply mechanisms of pathophysiological importance in the subpopulation of RA patients with high levels of anti-CII.

3

### Prothrombin fragment F1+2 in patients with antiphospholipid antibodies

A Ambrozic, B Bozic, S Cucnik, T Kveder, B Rozman

University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia  
*Arthritis Res Ther* 2004 **6**(Suppl 1):3 (DOI 10.1186/ar1045)

**Background** Studies of specific markers for *in vivo* activation of coagulation in patients with antiphospholipid antibodies (aPL) are very rare.

Increased levels of prothrombin fragment F1+2 (F1+2) in patients with APS were reported.

**Objective** Our aim was to ascertain the relationship of F1+2 plasma levels with positive anticardiolipin (aCL) and anti-β<sub>2</sub>-glycoprotein I (anti-β<sub>2</sub>-GPI), and to evaluate the effect of treatment on F1+2 values in patients with APS.

**Methods** A total of 205 samples from 177 patients with suspected or confirmed connective tissue disease without APS, and 15 samples from nine patients with APS receiving anticoagulant (n = 8) or antiplatelet (n = 1) therapy were tested for plasma F1+2 values (Enzygnost F1+2 micro, Behring, Germany), aCL (IgG, IgM) and anti-β<sub>2</sub>-GPI (IgG, IgM, IgA), all using in-house ELISAs.

**Results** Elevated values of F1+2 were statistically significantly associated with medium/high positive results for at least one isotype of aCL (P = 0.027), anti-β<sub>2</sub>-GPI (P = 0.019) and aCL and/or anti-β<sub>2</sub>-GPI (P = 0.014; Table 1). Furthermore, the mean level of F1+2 was significantly higher in patients with medium/high aCL or anti-β<sub>2</sub>-GPI than in those with negative/low positive aCL and anti-β<sub>2</sub>-GPI (P = 0.035). In all 15 plasma samples from APS patients, normal levels of F1+2 were measured during treatment.

**Table 1**

**Association of F1+2 with aCL and/or β<sub>2</sub>-GPI**

	Normal F1+2	Elevated F1+2	Total
aCL and β <sub>2</sub> -GPI negative/low positive	128 (81%)	31 (19%)	159
aCL and/or β <sub>2</sub> -GPI medium/high positive	29 (63%)	17 (37%)	46

**Conclusions** Our study showed a significant association of aCL and anti-β<sub>2</sub>-GPI with elevated levels of F1+2 in patients without APS not receiving anticoagulant or antiaggregation therapy. aPL are believed to be among the important causes of hypercoagulable state in those patients. Furthermore, plasma values of F1+2 could be a very useful indicator of successful treatment in APS patients.

**4**

**Concomitant appearance of anti-cardiolipin, anti-β<sub>2</sub>-glycoprotein I, anti-prothrombin and anti-annexin V antibodies**

**S Cucnik, N Gaspersic, T Kveder, B Bozic**

*University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia*  
*Arthritis Res Ther 2004 6(Suppl 1):4 (DOI 10.1186/ar1046)*

**Background** Anticardiolipin (aCL), anti-β<sub>2</sub>-glycoprotein I (anti-β<sub>2</sub>-GPI), anti-prothrombin (aPT) and anti-annexin V (aANXV) antibodies are anti-phospholipid antibodies (aPL) with different antigenic and diagnostic specificities.

**Objective** To ascertain a simultaneous appearance of antigenically undefined aCL and antigenically distinct anti-β<sub>2</sub>-GPI, aPT and aANXV.

**Methods** Sera from 92 patients (87 female, five male) were studied (63 SLE, 19 sAPS [SLE with APS] and 10 pAPS). IgG, IgM and IgA isotypes of aPL were determined using relevant ELISAs.

**Results** IgG was the most frequently detected isotype in all four analyzed aPL subtypes. According to diagnostic criteria, aCL were more frequently found in patients with pAPS and sAPS than in those with SLE. Similarly, aPT were more often elevated in patients with pAPS (7/10) and sAPS (6/19) than in SLE (16/63; P < 0.05). The prevalence of anti-β<sub>2</sub>-GPI and aANXV antibodies did not differ between patient groups. Regardless of diagnosis, aPT were always detected in combination with aCL and/or anti-β<sub>2</sub>-GPI. aPT and aANXV were regularly present in the sera positive also for aCL and/or anti-β<sub>2</sub>-GPI. aANXV was detected as a single antibody in only one patient. In the pAPS group concurrent multiple aPL varieties (three or four) were significantly more frequently present than one or two types (8/10 versus

2/10; P < 0.05). Statistically significant associations of particular aPL with clinical symptoms were as follows: elevated IgG anti-β<sub>2</sub>-GPI with arterial thromboses, thrombocytopenia and foetal loss; IgG aPT with arterial thromboses; and IgG aCL with venous thrombosis. IgA isotype did not improve the clinical significance of the four analyzed aPL.

**Conclusion** In patients with SLE and/or APS, individual aPL were found infrequently. Almost half of them had three or more aPL subsets elevated at the same time.

**5**

**Antibodies against 25-mer synthetic peptide of M3 muscarinic acetylcholine receptor**

**P Zigon, A Hocevar, S Cucnik, B Bozic, B Rozman, M Tomic, T Kveder**

*University Medical Centre, Ljubljana, Slovenia*

*Arthritis Res Ther 2004 6(Suppl 1):5 (DOI 10.1186/ar1047)*

**Background** Antibodies against the M3 muscarinic acetylcholine receptor (M3R) are believed to have inhibitory effects on parasympathetic neurotransmission in patients with Sjögren's syndrome (SJS), leading to lacrimal and salivary glandular dysfunction. The second extracellular loop domain of M3R is regarded as the ligand binding site.

**Objectives** The aim of our study was to optimize an ELISA for the determination of antibodies against M3R synthetic peptide and to analyze sera from patients with SJS, patients with systemic lupus erythematosus (SLE) and healthy blood donors.

**Methods** The M3R 25-mer peptide (KRTVPPGECFQIFLSEPTITFG-TAI) was synthesized (Diagen, Ljubljana, Slovenia) and used as the antigen for anti-M3R ELISA. Synthetic peptide (10 mg/l) was used to coat Costar medium binding plates; the detection system was alkaline phosphatase/pNPP. Sera from 94 SJS patients (primary and secondary, age 17–77 years), 92 SLE patients (age 18–68 years) and 142 blood donors as controls (age 18–65 years) were tested.

**Results:** According to the cutoff value, estimated at the 95 percentile of the controls (5/145 pos), positive values for anti-M3R were measured in 16/95 SJS and 8/92 SLE patients. Statistically significant differences in anti-M3R was found in patients with SJS compared with blood donors and compared with SLE patients (P = 0.0012 and P = 0.047, respectively). There was no significant difference between SLE patients and controls.

**Conclusions** This was the first study of anti-M3R antibodies using the 25-mer synthetic peptide as the antigen on large, well defined groups of patients and blood donors, showing highly statistically significant elevation in antibodies in primary and secondary SJS compared with controls and SLE patients.

**6**

**Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus**

**A Ambrozic, B Bozic, B Rozman, B Lestan, T Kveder**

*University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia*

*Arthritis Res Ther 2004 6(Suppl 1):6 (DOI 10.1186/ar1048)*

**Background** There is an unclear association of anti-P with neuropsychiatric (NP) SLE.

**Objective** Our objective was to determine the prevalence of anti-P in 150 SLE patients, focusing on psychosis and/or mood disorders, other diffuse NP syndromes and focal NP syndromes, and to analyze the manifestation of NP syndromes regarding SLE duration and anti-P status.

**Methods** One hundred and fifty Caucasian SLE patients (133 female, 17 male) were studied, 88 of whom had a disease duration of more than 5 years. IgG anti-P were detected by immunoblotting performed on ribosomal extract of HeLa cells and/or by line immunoassay (INNO LIA ANA). NP manifestations presenting at any time were defined according to ACR case definitions for NP SLE. Patients in whom

diffuse and focal NP manifestations occurred at the same time were classified according to the predominant manifestation.

**Results** Anti-P were positive in 17/150 (11.3%) patients. Diffuse NP manifestations were diagnosed in 9/17 (53%) anti-P positive patients (Table 1). Statistically significant associations of anti-P were found with (1) psychosis and/or mood disorders (3/11,  $P < 0.05$ ), (2) other diffuse NP syndromes (6/14,  $P < 0.0001$ ), and (3) all diffuse NP syndromes (9/25;  $P < 0.0001$ ), as compared with patients without diffuse NP manifestations (7/92). In the group of 88 patients with disease duration greater than 5 years, an even stronger statistically significant association of anti-P with diffuse NP manifestations was found.

**Table 1**

Study findings	Anti-P positive (n=17)	Anti-P negative (n=133)
1 Psychosis and/or mood disorders	3 (18%)	8 (6%)
2 Other diffuse NP syndromes	6 (35%)	8 (6%)
3 Only focal NP syndromes	1 (6%)	32 (24%)
4 Without NP manifestations	1 (41%)	85 (64%)

**Conclusion** In our study anti-P antibodies showed a strong association with diffuse but not focal NP syndromes in SLE patients, especially those with disease duration over 5 years.

## 7

### Human cartilage glycoprotein 39-directed T cell responses in health and arthritic diseases

**JHM van Bilsen<sup>1</sup>, LR Lard<sup>1</sup>, EIH van der Voort<sup>1</sup>, D Elferink<sup>2</sup>, A Bakker<sup>1</sup>, H van Dongen<sup>1</sup>, AMM Miltenburg<sup>3</sup>, T Huizinga<sup>1</sup>, R de Vries<sup>2</sup>, REM Toes<sup>1</sup>**

<sup>1</sup>Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; <sup>2</sup>Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands; <sup>3</sup>Organon BV, Oss, The Netherlands

*Arthritis Res Ther* 2004 **6**(Suppl 1):7 (DOI 10.1186/ar1049)

**Objective** Although (self)antigen-directed T cells are thought to be key mediators of many autoimmune diseases, a functionally distinct population of CD4<sup>+</sup> T cells – T regulatory cells (Treg cells) – dominantly inhibit induction and progression of autoimmunity, as demonstrated in several autoimmune models. In humans the presence of Treg cells has been shown, but their role in autoimmune disease is not known. Likewise, no (auto)antigens recognized by Treg cells have yet been identified at the molecular level. The aim of these studies was to gain a better understanding of the identity of (auto)antigens recognized by Treg cells.

**Results** When analyzing the natural T cell response against a candidate autoantigen in rheumatoid arthritis (RA), namely human cartilage gp-39 (HC gp-39), we found that healthy donors, although displaying a typical Th1 reaction against a mixture of recall antigens, reacted against HC gp-39 by producing IL-10. The IL-10 production was mediated by CD4<sup>+</sup> T cells. When HC gp-39-directed immunity of RA patients was analyzed, a marked contrast was observed as Th1-like reactivity was observed in a substantial number of patients as determined by the production of IFN- $\gamma$ . More importantly, we found that HC gp-39-directed immunity in healthy donors inhibits the T cell response against a mixture of recall antigens. Likewise, HC gp-39-specific immunity as well as HC gp-39-directed, IL-10-producing CD4<sup>+</sup> T cell lines were able to suppress MHC class I-restricted CTL reactivity.

**Conclusion** Together, these data point to a disease-associated bias in the type of T cell response against HC gp-39, and identify HC gp-39 as a naturally occurring autoantigen that is recognized by Treg cells in humans.

## 8

### Multiplex analysis of antinuclear antibodies by flow cytometry using FIDIS

**PJ Charles**

*Division of Immunology, Hammersmith Hospitals NHS Trust and Kennedy Division, Imperial College, London, UK*

*Arthritis Res Ther* 2004 **6**(Suppl 1):8 (DOI 10.1186/ar1050)

**Background** FIDIS (BMD, France) is a multiplex analytical flow cytometry system for the detection of antibodies. The aim of this study was to evaluate the FIDIS connective assay system for the detection of antinuclear antibodies (ANA), and to assess the clinical utility of these parameters in the diagnosis of connective tissue diseases. The FIDIS system simultaneously measures IgG antibodies directed at dsDNA, Ro, La, RNP, Sm, Jo-1, Scl-70, rRNP, and CENP-B.

**Methods** Sera were obtained from 100 patients with SLE and 100 patients with Sjögren's syndrome. A total of 78 sera from patients with rheumatoid arthritis (RA) and 100 from normal healthy blood donors were also tested.

**Results** Antibodies to Scl-70, Jo-1, and rRNP were not detected in any of the sera from the disease groups. In the normal control group, the only positive result obtained was in one sera that gave a weak positive result for anti-CENP-B.

**Table 1**

**Frequency of antibodies detected using FIDIS™**

	SLE	SS	RA
Anti-Ro	36	69	3.6
Anti-La	13	38	1.2
Anti-Sm	6	0	1.2
Anti-RNP/Sm	37	8	8
Anti-CENP-B	2	2	0
Anti-dsDNA	47	0	3.6

**Conclusion** The FIDIS connective assay system simultaneously measures IgG antibodies directed against nine different specificities. The data presented indicate that this system provides an alternative strategy for the measurement of specific ANA to the use of multiple single analyte assays currently employed in many immunology laboratories.

## 9

### Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice

**BF Hoyer<sup>1</sup>, K Moser<sup>1</sup>, AE Hauser<sup>1</sup>, A Peddinghaus<sup>1</sup>, C Voigt<sup>1</sup>, D Eilat<sup>2</sup>, A Radbruch<sup>1</sup>, RA Manz<sup>1</sup>, F Hiepe<sup>1</sup>**

<sup>1</sup>Department of Medicine, Rheumatology and Clinical Immunology, Charité University Hospital and German Rheumatism Research Center, Berlin, Germany; <sup>2</sup>Department of Medicine, Hadassah University Hospital, Jerusalem, Israel

*Arthritis Res Ther* 2004 **6**(Suppl 1):9 (DOI 10.1186/ar1051)

The current view holds that chronic autoimmune diseases are driven by the continuous activation of autoreactive B and T lymphocytes. However, despite the use of potent immunosuppressive drugs designed to interfere with this activation, the production of these autoantibodies often persists and contributes to progression of the immunopathology. In the present study, we analyzed the lifespan of (auto)antibody-secreting cells (ASC) in the spleens of NZB/W mice, a murine model of human systemic lupus erythematosus (SLE). The number of splenic ASC increased in mice aged 1–5 months and

became stable thereafter. Less than 60% of the splenic antibody-secreting cells were short-lived plasmablasts, whereas 40% were non-dividing, long-lived plasma cells with a half-life of more than 6 months. In NZB/W mice and D42 immunoglobulin heavy chain 'knock-in' mice, we found that a fraction of DNA-specific plasma cells were also long-lived. Although antiproliferative immunosuppressive therapy eliminates short-lived plasmablasts, long-lived plasma cells can survive and continue to produce (auto)antibodies. Thus, long-lived, autoreactive plasma cells are a relevant target for researchers aiming to develop curative therapies for autoimmune diseases.

**Acknowledgement** Both senior authors (RAM and FH) contributed equally to this work.

## 10

### Immune complexes from RA patients induce FcγRII-dependent and RF-correlated TNF-α and IL-8 production from healthy PBMC

L Mathsson<sup>1</sup>, J Lampa<sup>2</sup>, M Mullazehi<sup>1</sup>, J Rönnelid<sup>1,2</sup>

<sup>1</sup>Department of Clinical Immunology, Uppsala University, Uppsala, Sweden; <sup>2</sup>Department of Rheumatology, Karolinska Institute, Stockholm, Sweden


Arthritis Res Ther 2004 6(Suppl 1):10 (DOI 10.1186/ar1052)

**Background** Immune complexes (IC) induce production of cytokines from mononuclear cells via Fcγ-receptors. We investigated whether polyethylene glycol (PEG)-precipitated IC from serum and synovial fluid (SF) from rheumatoid arthritis (RA) patients can induce production of proinflammatory cytokines.

**Methods** In one study we compared sera and SF from 15 RA patients and 15 healthy control sera. In a second study we used paired sera and SF from 32 RA patients, 66% of which were rheumatoid factor (RF) positive. The precipitates were diluted to the original volume in PBS before 10% were added to serum-free PBMC cultures from two healthy blood donors. After 20 hours TNF-α and IL-8 levels were measured using ELISA. In separate cell culture experiments FcγRII and FcγRIII were blocked. RF in serum was determined by nephelometry and IgG levels in precipitates were measured using ELISA.

**Results** We found a correlation between TNF-α induced by PEG precipitates from RA SF and RF levels in sera. Using the normal ELISA, PEG precipitates were shown to contain some TNF-α but no IL-8, using both whole and F(ab')<sub>2</sub> anti-TNF-α antibody ELISA systems. TNF-α levels induced by SF precipitates, but not by serum precipitates, correlated with number of swollen and tender joints at the time of sampling. Blockade of FcγRII partly inhibited the TNF-α production in cultures stimulated with precipitated IC, whereas blockade of FcγRIII did not show any inhibitory effects.

**Figure 1**



scripts (IgG<sup>+</sup>, 48.7%), and (3) both IgM and IgG mRNAs (IgM<sup>+</sup>IgG<sup>+</sup>, 37.8%). The differences in mutational frequencies between them were significant (Table 1). Over 40% of analyzed cells coexpressed Rag mRNAs. Similar subsets and expression patterns were found in CD19<sup>+</sup>IgM<sup>+</sup> B cells; however, IgG<sup>+</sup> cells displayed significantly decreased mutational frequencies (3.6%;  $P < 0.0001$ ). This might reflect the presence of synovial B cell populations that differ in their maturational status or biological function.

**Table 1****Mutational frequencies of IgVH mRNAs in RA synovial CD19<sup>+</sup>CD38<sup>+</sup> and CD19<sup>+</sup>IgM<sup>+</sup> populations**

	CD19 <sup>+</sup> CD38 <sup>+</sup>			CD19 <sup>+</sup> IgM <sup>+</sup>		
	IgM <sup>+</sup>	IgM <sup>+</sup> IgG <sup>+</sup>	IgG <sup>+</sup>	IgM <sup>+</sup>	IgM <sup>+</sup> IgG <sup>+</sup>	IgG <sup>+</sup>
Total of nt	1761	6617	4683	2128	2570	2079
Mutated nt	94	465	462	75	110	75
MF (%)	5.3	7.0	9.9	3.5	4.3	3.6

### 13

#### Immunomics in inflammatory rheumatic diseases

**Z Konthur<sup>1</sup>, K Adolph<sup>2</sup>, G Burguera<sup>1</sup>, A Sternjak<sup>1,2</sup>, A Förster<sup>2</sup>, H Lehrach<sup>1</sup>, GR Burmester<sup>2</sup>, K Skriner<sup>1,2</sup>**

<sup>1</sup>Max-Planck-Institut für Molekulare Genetik, Berlin, Germany;

<sup>2</sup>Rheumatology & Clinical Immunology, Charité, Berlin, Germany

*Arthritis Res Ther* 2004 **6**(Suppl 1):13 (DOI 10.1186/ar1055)

Autoimmune diseases such as rheumatoid arthritis (RA) are characterized by autoantibodies to different autoantigenic proteins. Using proteomic 2D immunoblots, we identified a new 40 kDa autoantigen – hnRNP A3 – from HeLa nuclear extracts, which is frequently (30%) detected by RA. Moreover, we used a set of protein arrays of about 50 000 proteins derived from a human foetal brain cDNA expression library for screening with patient sera. Additionally, we utilized a human foetal brain cDNA library in a robot-based T7 phage display screening system with RA patient sera. To determine the diversity of the enriched library, we amplified the cDNA inserts and hybridized them onto the custom-made human ENSEMBL cDNA array. By these methods, over 80 clones were identified to bind patient immunoglobulins. Moreover, nine clones show only IgA-specific reactivity. We have now evaluated two different clones thoroughly: the carboxyl-terminal half of the nucleolar phosphoprotein p130 (NOPP 130) and a clone representing a 41-amino-acid mimetic peptide showing homology to calreticulin, a previously reported autoantigen. The remaining proteins are still undergoing thorough investigation. Applying state-of-the-art proteomic techniques, such as protein array and phage display, we have succeeded in identifying more than 80 potentially autoantigenic marker molecules, of which we have characterized a subset for RA specificity by screening with large numbers of patient and control sera. However, none of the molecules characterized thus far is exclusively discriminatory for RA and they all exhibit overlap with other autoimmune diseases.

#### Autoantibodies: anticitrullin antibodies

### 14

#### VIDAS-EDRA fully automated testing of autoantibodies to citrullinated proteins for the diagnosis of rheumatoid arthritis

**L Nogueira<sup>1</sup>, A Foussadier<sup>2</sup>, C Vincent<sup>1</sup>, C Clavel<sup>1</sup>, N Moinard<sup>1</sup>, M Jolivet<sup>2</sup>, G Serre<sup>1</sup>**

<sup>1</sup>UMR 5165 CNRS-Toulouse III, Toulouse, France; <sup>2</sup>Department of Immunoassays, bioMérieux, Marcy l'Etoile, France

*Arthritis Res Ther* 2004 **6**(Suppl 1):14 (DOI 10.1186/ar1056)

Antiperinuclear factor and antikeratin antibodies (AKA) were shown to belong to the same family of rheumatoid arthritis (RA)-specific autoantibodies directed at 'citrullinated' peptidic epitopes borne by (pro)filaggrins. We showed that their major target in the synovial tissue of RA patients is deiminated (citrullinated) fibrin. Although (pro)filaggrins are probably only cross-reactive proteins, their *in vitro* detection allowed the development of several highly efficient tests for the diagnosis of RA. Among those, the CCP ELISAs (CCP1 and CCP2), based on a cyclic citrullinated peptide derived from human filaggrin, and the ArFA-ELISA that we developed using a citrullinated recombinant rat filaggrin appear to be the most promising. The rapidly growing interest of rheumatologists in autoantibodies to citrullinated proteins rendered the development of a convenient, fully automated test the next challenge. Based on the ArFA-ELISA, we developed an automated test on the VIDAS machine (bioMérieux), called VIDAS-EDRA (early diagnosis rheumatoid arthritis). Thresholds were defined on a large series of 617 patients with well defined, established rheumatic diseases, including 181 patients with RA. Antibodies to CCP1 and CCP2 (Immunoscan, Eurodiagnostica) were sought following the manufacturer procedures. Rheumatoid factor (RF) and AKA were also analyzed in the series. The diagnostic performances of the tests were compared. In established diseases the diagnostic sensitivity of the VIDAS-EDRA was found to be identical to that of CCP2, and was significantly higher than tests for AKA, CCP1 and RF.

Autoantibodies to citrullinated proteins can be efficiently detected with the highly specific and sensitive automated test VIDAS-EDRA.

**Table 1****Diagnostic sensitivity (%) computed at thresholds allowing 95.2% and 98.6% diagnostic specificity to be achieved**

	95.2% specificity	98.6% specificity
AKA	51.4	42.5
RF	56.4	16
CCP1	65.7	56.9
CCP2	74	63.5
VIDAS-EDRA	71.8	63.5

### 15

#### Features of the citrullinating peptidylarginine deiminase enzymes

**ER Vossenaar, AJW Zendman, R Raijmakers, TJ Welting, A van der Heijden, WAM Horstman, K Cheung, JH Vogelzangs, S Nijenhuis, WJ van Venrooij, GJM Pruijn**

Department of Biochemistry, University of Nijmegen, Nijmegen, The Netherlands

*Arthritis Res Ther* 2004 **6**(Suppl 1):15 (DOI 10.1186/ar1057)

**Background** Autoantibodies to citrullinated proteins (anti-CCP) can be detected in up to 80% of rheumatoid arthritis (RA) patients with very

high specificity (98%). Citrulline residues, the target of the anti-CCP antibodies, are formed by post-translational modification of arginine residues, catalyzed by peptidylarginine deiminase enzymes (PAD; EC 3.5.3.15).

**Objective** Our aim was to investigate the full complexity of the family of PAD enzymes and to locate putatively important conserved residues or domains.

**Methods** We performed a thorough query for PAD sequences using EST and genomic databases. With these data we constructed a complete PAD alignment (ClustalW) and a phylogenetic tree (Treeview), and mapped the different genes.

**Results** Next to the previously described PADs, we found several (partial) novel sequences, both mammalian and nonmammalian. From the alignment (available online at <http://www.interscience.wiley.com/jpages/0265-9247/suppmat/2003/25/v25.1106.html>), it is clear that the carboxyl-terminal half is more conserved than the amino-terminal part. Some of the fully conserved residues (His475 and Cys655) have been suggested to be important for catalytic activity of murine PAD2. These residues would fit in the 'catalytic pocket', as has been described for other arginine converting enzymes (arginine deiminases EC 3.5.3.6. and amidinotransferases EC 2.1.4.1.). The negative charge (on average -14) and low pI (about 5.8) of the enzyme are important for its interactions with arginine substrates and with Ca<sup>2+</sup> ions, which are essential for PAD activity. A phylogenetic tree confirmed the human PAD5 to be the orthologue of the murine PAD4. By comparing mRNA and genomic sequences, the individual exons of all murine and human PADs could be mapped in a tight conserved gene cluster (human chromosome 1p36.1; mouse #4E1; rat #5q36). Structural characterization of PADs will yield valuable clues regarding the aetiology of RA and for the development of PAD inhibiting drugs.

16

**False positivity of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus**

**IEA Hoffman<sup>1</sup>, I Peene<sup>1</sup>, A Union<sup>2</sup>, L Meheus<sup>2</sup>, T Huizinga<sup>3</sup>, L Cebecauer<sup>4</sup>, D Isenberg<sup>5</sup>, K De Bosschere<sup>2</sup>, F Hulstaert<sup>2</sup>, EM Veys<sup>1</sup>, F De Keyser<sup>1</sup>**

<sup>1</sup>Rheumatology, Ghent University Hospital, Gent, Belgium; <sup>2</sup>Innogenetics, Gent, Belgium; <sup>3</sup>Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; <sup>4</sup>Research Institute for Rheumatic Diseases, Piestany, Slovakia; <sup>5</sup>Rheumatology, University College London, UK

Arthritis Res Ther 2004 6(Suppl 1):16 (DOI 10.1186/ar1058)

**Background** Rheumatoid factor (RF) is found in patients with systemic lupus erythematosus (SLE). Anti-citrullinated peptide antibodies (ACPA) are more specific for rheumatoid arthritis than RF.

**Objective** Our aim was to determine the prevalence of RF and ACPA in SLE patients.

**Methods** In this study, samples from 201 consecutive patients diagnosed with SLE and fulfilling ACR criteria were used. Fine ANA reactivities were tested by INNO-LIA<sup>TM</sup>ANA (Innogenetics, Gent, Belgium) and by IIF on *C. luciliae*. RF was detected by latex fixation. ACPA were detected by anti-CCP2 ELISA (Euro-Diagnostica, Arnhem, The Netherlands) and by a research INNO-LIA<sup>TM</sup>RA (Innogenetics, Gent, Belgium) for the detection of anti-pepA and anti-pepB antibodies. The prevalences of ACPA were compared by the McNemar test.

**Results** RF at a titre ≥ 160 was found in 26 patients (13.0%). ACPA were found in 16 samples (Table 1). The prevalence of anti-CCP2 antibodies was significantly higher than that of anti-pepA antibodies (P= 0.001) and anti-pepB antibodies (P= 0.022).

**Conclusion** RF is found in 13.0% of SLE patients. Anti-CCP2 antibodies are false-positive in 7.0% (n= 14) of SLE patients, which occurs significantly more often than anti-pepA (1.5%, n= 3) and anti-pepB (2.5%, n= 5) antibodies.

**Table 1**

	RF (titre)	Anti-CCP2	Anti-pepA	Anti-pepB	ANA fine reactivities
		(U/ml; cut-off 25 U/ml)			
1	1280	186	+	+	Ro60, SSB
2	0	28	-	-	SmB, SmD, histones, dsDNA
3	640	9	-	+	RNP-C
4	0	168	-	-	dsDNA
5	0	53	-	-	SmB, dsDNA
6	80	2	-	+	Histones, dsDNA
7	0	76	-	-	SmB, RNP-A, RNP-C, RiboP, histones
8	40	64	-	-	SmD, SmB, RNP-70k, RNP-C, RiboP
9	0	58	-	-	-
10	320	110	-	-	SmB, RNP-70k, RNP-A, RNP-C, Histones, dsDNA
11	0	28	-	-	-
12	0	36	-	-	-
13	320	78	+	+	SmB, RNP-70k, RNP-A, RNP-C
14	80	56	-	-	RNP-A, RiboP, Histones
15	640	52	-	-	RNP-70k, RNP-A
16	320	1600	+	+	Ro60

17

**Diagnostic performance and predictive value of serum markers for the diagnosis of rheumatoid arthritis**

**IEA Hoffman<sup>1</sup>, I Peene<sup>1</sup>, A Union<sup>2</sup>, L Meheus<sup>2</sup>, L De Clercq<sup>3</sup>, L Schatteman<sup>3</sup>, S Poriau<sup>4</sup>, H Mielants<sup>1,3</sup>, EM Veys<sup>1</sup>, F De Keyser<sup>1,4</sup>**


<sup>1</sup>Rheumatology, Ghent University Hospital, Gent, Belgium; <sup>2</sup>Innogenetics, Gent, Belgium; <sup>3</sup>Rheumatology, St-Augustinus Hospital, Wilrijk, Belgium; <sup>4</sup>Locomotion Center, Elisabeth Hospital, Sijsele, Belgium

Arthritis Res Ther 2004 6(Suppl 1):17 (DOI 10.1186/ar1059)

**Background** Rheumatoid factor (RF) is the classical serum marker for rheumatoid arthritis (RA). Anti-citrullinated peptide antibodies (ACPA) have a higher sensitivity and specificity (spec) for RA.

**Objective** Our aim was to evaluate the diagnostic and predictive value for RA of RF and antibodies to pepA and pepB (two synthetic substrates for ACPA detection) in a setting relevant to routine clinical practice.

**Methods** In this prospective multicentre study, samples were collected at academic and nonacademic centres from 1003 consecutive patients presenting for diagnostic work-up when the clinician included RA in the differential diagnosis. RF was detected by latex fixation. A research INNO-LIA<sup>TM</sup>RA (Innogenetics, Belgium) was used to detect anti-pepA and anti-pepB antibodies. Diagnoses were made by the clinician using ACR criteria after 1 year follow-up. ROC curve analysis was used to evaluate the diagnostic performance of the tests.

**Figure 1**

ROC curves.

**Results** The following diagnoses were made: definite RA ( $n = 144$ ), non-RA ( $n = 629$ ), undifferentiated ( $n = 156$ ), and lost to follow up ( $n = 74$ ). The first two groups were used to determine sensitivity, specificity, and positive predictive value (PPV). ROC curve analysis (Fig. 1) showed a higher area under the curve for RF than for anti-pepA and anti-pepB antibodies (0.839 versus 0.784 and 0.788, respectively), but in the high specificity region anti-pepA and anti-pepB antibodies performed better than RF (Table 1).

**Table 1****Diagnostic performance of serum markers using different cut offs**

Antibody	Cutoff	Sensitivity (%)	Specificity (%)	PPV (%)
PepA	Low	63.6	90.6	60.7
PepB		64.3	90.0	59.0
RF		69.2	90.1	61.5
PepA	Intermediate	62.9	95.1	74.4
PepB		61.5	95.1	73.3
RF		55.2	94.6	69.9
PepA	High	58.7	98.1	87.5
PepB		48.3	98.1	85.2
RF		42.0	97.8	81.1
PepA	Very high	41.3	99.0	90.8
PepB		37.1	99.0	89.8
RF		21.0	99.0	83.3

**Conclusion** When high specificity is required, anti-pepA and anti-pepB antibodies have a markedly higher sensitivity than RF. The highest PPV are found when ACPA are very high.

**18****Citrullinated proteins in arthritis: presence in joints and effects on immunogenicity**

**K Lundberg<sup>1</sup>, S Nijenhuis<sup>2</sup>, E Vossenaar<sup>2</sup>, L Klareskog<sup>1</sup>, WJ van Venrooij<sup>2</sup>, H Erlandsson Harris<sup>1</sup>**

<sup>1</sup>Department of Medicine, Karolinska Institutet, Stockholm, Sweden;

<sup>2</sup>Department of Biochemistry, University of Nijmegen, Nijmegen, The Netherlands

*Arthritis Res Ther* 2004 **6**(Suppl 1):18 (DOI 10.1186/ar1060)

**Background** Autoantibodies (Ab) directed against citrulline (Cit)-containing proteins have a specificity of nearly 100% in rheumatoid arthritis

(RA) patients. The presence of these markers early in disease, even before clinical onset, and the observation that these autoantibodies are produced locally in the pannus suggest an involvement in the pathogenesis. The targeted epitopes are generated by deimination, a post-translational modification catalyzed by the enzyme peptidyl arginine deiminase.

**Objective** Our aim was to analyze the presence of Cit-proteins and fibrinogen in the joints at different time points in collagen-induced arthritis (CIA) in rats and to investigate how citrullination of an autoantigen affects its immunogenicity.

**Methods** Synovial tissue sections from DA rats were stained for expression of citrulline and fibrinogen. Lew1AV1 rats were immunized with Cit-rat serum albumin (RSA) or unmodified RSA, and antibody and T-cell responses were evaluated.

**Results** Citrulline was detected in arthritic joints from disease onset and increased expression was noted as disease progressed into a more chronic state. Naïve rats or time points before arthritis onset were negative for citrulline-specific staining. Infiltrating cells, as well as the cartilage surface, stained positive for citrulline, although the major source of citrullinated proteins appeared to be fibrin depositions. A specific Cit-RSA T-cell response was observed in animals challenged by Cit-RSA. In contrast, no response was recorded when RSA was used as a stimulus. The IgG response revealed not only a response toward the modified protein but also cross-reactivity to the unmodified form of RSA.

**Conclusion** In CIA, joint inflammation precedes the presence of Cit-proteins and citrullination increases immunogenicity of an autoantigen. Our results suggest that citrullination is induced by inflammation and might be contributing to the development of autoreactive T and B cells.

**19****Antifilaggrin antibodies in serum and synovial fluid samples of patients with rheumatoid arthritis show similar reactivity pattern towards citrulline containing peptides**

**M Brózik<sup>1</sup>, A Magyar<sup>2</sup>, R Tobi<sup>2</sup>, G Bálint<sup>1</sup>, ZS Balogh<sup>1</sup>, A Polgár<sup>1</sup>, F Hudecz<sup>2</sup>, K Merétey<sup>1</sup>**

<sup>1</sup>National Institute of Rheumatology, Budapest, Hungary; <sup>2</sup>Peptide Chemistry Research Group, Eötvös Lóránd University, Academy of Science, Budapest, Hungary

*Arthritis Res Ther* 2004 **6**(Suppl 1):19 (DOI 10.1186/ar1061)

**Background** Antifilaggrin antibodies are highly specific serological markers of rheumatoid arthritis (RA). They have been shown to comprise a heterogeneous population of antibodies directed at citrullinated peptides. Recent studies suggest that the site of the initial antigenic trigger where these autoantibodies are produced can be localized to the synovial tissue.

**Objective** The aim of this study was to compare the recognition patterns of antibodies in paired serum and synovial fluid samples of RA patients toward citrullinated peptide sequences to investigate whether or not they comprise the same antibody population.

**Methods** Arginine-rich peptide sequence corresponding to human proflaggrin (amino acid residues 306–324) and sequences with citrulline substitution at different positions were synthesized by multipin peptide synthesis on solid support. Completely citrullinated variant of the 19-mer peptide and shortened sequences were also produced. The reactivity of these peptides with paired sera and synovial fluid samples of RA patients were determined ( $n = 25$ ). Results were evaluated statistically using the paired  $t$  test.

**Results and Conclusion** The results (Table 1) show that the 12–19 amino acid long epitopes are recognized by homogeneous antibody population present in serum and synovial fluid, whereas the reactivities toward short citrullinated sequences differs significantly.

**Acknowledgement** This work was supported by the Hungarian grant: OTKA T037876.

**Table 1**

<b>Comparison of the reactivities of antibodies in paired serum and synovial fluid samples</b>			
Sequence	P value	Sequence	P value
SHQESTXGXSGXSGXSGS	0.754	TXGRSRGRSGRSG	0.598
SHQESTXGXSGXSGRSGS	0.382	TXGRSRGRSGRS	0.129
SHQESTXGXSGRSGRSGS	0.09	TXGRSRGRSGR	0.04*
SHQESTRGXSGXSGXSGS	0.081	TXGRSRGRSG	0.122
SHQESTRGRSGXSGXSGS	0.143	TXGRSRGRS	0.128
SHQESTRGRSRGXSGXSGS	0.192	TXGRSRGR	0.039*
		TXGRSRG	0.019*
		TXGRSR	0.003*
		TXGRS	0.003*
		TXGR	0.011*

\*Significant difference. X, citrulline.

**20**

**The presence of deiminated fibrin in the synovial membrane is not specific for rheumatoid arthritis**

**S Chapuy-Regaud<sup>1</sup>, M Sebbag<sup>1</sup>, D Baeten<sup>2</sup>, C Clavel<sup>1</sup>, F De Keyser<sup>2</sup>, G Serre<sup>1</sup>**

<sup>1</sup>UMR 5165 CNRS-Toulouse III, France; <sup>2</sup>Department of Rheumatology, University Hospital, Ghent, Belgium

*Arthritis Res Ther* 2004 **6**(Suppl 1):20 (DOI 10.1186/ar1062)

**Background** Autoantibodies to deiminated (citrullinated) forms of the  $\alpha$  and  $\beta$  chains of fibrin (AhFibA), also known as antifilaggrin autoantibodies (AFA), are the most specific serological markers of rheumatoid arthritis (RA). Deimination is critical in generating the AhFibA epitopes and, in the synovial tissue (ST), deiminated fibrin is their major antigenic target. Existence of fibrin deimination specifically in RA patients could explain why the AhFibA response is RA specific.

**Methods and Results** To explore such an association, the presence of deiminated fibrin in the ST was assessed in a series of 32 patients, 13 with RA and 19 with non-RA rheumatological disorders (controls). ST biopsies were collected in macroscopically inflamed areas identified under needle arthroscopy of the knee. Histopathological examination confirmed the existence of synovitis in all of the samples. The presence of deiminated fibrin was first assessed by immunoblotting of ST extracts using antibodies to citrullyl residues and to the  $\alpha$  and  $\beta$  chains of fibrin, and AhFibA purified from a pool of RA sera. Deiminated fibrin was evidenced in all of the ST samples. Moreover, variations in the ratio of deiminated to total fibrin were not related to diagnosis. Immunohistochemical analysis, performed on adjacent synovial biopsy sections of 19 of the 32 patients, using antibodies to the  $\beta$  chain of fibrin and to citrullyl residues, allowed us to confirm the results obtained by immunoblotting, because deiminated fibrin was detected in six RA patients and six controls.

**Conclusion** Our results show the presence of deiminated fibrin in the ST is not specific for RA and suggest that it is induced by ST inflammation. Moreover, they show the production of AhFibA is not a direct consequence of the presence of deiminated fibrin in the ST. Nonetheless, AhFibA are tightly associated with RA. Because they are also present very early in the disease course, linked to disease severity and produced in the ST, they probably play an important role in RA pathophysiology.

**21**

**The rheumatoid arthritis specific Sa antigen is citrullinated vimentin**

**ER Vossenaar<sup>1</sup>, N Depres<sup>2</sup>, M Lora<sup>2</sup>, A van der Heijden<sup>1</sup>, E Lapointe<sup>2</sup>, AJW Zendman<sup>1</sup>, T Senshu<sup>3</sup>, WJ van Venrooij<sup>1</sup>, HA Ménard<sup>2</sup>**

<sup>1</sup>Department of Biochemistry, University of Nijmegen, Nijmegen, The Netherlands; <sup>2</sup>Division of Rheumatology, McGill University Health Centre, Montreal, Canada; <sup>3</sup>Graduate School of Integrated Sciences, Yokohama City University, Yokohama, Japan

*Arthritis Res Ther* 2004 **6**(Suppl 1):21 (DOI 10.1186/ar1063)

**Background** Antibodies directed at the Sa antigen are highly specific for rheumatoid arthritis (RA) and can be detected in approximately 40% of RA sera. The antigen, a doublet of protein bands of about 50 kDa, is present in placenta and in RA synovial tissue. Although it has been suggested that the Sa antigen is identical to citrullinated vimentin, experimental proof for this has never been published.

**Objective** In this study we investigated the precise nature of the Sa antigen.

**Methods** Freshly purified Sa antigen from placenta was analyzed by mass spectrometry. Immunoprecipitation and Western blot studies were performed with anti-Sa patient sera, anti-vimentin antibodies and antibodies specifically recognizing citrullinated proteins.

**Results and Conclusion** Peptide sequences that were obtained from highly purified Sa antigen were unique to vimentin. Recombinant vimentin, however, was not recognized by anti-Sa reference sera. *In vivo*, vimentin is subjected to various post-translational modifications, including citrullination. Because antibodies to citrullinated proteins are known to be highly specific for RA, it was investigated whether Sa was citrullinated. Our data show that Sa indeed is citrullinated vimentin. Anti-Sa antibodies thus belong to the growing family of anti-citrullinated protein antibodies, which also includes the well described anti-flaggrin and anti-CCP antibodies. The presence of the Sa antigen in RA synovial tissue, the observations that vimentin is citrullinated in dying human macrophages and that citrullinated vimentin peptides are preferentially presented by HLA-DR4/shared epitope, make Sa a unique autoantigen in RA. Studies on Sa may provide new insights on the potential role of citrullinated synovial antigens and the antibodies directed at them in the pathophysiology of RA.

**Cytokines and chemokines**

**22**

**Elevated expression of IL-18 in Sjögren's syndrome: distinct expression patterns of the active and proactive forms**

**S Boiu-Zahiu, EK Kapsogeorgou, ID Dimitriou, MP Spahidou, HM Moutsopoulos, MN Manoussakis**

Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece

*Arthritis Res Ther* 2004 **6**(Suppl 1):22 (DOI 10.1186/ar1064)

**Background** IL-18 is an important immunoregulatory and proinflammatory cytokine that is produced by various cell types, including antigen-presenting cells and epithelial cells. IL-18 is synthesized as a biologically inactive precursor molecule (proactive IL-18) that converts into an active, mature molecule after enzymatic cleavage. Upregulated levels of IL-18 have been identified in several autoimmune diseases, but its role in Sjögren's syndrome (SS) is uncertain.

**Objective** The aim of the study was to investigate the role of IL-18 in SS.

**Methods** RT-PCR analysis, immunohistochemistry and immunoblotting (with distinct anti-IL-18 antibodies against the proactive and active forms) were applied for the detection of IL-18 in cultured SG epithelial cell (SGEC) lines established from patients with SS ( $n=5$ ) and from non-SS disease control patients ( $n=5$ ), as well as in minor SG biopsy specimens obtained from patients with primary SS ( $n=12$ ), secondary SS ( $n=5$ ) and non-SS disease controls ( $n=7$ ) were used.



**Results** The expression of IL-18 mRNA was detected in all SGEN lines tested. In addition, cultured SGEN express constitutively the proactive, but not the mature, form of IL-18 protein, as demonstrated by immunoblotting. In minor SG biopsies, strong expression of the IL-18 proactive protein was detected in the ductal epithelial and CD68<sup>+</sup> infiltrating macrophages of the SS patients, but not in the controls. The expression of the active form of IL-18 was detected only in SS patients and mainly in those with extended inflammatory lesions. In these samples, active IL-18-positive cells were observed exclusively among the CD68<sup>+</sup> macrophages of the mononuclear cell infiltrates.

**Conclusion** Our data possibly indicate the role of IL-18 in the expansion of lymphoepithelial lesions of SS patients. SGEN were found to express only the proactive form of IL-18, the biological significance of which remains to be determined.

## 23

### Cytokine imbalance in NZB/W mice is associated with autoantibody levels and nephritis

P Enghard<sup>1</sup>, D Langnickel<sup>1</sup>, F Hiepe<sup>1,2</sup>, GR Burmester<sup>1</sup>, G Riemekasten<sup>1</sup>

<sup>1</sup>Department of Rheumatology, Charité University Hospital, Berlin, Germany; <sup>2</sup>German Rheumatology Research Center, Berlin, Germany  
*Arthritis Res Ther* 2004 **6**(Suppl 1):23 (DOI 10.1186/ar1065)

**Background** In the NZB/W murine model of lupus, various studies have analyzed cytokine production during disease development with contradictory results.

**Objective** The aim of this study was to analyze cytokine pattern of splenic T cells from NZB/W mice. We assessed the possibility that a shift in cytokine production is associated with age, disease activity, or manifestation of nephritis.

**Methods** NZB/W mice of different ages spanning 5–36 weeks were analyzed, and healthy (BALB/c x NZW) F1 mice were used as controls. Proteinuria was measured using albutix. Plasma creatinine and autoantibody levels were detected by commercial test kit and by ELISA, respectively. Splenic CD4<sup>+</sup> T cells stimulated with PMA/Ionomycin were analyzed for intracellular cytokine staining by FACS analysis.

**Results** The increased frequency of IFN- $\gamma$  producing CD4<sup>+</sup> T cells correlated with age, anti-dsDNA IgG antibody levels and proteinuria. The increasing number of IL-10 producers was only associated with anti-dsDNA antibody levels and proteinuria. A small gain in IL-4<sup>+</sup> T cells correlated with plasma creatinine. Neither the number of IL-10 nor that of IL-4 exhibiting T cells correlated with age. There was no significant change observed in the production of TNF- $\alpha$ . Calculating the IFN- $\gamma$ /IL-4 ratio, an increasing shift toward a Th1 response was observed. The shift strongly correlated with anti-dsDNA antibody titres and proteinuria. In contrast, no cytokine shift could be observed in control mice with increasing age.

## 24

### Anti-tumour necrosis factor therapy modulates the OPG/OPGL system in rheumatoid arthritis synovium

AI Catrina<sup>1</sup>, S Ernestam<sup>2</sup>, E af Klint<sup>1</sup>, L Klareskog<sup>1</sup>, AK Ulfgren<sup>1</sup>

<sup>1</sup>Rheumatology Department, Karolinska Institutet/Hospital; <sup>2</sup>Rheumatology Department, Huddinge Hospital, Stockholm, Sweden  
*Arthritis Res Ther* 2004 **6**(Suppl 1):24 (DOI 10.1186/ar1066)

**Background** Osteoprotegerin (OPG) is a soluble decoy receptor that acts as a receptor antagonist, blocking OPG ligand (OPGL) induced osteoclastogenesis. *In vitro*, proinflammatory cytokines such as tumour necrosis factor (TNF) upregulate endothelial OPG expression. However, low levels of endothelial OPG expression are seen in synovial biopsies from patients with active rheumatoid arthritis (RA) associated with high levels of TNF. In order to elucidate the *in vivo* interaction between TNF and the OPG/OPGL system in RA, we investigated the effect of anti-TNF therapy on synovial expression of OPG and OPGL.

**Methods** OPG, OPGL and CD31 were evaluated by immunohistochemistry in serial synovial biopsies obtained from 20 RA patients before and after 8 weeks of treatment with Etanercept (Amgen and Wyeth Pharmaceuticals, USA) or Infliximab (Schering-Plough, Stockholm, Sweden). Biopsies were evaluated by double-blind semiquantitative analysis and image analysis. Statistical analysis was performed using the Wilcoxon's signed-rank test followed by Bonferroni corrections for multiple comparisons.

**Results** OPG was expressed in all studied synovial biopsies, mainly in the CD31-positive endothelial cells. OPGL expression was detected in synovial areas rich in T cells, with low expression in endothelial cells and macrophages. Treatment with Infliximab significantly increased synovial OPG expression whereas the increase in synovial OPG expression observed after Etanercept treatment did not reach statistical significance. Neither infliximab nor etanercept influenced OPGL expression following 8 weeks of treatment. The ratio between synovial OPGL and OPG expression decreased following treatment with infliximab ( $P < 0.05$ , after Bonferroni comparisons) and etanercept (NS after Bonferroni correction).

**Conclusion** Our findings suggest a particular OPG-TNF interaction *in vivo* as well as a potential difference in action between the two anti-TNF agents tested.

## 25

### IL-20 is expressed in inflamed synovium of patients with psoriatic arthritis and rheumatoid arthritis

TJM Smeets<sup>1</sup>, Y Chandrasekher<sup>2</sup>, JJ Haringman<sup>1</sup>, PP Tak<sup>1</sup>

<sup>1</sup>Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, The Netherlands; <sup>2</sup>Department of In Vitro Biology, ZymoGenetics, Inc., Seattle, WA, USA  
*Arthritis Res Ther* 2004 **6**(Suppl 1):25 (DOI 10.1186/ar1067)

**Background and Objective** IL-20 is a novel cytokine that is involved in skin inflammation, in part by serving as an autocrine factor for keratinocytes. The aim of this study was to investigate the expression of IL-20 in the inflamed synovium of patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA) to provide more insight into the possible role of this cytokine in inflammatory joint disease. To further assess the regulation of IL-20 expression, *in vitro* experiments were conducted to determine the effects of IL-1 $\beta$  and TNF- $\alpha$  on the expression of IL-20 by RA fibroblast-like synoviocytes (FLS).

**Methods** Synovial biopsy specimens of patients with PsA ( $n = 11$ ) and RA ( $n = 10$ ) were obtained from actively inflamed joints by needle arthroscopy. Immunohistologic analysis was performed using a monoclonal antibody (mAb) specific for IL-20. In addition, we measured IL-20 expression in RA FLS in the presence or absence of 250 pg/ml IL-1 $\beta$  and 100 ng/ml TNF- $\alpha$  by immunocytochemistry.

**Results** IL-20 was expressed in the intimal lining layer, in the synovial sublining and on endothelium in both PsA and RA patients. Digital microscopic analysis of synovial tissue revealed clear IL-20 expression with comparable overall scores in both patient groups (RA  $149775 \pm 56466$ , PsA  $123862 \pm 50630$  [mean integrated optical density  $\pm$  SEM]; NS). The *in vitro* experiments revealed marked induction of IL-20 after stimulation with IL-1 $\beta$  and TNF- $\alpha$  in RA FLS.

**Conclusion** IL-20 expression is induced in FLS by proinflammatory cytokines, including TNF- $\alpha$  and IL-1 $\beta$ . In addition, IL-20 is markedly expressed in psoriatic skin lesions, but also in the synovium of patients with PsA and RA, suggesting a role in various forms of inflammatory joint disease.

## 26

### Cross-talk between TRAIL and TGF- $\beta$ in regulation of collagen production in scleroderma lung disease

VV Yurovsky

University of Maryland School of Medicine, Baltimore, MD, USA  
*Arthritis Res Ther* 2004 **6**(Suppl 1):26 (DOI 10.1186/ar1068)

**Background** Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a TNF family member, which has been closely associated with

regulation of the immune response and pathogenesis of autoimmune diseases. The expression of TRAIL was found in CD8 T cells that had undergone oligoclonal expansion in the lungs of patients with systemic sclerosis (scleroderma) and were able to stimulate collagen production in lung fibroblasts *in vitro*. Among the family members, TRAIL displays highest homology to Fas ligand, the receptor of which may mediate not only cell apoptosis but also the proliferation of normal human fibroblasts. **Objective** Considering structural and functional similarities between TRAIL and Fas ligand, we examined the effects of soluble multimerized TRAIL on normal human lung fibroblasts.

**Methods and Results** TRAIL at doses in excess of 100 ng/ml induced apoptotic death of fibroblasts. However, at lower concentrations it was found to stimulate collagen production. Collagen alpha2(I) mRNA expression was assessed by real-time RT-PCR; and total soluble collagen was measured in culture supernatants using the Sircol assay. Both alpha2(I) collagen mRNA and total soluble collagen were increased upon TRAIL stimulation, with peak response (more than fourfold increase in mRNA) at 1 ng/ml TRAIL. DNA microarray analysis revealed TRAIL-induced increase in the expression of a number of genes involved in tissue remodeling, including those related to the transforming growth factor (TGF)- $\beta$  pathway. The microarray results were confirmed by Northern blot analysis of TGF- $\beta_1$  mRNA expression and by measurements of total active TGF- $\beta_1$  in culture supernatants. In addition, antibody-mediated blocking of TGF- $\beta$  was shown to abrogate TRAIL-induced collagen synthesis.

**Conclusion** These data suggest that TRAIL can enhance extracellular matrix production in fibroblasts by triggering TGF- $\beta$  expression, which acts in an autocrine manner. If this process continues uncontrolled, it may contribute to the development of fibrosis, particularly in the lungs of patients with scleroderma.

## 27

### Effects of reduced ATP-formation on cytokine production and proliferation in human peripheral CD4<sup>+</sup> T cells

R Tripmacher<sup>1</sup>, T Gaber<sup>1</sup>, GR Burmester<sup>1</sup>, A Radbruch<sup>2</sup>, A Scheffold<sup>2</sup>

<sup>1</sup>Buttgereit F Med. Klinik m.S. Rheumatologie, Charité; <sup>2</sup>DRFZ, Berlin, Germany

Arthritis Res Ther 2004 6(Suppl 1):27 (DOI 10.1186/ar1069)

**Background and Objective** The function of immune cells is dependent upon a constant and adequate supply of energy (ATP), which is mainly formed by oxidative phosphorylation (OXPHOS). In arthritis, microenvironmental conditions are characterized by low levels of oxygen and glucose. Thus, effector cells of the innate immune system are recruited to sites where they face an acute need to respond to these demanding conditions. We investigated how immune cells maintain viability and function under these circumstances, and which immune processes are limited to what extent by energy deficiency.

**Methods** From peripheral mononuclear cells obtained from healthy donors, we isolated CD4<sup>+</sup> T-cells (MACS, >98% purity) and incubated them (37°C, 5% CO<sub>2</sub>) in RPMI 1640 with 11.1 mmol/l glucose (permits OXPHOS and glycolysis) and without glucose (permits OXPHOS only). As a measure of oxidative ATP formation, cellular oxygen consumption was determined amperometrically with a Clark electrode. Under the conditions of unaffected ATP production and ATP production inhibited stepwise using myxothiazole, PMA/ionomycin-stimulated cytokine production (IL-2, IL-4, IFN- $\gamma$ , TNF- $\alpha$ , 6 hours) and anti-CD3-/anti-CD28-stimulated proliferation (over 96 hours) were quantified.

**Results** In the glucose-containing medium, both stimulated cytokine production and proliferation were unaffected, even under complete suppression of OXPHOS. Only when OXPHOS and glycolysis were suppressed simultaneously and almost completely were cytokine production and proliferation significantly decreased.

**Conclusions** We have quantified the energy requirement of specific immune functions in human CD4<sup>+</sup> T cells. Under maximally inhibited OXPHOS, glycolysis fully compensates for the ATP supply for the energy

requirements of the immune functions investigated. These data demonstrate a high adaptive potential of CD4<sup>+</sup> T cells to maintain specific immune functions even under massively impaired energetic conditions.

## 28

### Intra-articular steroid treatment reduces synovial HMGB1 but not IL-1 expression in chronic arthritis

C Grundtman<sup>1</sup>, E af Klint<sup>1</sup>, U Andersson<sup>2</sup>, L Klareskog<sup>1</sup>, A Ulfgren<sup>1</sup>

<sup>1</sup>Rheumatology Unit, Department of Medicine, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden; <sup>2</sup>Department of Woman and Child Health, Karolinska Hospital, Stockholm, Sweden

Arthritis Res Ther 2004 6(Suppl 1):28 (DOI 10.1186/ar1070)

**Objective** In this study we examined the effect of glucocorticosteroids (GCs) in chronic arthritis on IL-1 $\alpha$ , IL-1 $\beta$ , TNF and the newly discovered proinflammatory cytokine HMGB1, which was previously thought of only as a DNA-binding protein.

**Methods** Seventeen chronic inflammatory arthritis patients with swelling and pain in at least one large joint were chosen. Synovial biopsies were sampled by arthroscopy before and 9–12 days after intra-articular injection of 40 mg triamcinolone hexacetonide. Synovial membrane T cells (CD3), macrophages (CD68, CD163), as well as the proinflammatory cytokines IL-1 $\alpha$ , IL-1 $\beta$ , TNF and HMGB1 were studied by immunohistochemistry followed by semiquantitative analysis and/or digital image analysis.

**Results** All investigated joints had clinical signs of active arthritis with swelling and pain of the joint before treatment, which was reduced in all joints after treatment. Numbers of T cells were reduced whereas numbers of macrophages were not significantly changed. Expression of HMGB1 was significantly reduced, whereas no significant effects were seen on the expression of IL-1 $\alpha$ , IL-1 $\beta$  or TNF. Before treatment HMGB1 staining was mainly extracellular and cytoplasmic in the mononuclear inflammatory follicles and lining layer, whereas endothelial cells of scattered capillaries, arterioles and venules had a primarily cytoplasmic staining. After treatment staining pattern was more prominent in the nucleus and reduced extracellularly.

**Conclusions** Proinflammatory cytokines in chronic arthritis are affected differently by intra-articular GCs. The marked reduction in HMGB1 expression and the lack of significant change in IL-1 and TNF thus indicate that GCs may exert their *in vivo* effects in arthritis via partly different pathways than in previous *in vitro* experiments.

## 29

### Human adipose tissue: an important novel source of IL-1Ra

J-M Dayer, C Meier

Department of Internal Medicine, University Hospital, Geneva, Switzerland

Arthritis Res Ther 2004 6(Suppl 1):29 (DOI 10.1186/ar1071)

The increased production of proinflammatory IL-1, TNF- $\alpha$  and IL-6 is part of the pathogenesis of various immunoinflammatory diseases, often accompanied by metabolic and cardiovascular complications. Cachexia and obesity have been shown to accompany these diseases, and the cytokines IL-1, TNF- $\alpha$ , IL-6 are said to be increased in white adipose tissue (WAT). Few studies have been conducted to examine counter-regulatory mechanisms of cytokine inhibitors. Sera of obese patients showed a more than sevenfold increase in IL-1Ra, which matches levels present in inflammatory autoimmune diseases and sepsis, and correlates with body mass index and insulin resistance. Subcutaneous and visceral human WAT of obese patients contained 0.4 and 0.7 ng of IL-1Ra/mg protein, respectively. Thus, in an obese individual weighing 120 kg with 50% body fat, total WAT is estimated to contain 0.6 mg IL-1Ra protein (i.e. 200 times the amount of IL-1Ra in total serum), thus representing one of the main sources of IL-1Ra production. The

increased IL-1Ra expression – not associated with an increase in IL-1 $\beta$  – argues for an anti-inflammatory, compensating mechanism associated with obesity. Our experiments with human WAT explants showed a strong stimulatory effect of PMA and, more importantly, of IFN- $\beta$  (as much as 5- to 10-fold). Because the latter is a fibroblast-derived IFN, it is tempting to speculate that stromal cells and adipocytes might be part of a paracrine mechanism that regulates IL-1Ra secretion. In fact, newly formed adipose tissue is often found close to inflammatory lesions (i.e. synovial tissue). The functional consequences of the increased production of IL-1Ra by adipose tissue may represent an important counter-regulatory mechanism to inflammation at the local level. Furthermore, IL-1RI and IL-1 IL-1RAcP were also expressed in human WAT. Thus, substances that increase the production ratio of IL-1Ra/IL-1 $\beta$  by adipose tissue might serve as a novel target for therapeutic strategies in human immunoinflammatory diseases.

### 30

#### IL-1-dependent cartilage damage in a macrophage-driven arthritis model can be circumvented by T cell IL-17

MI Koenders<sup>1</sup>, E Lubberts<sup>1</sup>, LAB Joosten<sup>1</sup>, JK Kolls<sup>2</sup>, WB van den Berg<sup>1</sup>

<sup>1</sup>Experimental Rheumatology and Advanced Therapeutics, University Medical Center Nijmegen, Nijmegen, The Netherlands; <sup>2</sup>Department of Medicine, Louisiana State University, New Orleans, USA

*Arthritis Res Ther* 2004 **6**(Suppl 1):30 (DOI 10.1186/ar1072)

**Background** In the murine macrophage-mediated SCW-induced arthritis, IL-1 plays a dominant role in cartilage destruction, as was shown in previous studies using cytokine gene knockout mice or antibodies against IL-1. T cell IL-17 is a proinflammatory cytokine that has many IL-1-like activities. IL-17 is expressed in the synovium of RA patients and may play a role in rheumatoid arthritis (RA) pathology.

**Objective** In the present study we examined the potency of T cell IL-17 to bypass the relative IL-1 dependency of cartilage damage during macrophage-driven SCW-induced arthritis.

**Methods** SCW-arthritis was induced in IL-1 deficient mice and their C57Bl/6 controls by intra-articular injection of 25  $\mu$ g SCW fragments. Sixteen hours before the induction of arthritis, an adenoviral vector expressing murine IL-17 or a control virus was injected into the knee joint. Total knee joints were isolated for histological analysis of joint inflammation by H&E staining and cartilage damage was measured as proteoglycan (PG) depletion by Safranin O staining.

**Results** During SCW-induced arthritis, cartilage damage was clearly suppressed in IL-1 deficient mice. Overexpression of T cell IL-17 in the SCW arthritis model caused aggravation of the synovial inflammation and induces more severe PG depletion. IL-1<sup>-/-</sup> mice showed the same influx of inflammatory cells and comparable degree of cartilage damage

as control mice (Fig. 1), indicating that overexpression of IL-17 causes loss of IL-1 dependency in this model.

**Discussion** These data show circumvention of the IL-1 dependency of cartilage damage by T cell IL-17 in the macrophage-driven SCW arthritis model. IL-1 and its receptor share the same signaling pathway through TRAF-6 and NF- $\kappa$ B as IL-17. These data suggest that T cell IL-17 can replace the catabolic function of IL-1 regarding cartilage damage, directly or via interplay with other macrophage-driven factors.

### 31

#### IL-13 overexpression during immune complex arthritis diminishes MMP-mediated VDIPEN expression

KC Nabbe<sup>1</sup>, PL van Lent<sup>1</sup>, AE Holthuysen<sup>1</sup>, AE Koch<sup>2</sup>, WB van den Berg<sup>1</sup>

<sup>1</sup>Department of Rheumatology, UMC Nijmegen, The Netherlands;

<sup>2</sup>Department of Medicine, UMS Chicago, USA

*Arthritis Res Ther* 2004 **6**(Suppl 1):31 (DOI 10.1186/ar1073)

**Background** We recently found that overexpression of the Th1 cytokine IFN- $\gamma$  during immune complex arthritis (ICA) resulted in deterioration of matrix metalloproteinase (MMP)-mediated VDIPEN expression. On the contrary, overexpression of a Th2 cytokine might protect against cartilage destruction.

**Objective** The aim of the study was to investigate whether local overexpression of the Th2 cytokine IL13 by gene transfer is able to diminish MMP-mediated VDIPEN expression during ICA and, if so, what mechanism is involved.

**Methods** Human IL-13 (hIL-13) was locally overexpressed in the knee joint using an adenovirus (AdhIL13) and hIL-13 was detected in synovial washouts after 1, 2, 3, and 7 days. ICA was induced in C57Bl/6 by ia injection of lysozyme-antilysozyme complexes 1 day after AdhIL13 injection. Histology and synovium specimens were taken at days 1, 3 and 7 after ICA onset. Joint inflammation and MMP-mediated VDIPEN expression were determined. mRNA levels of MMP-3, MMP-12, and MMP-13 were detected in the synovium by Q-PCR.

**Results** AdhIL13 injected in naïve knee joints results in 1000 pg/ml hIL-13 after 1 day, and increased to 3000 pg/ml detected at days 2, 3 and 7. Surprisingly, IL-13 did not diminish joint inflammation, because the influx of inflammatory cells was similar in the Adde170 and AdhIL13 group. MMP-mediated VDIPEN expression was not found 1 day after ICA onset because of the early time point. At day 3, IL-13 overexpression resulted in a twofold reduction in VDIPEN expression and a threefold reduction at day 7, compared with the control group. This decrease might be the result of a declined production of MMPs. However, the mRNA level of MMP-3 was comparable between the two groups, whereas MMP-12 and MMP-13 mRNA levels were three times higher in the IL-13 group.

**Conclusion** IL-13 overexpression during ICA does not alter the inflammatory response. VDIPEN expression was decreased, but this was not reflected by declined MMP production, suggesting that IL-13 interferes at the level of activation of pro-MMPs.

### 32

#### Overexpression of TNF causes bilateral sacroiliitis


K Redlich<sup>1</sup>, B Görtz<sup>1</sup>, S Hayer<sup>1</sup>, J Zwerina<sup>1</sup>, G Kollias<sup>2</sup>, G Steiner<sup>1,3</sup>, JS Smolen<sup>1,3</sup>, G Schett<sup>1</sup>

<sup>1</sup>Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria; <sup>2</sup>Molecular Genetics Laboratory, Institute of Immunology, Alexander Fleming Biomedical Sciences Research Center, Vari, Greece; <sup>3</sup>Center of Molecular Medicine, Austrian Academy of Sciences, Vienna, Austria

*Arthritis Res Ther* 2004 **6**(Suppl 1):32 (DOI 10.1186/ar1074)

**Objective** To study the role of TNF in sacroiliitis using a TNF- $\alpha$  transgenic (hTNFtg) mouse model.

**Figure 1**



PG depletion 10 days after induction of SCW arthritis, in combination with the ia injection of control virus or AdIL-17.

**Methods** hTNF $\alpha$  mice were divided into two groups receiving either phosphate-buffered saline (PBS) or anti-TNF (infliximab). Wild-type mice served as negative control. Treatment was initiated at week 4 and continued over 6 weeks. Thereafter the sacroiliac joints were histologically assessed for joints inflammation, local bone erosion and cartilage destruction.

**Results** All hTNF $\alpha$  mice showed a severe bilateral sacroiliitis. Treatment of hTNF $\alpha$  mice with anti-TNF, however, resulted in a significant ( $P < 0.05$ ), over 80% reduction in sacroiliac inflammation. Furthermore, in hTNF $\alpha$  mice severe erosions of the iliac as well as sacral subchondral bones were detectable, whereas treatment with anti-TNF virtually abrogated local bone erosions indicated by a reduction by over 99%. In addition, application of anti-TNF also significantly ( $P < 0.05$ ) reduced the numbers of osteoclasts at the front of erosions by 98% compared with PBS-treated hTNF $\alpha$  mice. The amount of sacroiliac cartilage of hTNF $\alpha$  mice was significantly ( $P < 0.05$ ) reduced by 73% compared with anti-TNF treated mice.

**Conclusion** These data clearly indicate that TNF overexpression causes bilateral, erosive sacroiliitis and that anti-TNF therapy is a suitable tool with which to treat this condition.

## Major histocompatibility complex

### 33

#### Characterization of the T cell response to hnRNP-A2 (RA33) in HLA-DR4 transgenic mice

M Hoffmann<sup>1</sup>, S Trembleau<sup>1</sup>, S Hayer<sup>2</sup>, JS Smolen<sup>1,2</sup>, G Steiner<sup>1,2</sup>

<sup>1</sup>Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; <sup>2</sup>Division of Rheumatology, University Hospital of Vienna, Vienna, Austria

*Arthritis Res Ther* 2004 **6**(Suppl 1):33 (DOI 10.1186/ar1075)

**Background** HnRNP-A2 (RA33) is a multifunctional RNA-binding protein involved in various aspects of post-transcriptional regulation of gene expression. Autoantibodies to A2/RA33 are present in approximately 30% of rheumatoid arthritis (RA) patients whereas autoreactive T cells have been found in almost 60% of the patients.

**Objective** The aim of the study was to analyze the T cell response to A2/RA33 and its possible involvement in the pathogenesis of RA.

**Methods** The Tepitope programme as well as ELISAs were used to define peptide sequences within A2/RA33 that may bind to the RA associated MHC molecules HLA-DR\*0401 and DR\*0404. Candidate peptides were analyzed *in vivo* by immunizing DR\*0401 transgenic (tg) mice and restimulating lymph node cells or purified CD4<sup>+</sup> or CD8<sup>+</sup> T cells with the peptides. The potential of A2/RA33 to induce disease was studied by immunizing arthritis-prone DBA/1 mice, a strain bearing the DR\*0401 transgene on the DBA/1 background and TNF tg mice (which spontaneously develop erosive arthritis).

**Results** Immunogenic sequences were found clustered in the RNA binding domains of A2/RA33. In immunized HLA-DR4 tg mice the reaction to A2/RA33 peptides seemed to be entirely produced by CD4<sup>+</sup> T cells showing a Th1 phenotype, with some of the peptides inducing high production of IFN- $\gamma$ . However, immunization of HLA-DR4 tg or DBA/1 mice with A2/RA33 protein induced only mild swellings in some animals with no pathological findings in the histological analysis. On the other hand, immunization of TNF tg mice enhanced arthritis significantly. These mice overexpressed A2/RA33 in the joint, whereas expression was very low in wild-type mice.

**Conclusion** A2/RA33 derived peptides can bind to RA associated HLA class II molecules and induce a proinflammatory Th1 response. The increased arthritis observed in immunized TNF tg mice suggests that the autoimmune response to A2/RA33 may indeed be involved in the pathogenesis of RA by inducing or enhancing disease in a proinflammatory environment.

### 34

#### Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCP) affects severity of rheumatoid arthritis

FA van Gaalen, J van Aken, TWJ Huizinga, GMTh Schreuder, FC Breedveld, E Zanelli, WJ van Venrooij, CL Verweij, RRP de Vries, REM Toes

Department of Rheumatology, LUMC, Leiden, The Netherlands

*Arthritis Res Ther* 2004 **6**(Suppl 1):34 (DOI 10.1186/ar1076)

**Objective** The role of HLA class II molecules in the pathogenesis of rheumatoid arthritis (RA) is unclear. HLA class II molecules are involved in the interaction between T and B lymphocytes required for long-lived B-cell responses and generation of high-affinity IgG antibodies. The relationship between HLA class II polymorphisms and RA-specific IgG anti-cyclic citrullinated peptide (CCP) antibodies was investigated.

**Methods** High-resolution HLA-DR and DQ typing and anti-CCP2 antibody testing was performed in 279 RA patients from the Leiden Early Arthritis cohort. The presence of anti-CCP antibodies was analyzed in carriers of the different DR and DQ alleles. Disease progression was measured over a period of 4 years by scoring radiographs of hands and feet using the Sharp/Van der Heijde method.

**Results** Carriers of DQ-DR genotypes containing proposed RA susceptibility alleles were significantly more frequently anti-CCP antibody positive. Carriership of one or two HLA-DRB1 shared epitope (SE) alleles was significantly associated with production of anti-CCP antibodies (OR 2.9, 95% CI 1.6–5.2 and OR 10.2, 95% CI 3.8–28.5, respectively). In SE carrying, anti-CCP antibody positive patients an increased rate of joint destruction was observed (mean Sharp score 7.6 points/year) compared with non-SE carrying, anti-CCP positive (2.4 points;  $P = 0.03$ ), SE carrying, anti-CCP-negative patients (1.6 points;  $P < 0.001$ ) and non-SE carrying, anti-CCP negative patients (1.6 points;  $P < 0.001$ ).

**Conclusions** Anti-CCP antibodies are associated with HLA class II RA susceptibility alleles and presence of both factors is indicative of a severe disease course. As the principal role of HLA class II molecules is antigen presentation to T cells, these data point toward a pivotal role of citrulline-directed T cells in the production of anti-CCP antibodies.

### 35

#### HLA-DRB1 encoded predisposition to rheumatoid arthritis: the anchor hypothesis

N de Vries<sup>1</sup>, H Tijssen<sup>2</sup>, PLCM van Riel<sup>3</sup>, LBA van de Putte<sup>3</sup>, PP Tak<sup>1</sup>

<sup>1</sup>Division of Clinical Immunology and Rheumatology F4-218, AMC/University of Amsterdam, Amsterdam, The Netherlands; <sup>2</sup>Blood Transfusion and Transplantation Immunology; <sup>3</sup>Rheumatology, UMC St Radboud, Nijmegen, The Netherlands

*Arthritis Res Ther* 2004 **6**(Suppl 1):35 (DOI 10.1186/ar1077)

**Objective and Methods** Antigenic peptides anchor by amino acid residues to pockets within the antigen-binding groove of the HLA-DRB1 molecule. In order to assess whether a pocket-wise analysis of HLA-encoded susceptibility might provide a better fit to the immunogenetic data in rheumatoid arthritis (RA) than the shared epitope hypothesis, HLA-DRB1 typing findings in 167 patients with recent onset RA and in 166 controls were analyzed.

**Results** The shared epitope (residues 67–74) borders pockets 4 and 7. After stratification for pocket 4, polymorphisms in pocket 7 did not influence RA risk. However, after stratification for pocket 7, both substitutions in the  $\alpha$  helix bordering pocket 4 and substitutions at position 13 in the floor of this pocket independently and significantly influenced RA risk. Furthermore, substitutions at position 86 in pocket 1 also had an effect on RA risk. Pairs of HLA-DRB1 alleles that only differ in the glycine/valine dimorphism showed a consistent tendency toward increased risk for the glycine variant in a pooled analysis (pooled OR

1.66;  $p1 = 0.08$ ). This observation is also strongly supported by data from previous publications.

**Conclusion** Structural data indicate that HLA disease association may be determined by the make-up of individual pockets within the antigen-binding groove of the HLA molecule. In RA, susceptibility is influenced by genetic polymorphisms in pocket 4 of the HLA-DRB1 molecule, both in the floor of this pocket and in the  $\alpha$  helix bordering this pocket. In addition, genetic variation in pocket 1 modifies RA risk.

## 36

### Influence of the physicochemical properties of the HLA-DRB1 shared epitope negative alleles on rheumatoid arthritis susceptibility

L Michou<sup>1</sup>, E Petit-Teixeira<sup>1</sup>, I Lemaire<sup>2</sup>, C Pierlot<sup>1</sup>, J Osorio<sup>1</sup>, W Frigui<sup>1</sup>, S Lasbleiz<sup>3</sup>, P Quillet<sup>2</sup>, T Bardin<sup>1,3</sup>, B Prum<sup>4</sup>, F Cornélis<sup>1,3</sup>, for the European Consortium on Rheumatoid Arthritis Families

<sup>1</sup>GenHotel, Evry-Genopole, France; <sup>2</sup>Centre Hospitalier Sud Francilien, Corbeil Essonne, France; <sup>3</sup>Unité de Génétique Clinique, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France;

<sup>4</sup>Laboratoire Statistique et Génome, Evry-Genopole, France

*Arthritis Res Ther* 2004 **6**(Suppl 1):36 (DOI 10.1186/ar1078)

**Objective** HLA-DRB1 alleles encoding the shared epitope (SE) are associated with rheumatoid arthritis (RA) but the underlying biological mechanism is unknown. Several case-control studies have been published on the protective effect of particular SE negative alleles, according to the physicochemical properties of the fourth antigenic peptide binding pocket (P4). The present study was undertaken to test those hypotheses taking advantage of a familial based association analysis.

**Methods** One hundred French Caucasian families with one RA patient and both parents were genotyped for HLA-DRB1. The analysis relied on the allelic frequency calculation, the transmission disequilibrium test (TDT) and the genotype relative risk analysis (GRR).

**Results** After the demonstration of the association of SE with RA in our sample ( $P = 4.8 \times 10^{-14}$ ), we replicated the strong protective effect of HLA-DRB1\*1501 alleles ( $P = 4.77 \times 10^{-7}$ ). We also replicated a protective effect against RA of the alleles with an isoleucine at position 67 ( $P = 1.93 \times 10^{-5}$ ) and the alleles with an aspartic acid at position 70 ( $P = 3 \times 10^{-3}$ ). We failed to replicate any protective effect of the alleles with a neutral or negative electric charge of the P4 pocket, nor a modulation of SE effect by those alleles. We also failed to replicate the protective effect of Q and De alleles according to the functional categorization of HLA-DRB1 alleles.

**Conclusion** Our findings are in keeping with a protective effect against RA of SE negative alleles (HLA-DRB1\*1501, alleles with an isoleucine at position 67 and alleles with an aspartic acid at position 70).

## T-cells

## 37

### CD28nullCD4<sup>+</sup> T cells: an effector memory T cell population in patients with rheumatoid arthritis

AER Fasth, D Cao, R van Vollenhoven, C Trollmo, V Malmström

Rheumatology Unit, Department of Medicine, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden

*Arthritis Res Ther* 2004 **6**(Suppl 1):37 (DOI 10.1186/ar1079)

**Background** CD4<sup>+</sup> T cells lacking the costimulatory molecule CD28 have been described in both elderly individuals and in several chronic inflammatory disorders, one being rheumatoid arthritis (RA).

**Objective** We characterized such CD28nullCD4<sup>+</sup> T cells from RA patients in order to identify surface markers correlating with function.

**Methods** Peripheral blood mononuclear cells were analyzed for surface marker expression by flow cytometry and *in vitro* cultures were set up for functional studies.

**Results** One-third of the RA patients had a persistent and expanded CD28null population, which comprised up to half of the CD4<sup>+</sup> T cells in peripheral blood. Functionally, CD28nullCD4<sup>+</sup> T cells were potent effector memory cells with regard to their proliferation and cytokine secretion profiles. This functional capacity correlated with a hitherto unpublished surface phenotype, the cells being uniformly CCR7-negative and CD43high. In addition, we re-evaluated previously suggested cell surface markers, and found CD57 and CD11b expressed on the majority of these NKT-like CD4<sup>+</sup> T cells. When combining phenotypic and functional analyses of subpopulations of the CD28nullCD4<sup>+</sup> T cells a new terminally differentiated T cell population was identified.

**Conclusion** We believe that in the balanced immune system of healthy individuals, CD28nullCD4<sup>+</sup> T cells are under homeostatic control, whereas in an unbalanced immune system such as in autoimmune disease CD28nullCD4<sup>+</sup> T cells are allowed to expand and have the capacity to enhance ongoing inflammatory reactions.

## 38

### Autoreactive T cells specific for a natural intracellular hapten: an example from patients with acute myocarditis and possible consequences for other inflammatory diseases

I Melchers<sup>1</sup>, G Cicek<sup>2</sup>, E Schiltz<sup>3</sup>, J Staiger<sup>4</sup>, F-J Neumann<sup>5</sup>, R Brandsch<sup>2</sup>

<sup>1</sup>Clinical Research Unit for Rheumatology, University Medical Center Freiburg, Germany; <sup>2</sup>Institute for Biochemistry and Molecular Biology, University Freiburg, Germany; <sup>3</sup>Institute for Organic Chemistry and Biochemistry, University Freiburg, Germany; <sup>4</sup>Department of Internal Medicine, University Freiburg, Germany; <sup>5</sup>Heart Center, Bad Krozingen, Germany

*Arthritis Res Ther* 2004 **6**(Suppl 1):38 (DOI 10.1186/ar1080)

**Background** All organisms contain naturally occurring haptens in the form of enzyme cofactors bound covalently to apoproteins. One example is flavine adenine dinucleotide (FAD). Autoantibodies recognizing flavoproteins, with specificity for flavin or flavin-peptide were described in patients with myocarditis or other muscular diseases.

**Objective** We wanted to test the hypothesis that FAD-peptide reactive T cells exist in patients with acute myocarditis.

**Methods** Peripheral blood mononuclear cells (PBMNC) were tested *in vitro* with a purified FAD-peptide (from a trypsin digested, affinity purified flavoprotein) or a synthetic peptide with the same amino acid sequence. Proliferation was measured by <sup>3</sup>H-TdR incorporation, and the secretion of IFN- $\gamma$  by ELISA.

**Results** PBMNC from four patients with acute myocarditis showed positive responses to the FAD-peptide, in contrast to control individuals. The synthetic FAD-free peptide did not induce a response.

**Conclusions** The results are consistent with the hypothesis that during the inflammation of the heart cardiomyocytes liberate normally cryptic mitochondrial FAD-peptides, which induce a T cell response. Similar mechanisms could be envisaged in inflammatory diseases of other compartments (e.g. the joints in rheumatic diseases [1]).

**Acknowledgement** Supported by grants of the DFG.

#### Reference

1. Cicek G, Schiltz E, Staiger J, Neumann F-J, Melchers I, Brandsch R: Specific stimulation of peripheral blood mononuclear cells from patients with acute myocarditis by peptide-bound flavin adenine dinucleotide (FAD), a naturally occurring autologous hapten. *Clin Exp Immunol* 2003, **132**:366-370.

39

**T cell response in *Shigella*-induced reactive arthritis**

H Brandt<sup>1,2</sup>, U Stelzl<sup>2</sup>, W Kuon<sup>1</sup>, T Adam<sup>3</sup>, KH Nierhaus<sup>2</sup>, J Sieper<sup>1</sup>

<sup>1</sup>Department of Rheumatology, Charité Campus Benjamin Franklin, Berlin, Germany; <sup>2</sup>Max-Planck-Institut für molekulare Genetik, Berlin, Germany; <sup>3</sup>Department of Microbiology and Hygiene, CCM/CRV, Berlin, Germany

Arthritis Res Ther 2004 6(Suppl 1):39 (DOI 10.1186/ar1081)

**Background** *Shigella flexneri* is one of the bacteria causing reactive arthritis (ReA). However, no target antigen for the cellular and humoral immune response against *Shigella* is yet known.

**Methods** *Shigella* were grown in culture followed by differential centrifugation, after which a cytoplasmic and the 70S ribosomal fraction were obtained. By means of density gradient centrifugation the 70S ribosome was divided into its two subunits, the small ribosomal subunit 30S and the large ribosomal subunit 50S. The proteins derived from both subunits were further separated by FPLC-ion exchange chromatography. Mononuclear cells from synovial fluid of 3 HLA-B27 positive patients with *Shigella*-induced ReA were stimulated with whole *Shigella*, the cytoplasmic fraction, the ribosomal subunits and with single protein fractions from the ribosomal subunits gained by FPLC. Stimulatory protein fractions were subsequently cleaned by RP-HPLC and identified by stamp-size 2D PAGE.

**Results** Seventeen protein fractions from the 30S subunit and 23 protein fractions from the 50S subunit were obtained. A lymphocyte proliferation was seen after stimulation with whole *Shigella*, with the cytoplasmic fraction and the two ribosomal subunits but not with control antigens. More interestingly, five single ribosomal proteins out of 40 were equally stimulatory in all three patients, indicating that they represent immunodominant T cell antigens. Characterization by 2D PAGE identified the ribosomal proteins L15, L18, L21, L22 and L23 from 50S ('L' for large subunit) and S3 from the 30S ('S' for small subunit).

**Conclusion** This approach allows the identification of T-cell epitopes derived from bacteria in ReA patients. In a first step we identified proteins from the highly conserved ribosomal fraction of *Shigella flexneri*. Their role in the pathogenesis must be further investigated.

40

**CD25<sup>+</sup> regulatory T cells can be used therapeutically in collagen-induced arthritis**

ME Morgan<sup>1</sup>, R Flierman<sup>1</sup>, HJ Witteveen<sup>1</sup>, TWJ Huizinga<sup>1</sup>, RRP de Vries<sup>2</sup>, REM Toes<sup>1</sup>

<sup>1</sup>Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; <sup>2</sup>Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands

Arthritis Res Ther 2004 6(Suppl 1):40 (DOI 10.1186/ar1082)

**Background** Naturally occurring CD4<sup>+</sup>CD25<sup>+</sup> T cells have been shown to suppress immune responses both *in vivo* and *in vitro*. Finding a way to harness their regulatory abilities is of particular value in both transplantation and autoimmunity, where unwanted immune reactions need to be eliminated. Tantalizing evidence for their future potential is demonstrated by their ability to cure T cell mediated colitis induced in SCID mice [1]. However, many autoimmune diseases display a strong humoral component, such as rheumatoid arthritis. It is unknown whether CD4<sup>+</sup>CD25<sup>+</sup> T cells are effective in these B cell-mediated autoimmune diseases.

**Objective** We tested the ability of CD4<sup>+</sup>CD25<sup>+</sup> T cells to modulate collagen-induced arthritis (CIA), a disease dependent on the presence of B cells [2].

**Methods** In order to determine the role of endogenous CD25<sup>+</sup> T cells in CIA, CD25<sup>+</sup> cells were first depleted in mice before immunizations to induce CIA. The therapeutic value of these cells was assessed by adoptively transferring preactivated CD4<sup>+</sup>CD25<sup>+</sup> T cells into mice during the onset of disease.

**Results** Depletion of CD25<sup>+</sup> cells before CIA induction lead to a hastened severe disease in comparison with nondepleted control mice. If CD4<sup>+</sup>CD25<sup>+</sup> T cells were transferred to mice therapeutically, the mice had a significantly milder disease.

**Conclusion** CD4<sup>+</sup>CD25<sup>+</sup> T cells can treat chronic arthritis and probably have the potential to treat a wide spectrum of autoimmune diseases, including those that are mainly mediated by B cells.

**References**

1. Mottet C, Uhlir HH, Powrie F: **Cutting edge: cure of colitis by CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells.** *J Immunol* 2003, **170**:3939-3943.
2. Svensson L, Jirholt J, Holmdahl R, Jansson L: **B cell-deficient mice do not develop type II collagen-induced arthritis (CIA).** *Clin Exp Immunol* 1998, **111**:521-526.

41

**Characterization of kidney infiltrating T cells in the NZB/W F1 lupus model**

P Enghard<sup>1</sup>, D Langnickel<sup>1</sup>, GR Burmester<sup>1</sup>, F Hiepe<sup>1,2</sup>, A Radbruch<sup>2</sup>, G Riemekasten<sup>1</sup>

<sup>1</sup>Department of Rheumatology, Charité University Hospital, Berlin, Germany; <sup>2</sup>German Rheumatology Research Center, Berlin, Germany

Arthritis Res Ther 2004 6(Suppl 1):41 (DOI 10.1186/ar1083)

**Background** Lupus nephritis is one of the hallmarks of systemic lupus erythematosus (SLE). Although there is increasing evidence that these T lymphocytes might play a major role in the initiation and maintenance of nephritis, there is hardly any functional data about these cells.

**Objective** The aim of the present study was to characterize kidney infiltrating T cells with respect to their activation state, their memory/effector phenotype, proliferation, and cytokine production. Furthermore, the ability to provide T cell help for the generation of autoantibodies was tested.

**Methods** CD4<sup>+</sup> T cells derived from inflamed kidney tissues of 7- to 9-month-old NZB/W F1 mice were analyzed for the expression of CD69, CD25, CD28, CD62L, CD45RB, CD44, and CD71 by FACS. Furthermore, intracellular cytokine staining was measured after PMA/Ionomycin stimulation, and the ability of kidney T cells to respond to the SmD1 83-119 peptide with increased generation of anti-dsDNA antibodies was tested by ELISPOT.

**Results and Conclusion** The kidney infiltrating CD4<sup>+</sup> T cells were highly activated in terms of CD69 expression (28%). The expression of CD25 was lower compared with splenic T cells (8.6% versus 15.2%). The CD4<sup>+</sup> T cells were mainly of the effector/memory phenotype (55-60%), but there was also a high frequency of naïve T cells (40-45%). There was a low frequency of proliferating T cells (5%), as detected by CD71 expression. Most T cells were of the Th1 phenotype and produce proinflammatory cytokines such as IFN-γ (16.8%) and TNF-α (11.8%). Kidney T cells give no help for the generation of anti-dsDNA antibodies.

42

**CD25brightCD4<sup>+</sup> regulatory T cells accumulate in inflamed joints of patients with chronic rheumatic disease**

D Cao, R van Vollenhoven, L Klareskog, C Trollmo, V Malmström

Rheumatology Unit, Department of Medicine, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden

Arthritis Res Ther 2004 6(Suppl 1):42 (DOI 10.1186/ar1084)

**Background** CD25<sup>+</sup>CD4<sup>+</sup> regulatory T cells participate in the regulation of immune responses. We recently demonstrated an enrichment of CD25brightCD4<sup>+</sup> T cells with a capacity to control T cell proliferation in the joints of patients with rheumatoid arthritis (RA).

**Objective** Here, we extend these studies to investigate a possible accumulation of regulatory T cells in the joints of other inflammatory diseases, and their potential to suppress cytokine production in patients with rheumatic diseases, including RA.

**Methods** Synovial fluid and peripheral blood samples were obtained during relapse from 204 patients with spondyloarthropathies, juvenile chronic arthritis, and RA, and the frequency of CD25brightCD4<sup>+</sup> T cells was determined. For functional studies, synovial cells from six patients were sorted by flow cytometry and the suppressive capacity of these CD25brightCD4<sup>+</sup> T cells was determined in *in vitro* coculture.

**Results** Of 204 patients, 198 patients exhibited a higher frequency of CD25brightCD4<sup>+</sup> T cells in synovial fluid as compared with peripheral blood. Additionally, in comparison with healthy individuals, the patients had significantly fewer CD25brightCD4<sup>+</sup> T cells in peripheral blood. Functionally, the CD25brightCD4<sup>+</sup> T cells suppressed both type 1 and 2 cytokine production, and proliferation, independent of diagnosis.

**Conclusion** Irrespective of diagnosis of the inflammatory joint disease, an accumulation of CD25brightCD4<sup>+</sup> T cells in the joint and reduced numbers in peripheral blood suggest an active recruitment of regulatory T cells to the affected joint. Their capacity to suppress both proliferation and cytokine secretion might contribute to dampen the local inflammatory processes.

## Dendritic cells

43

### Increased expression of chemokines DC-CK1, ELC and TARC by dendritic cells and in synovium from patients with rheumatoid arthritis

T Radstake<sup>1</sup>, R van der Voort<sup>2</sup>, A Sloetjes<sup>1</sup>, C Figdor<sup>2</sup>, W van den Berg<sup>1</sup>, P Barrera<sup>1</sup>, G Adema<sup>2</sup>

<sup>1</sup>Department of Rheumatology, University Medical Center Nijmegen, Nijmegen, The Netherlands; <sup>2</sup>Department of Tumor Immunology, University Medical Center Nijmegen, Nijmegen, The Netherlands  
*Arthritis Res Ther* 2004 **6**(Suppl 1):43 (DOI 10.1186/ar1085)

**Background** Dendritic cells (DCs) are the professional antigen-presenting cells that produce a large set of chemokines. Recent evidence suggests that DCs, by their production of chemokines, are important in the inflammatory cascade.

**Objective** The aim of the study was to evaluate the expression of chemokines by DCs and synovial tissue from patients with RA in comparison with that from healthy individuals.

**Methods** Immature and mature DCs were obtained using standardized protocols as described previously. The expression of the chemokines DC-CK1, ELC, IL-8, MIP-1a, SDF-1a, SDF-1a, lymphotactin, SLC, MIP-3a, TARC and MDC in iDCs, mDCs and synovial tissue was determined by using real-time quantitative RT-PCR techniques (PRISM).

**Results** iDCs of RA patients ( $n=10$ ) express low levels of ELC and MIP-1a, and high levels of MDC and TARC, which were equal when compared with DCs from healthy individuals ( $n=8$ ). However, the expression of DC-CK1 ( $P<0.001$ ) and IL-8 ( $P=0.02$ ) by iDCs from RA patients was significantly higher. After full maturation, expressions of DC-CK1 ( $P<0.001$ ), ELC ( $P<0.001$ ), IL-8 ( $P=0.02$ ), MIP-1a ( $P<0.001$ ) and TARC ( $P<0.001$ ) were significantly higher in DCs from RA patients relative to healthy donors. In RA synovial tissue, DC-CK1 (230-fold), ELC (400-fold) and IL-8 (36-fold) were expressed at much higher levels when compared with healthy individuals. TARC was also expressed at higher levels in RA synovial tissue but this failed to achieve significance.

**Conclusion** In DCs both from patients with RA and in biopsies of rheumatoid synovium, significantly higher levels of DC-CK1, ELC and IL-8 mRNA are present relative to their normal counterparts. MIP-1a and TARC were expressed at higher levels exclusively by DCs from RA. These results suggest that DC-CK1, ELC, MIP-1a and TARC, along with DCs, play a critical role in RA.

44

### Effect of an empty plasmid containing CpG on dendritic cells: *in vitro* steady state of stimulation, *in vivo* prevention of collagen-induced arthritis

O Jaen, MC Boissier, G Falgarone

*Immunopathology UPRES EA-3408, Rheumatology, Avicenne Hospital AP-HP, Université Paris, Bobigny, France*

*Arthritis Res Ther* 2004 **6**(Suppl 1):44 (DOI 10.1186/ar1086)

**Objective** We studied the immune response against pcDNA3.1 in a model of rheumatoid arthritis (RA), namely collagen-induced arthritis (CIA), to understand the role of innate immunity in RA and the inocuity of this empty plasmid used in gene therapy.

**Methods** CIA was induced in DBA/1 mice by type II collagen sc injections. At D10 and D24 after immunization, 1 µg pcDNA3.1neo (CpG islets-containing plasmid) or pCor (control plasmid) were injected in lower limbs. DBA/1 BMDC were stimulated *in vitro* with pcDNA3.1neo, pCor, LPS<sup>+/-</sup> TNF for 24 and 48 hours. BMDC were analyzed in flow cytometry, and IL-12, TNF-α, IFN-γ and IL-10 were tested by ELISA in BMDC supernatants. BMDC endocytosis capacity and MLR functional capacity were also studied. CIA was treated with a stimulated dendritic cell population after immunization.

**Results** PcDNA3 decreases the incidence of arthritis in collagen immunized DBA mice. Stimulation of BMDC with pcDNA3 increased costimulation molecule expression, cytokine production (IL-12, TNF-α, IFN-γ and IL-10), and allogeneic T cell proliferation, but at a lower level than LPS stimulation. Moreover, pcDNA3 stimulated BMDC have higher endocytosis capacity than LPS stimulated BMDC. Treatment of collagen immunized mice with this steady-state activated-dendritic cell population decreases the incidence of arthritis.

**Conclusion** We demonstrated that the stimulation of dendritic cells with an empty plasmid, pcDNA3.1neo, could lead to a steady state of activation that could support tolerance induction. This effect needs to be further characterized and seems to be a 'yes' or 'no' answer, as incidence is decreased but total clinical scores are not statistically modified. Histological studies will help to understand this mechanism.

45

### RANK and RANKL expression in rheumatoid arthritis synovium and lymph nodes as markers of dendritic cell-T cell interactions

G Page, P Miossec

*INSERM U403 and Unité Mixte Hospices Civils de Lyon-Biomérieux, Pavillon P Hôpital Edouard Herriot, Lyon cedex, France*

*Arthritis Res Ther* 2004 **6**(Suppl 1):45 (DOI 10.1186/ar1087)

**Background** The RANK/RANKL pathway is critical in osteoclastogenesis and bone destruction, and is implicated in focal bone erosion in rheumatoid arthritis (RA). Because deficient mice show major lymph node (LN) abnormalities, here we looked at its involvement in the immune response during chronic inflammation.

**Methods** We investigated, by immunohistochemistry, RANK and RANKL expression by DC and T cell subsets in paired RA synovium-LN and also in normal peripheral blood mononuclear cells (PBMC) stimulated with PMA/PHA.

**Results** In RA synovium, RANKL<sup>+</sup> cells were detected in the lining layer and the lymphocytic infiltrates whereas RANK expression was restricted to the perivascular infiltrates. In LN, RANK<sup>+</sup> and RANKL<sup>+</sup> cells were diffusely expressed in both T-cell zone and germinal centres. Double staining with anti-RANK or anti-RANKL and anti-CD1a or anti-DC-LAMP antibodies revealed that, in paired RA synovium-LN sections, some immature CD1a<sup>+</sup> DC express RANK and RANKL whereas some mature DC-LAMP<sup>+</sup> DC expressed only RANK. Double staining with the CD3, CD4 T-cell markers and the IFN-γ and IL-17 Th1 cell markers showed that some of CD3<sup>+</sup>, CD4<sup>+</sup>, IFN-γ<sup>+</sup> and IL-17<sup>+</sup> cells expressed RANKL, whereas none of them expressed RANK. The same

pattern was observed on activated PBMC. The RANK<sup>+</sup> cells, detected in unstimulated PBMC, were identified as CD14<sup>+</sup> monocytes.

**Conclusion** This study showed the involvement of RANK/RANKL in DC-T cell interactions occurring during the inflammatory process. In particular, RANK expression appears to be limited to the sites of immune reaction both in synovium and LN.

**46**

**Characterization of BDCA1 and BDCA4 dendritic cell subsets in rheumatoid arthritis patients**

**MC Lebre, SW Tas, P Reinders-Blankert, TJM Smeets, PP Tak**

*Division of Clinical Immunology/Rheumatology, AMC, UvA, Amsterdam, The Netherlands*

*Arthritis Res Ther 2004 6(Suppl 1):46 (DOI 10.1186/ar1088)*

**Background** Rheumatoid arthritis (RA) is an autoimmune disease that is characterized by chronic inflammation of the joints leading to destruction of cartilage and bone. RA is characterized by synovial lining hyperplasia and chronic infiltration by T and B cells, monocyte/macrophages, dendritic cells (DC) and other cells. DC are the only antigen-presenting cells that can prime naive Th cells and initiate immune responses. In peripheral blood two major DC subsets can be found: BDCA1<sup>+</sup>CD11c<sup>+</sup>CD123<sup>low</sup> (myeloid), with the ability to produce IL-12; and BDCA4<sup>+</sup>CD11c<sup>-</sup>CD123<sup>high</sup> (plasmacytoid), which produce large amounts of type I interferons (IFN- $\alpha/\beta$ ).

**Objectives** To gain insight into the *in vivo* characteristics of DC, we investigated the distribution of BDCA1<sup>+</sup> and BDCA4<sup>+</sup> DC in RA patients compared with healthy controls and non-RA patients.

**Methods** The frequencies of BDCA1<sup>+</sup> and BDCA4<sup>+</sup> DC in peripheral blood and synovial fluid were analyzed by FACS analysis. Immunohistochemistry was performed in synovial tissue from RA patients to get more insight into the distribution of these two DC subsets *in vivo*.

**Results** We found that the frequencies of both BDCA1<sup>+</sup> and BDCA4<sup>+</sup> DC in peripheral blood of RA patients are decreased compared with healthy controls and non-RA patients. Although the frequencies of both DC subsets in synovial fluid from RA patients were increased compared with peripheral blood, they did not differ significantly from non-RA patients. In rheumatoid synovial tissue, both DC subsets were localized close to CD3 and CD8 T cell infiltrates.

**Conclusion** BDCA1<sup>+</sup> and BDCA4<sup>+</sup> DC are preferentially localized in the synovium of RA patients, where they could stimulate memory T cells and sustain the inflammatory process. Conceivably, immunomodulation by targeting synovial DC might provide a novel anti-rheumatic strategy.

**47**

**Differential dendritic cell expression in chronic inflammatory arthritis: implications for their maturation, recruitment and involvement in disease**

**S Jongbloed<sup>1</sup>, A Fraser<sup>2</sup>, JA Gracie<sup>1</sup>, IB McInnes<sup>1</sup>**

*<sup>1</sup>CRD, University of Glasgow, Glasgow, UK; <sup>2</sup>ATMU, University of Glasgow, Glasgow, UK*

*Arthritis Res Ther 2004 6(Suppl 1):47 (DOI 10.1186/ar1089)*

**Background** Dendritic cells (DC) from both myeloid and lymphoid haematopoietic lineages comprise a complex network of professional antigen-presenting cells, directly linking innate and adaptive immunity. Although implicated in the pathogenesis of inflammatory arthritides, their subset analysis has been hampered by a lack of specific DC markers and reliable quantitation.

**Objectives** The study was conducted to quantify circulating plasmacytoid DC (pDC) and myeloid DC (mDC) populations in different chronic

inflammatory arthritides utilizing a novel assay involving the DC-specific markers BDCA-1 and BDCA-2.

**Methods** Peripheral blood (PB) was obtained from RA ( $n=12$ ), PsA ( $n=13$ ), AS ( $n=11$ ) and healthy donors ( $n=12$ ). Synovial fluids (SF) were also examined from a subset of PB samples (4 RA, 2 PsA, 1 AS). A white blood count (WBC) was performed on all samples, followed by DC enumeration using the blood DC enumeration kit (Miltenyi Biotec). **Results** Circulating PB mDC populations were significantly decreased in RA patients ( $P=0.004$ ), but not in PsA or AS patients, compared with healthy donors (normal =  $175 \times 10^2$ , RA =  $95.5 \times 10^2$ , PsA =  $141 \times 10^2$ , AS =  $152 \times 10^2$ ). Circulating PB pDC populations were significantly decreased in RA ( $P=0.01$ ) and PsA ( $P=0.01$ ) but not AS patients (normal =  $137 \times 10^2$ , RA =  $54.6 \times 10^2$ , PsA =  $69.5 \times 10^2$ , AS =  $104 \times 10^2$ ). The mDC : pDC ratio in PB of all patient groups was similar to that in healthy donors, whereas mDC exceeded pDC in SF in all patient cohorts analyzed (RA 6.6 : 1, PsA 7.35 : 1 and AS 100 : 1).

**Conclusions** We report the *ex vivo* tracking of circulating pDC and mDC populations, revealing significantly reduced numbers of pDC in RA and PsA and mDC in RA patients. mDC subsets appear to be the predominant population in SF in all patient cohorts studied. Understanding the biology of DC subsets in chronic inflammatory arthritis will elucidate their presumed critical role at the interface of innate and acquired (autoreactive) immune responses.

**48**

**Triggering of FcGR during dendritic cell maturation leads to a decreased expression of the chemokines DC-CK1, ELC and TARC**

**TRDJ Radstake<sup>1</sup>, R van der Voort<sup>2</sup>, C Figdor<sup>2</sup>, W van den Berg<sup>1</sup>, P Barrera<sup>1</sup>, GJ Adema<sup>2</sup>**

*<sup>1</sup>Department of Rheumatology, University Medical Center Nijmegen, Nijmegen, The Netherlands; <sup>2</sup>Tumor Immunology, University Medical Center Nijmegen, Nijmegen, The Netherlands*

*Arthritis Res Ther 2004 6(Suppl 1):48 (DOI 10.1186/ar1090)*

**Introduction** Dendritic cells (DCs) determine the balance between tolerance and immunity in which Fc  $\gamma$  receptors (Fc $\gamma$ R) are thought to play a decisive role. Previously, we found that DCs from RA patients expressed a different Fc $\gamma$ R profile.

**Objective** The aim of the study was to determine the potential difference in chemokine expression and production between DC from RA patients and healthy controls upon Fc $\gamma$ R mediated triggering.

**Methods** Immature and mature DC were obtained using standardized protocols as described recently. The expressions of the chemokines DC-CK1, ELC, IL-8, MIP-1a, TARC and MDC were determined by using real-time quantitative RT-PCR techniques (PRISM). The production of DC-CK1 was confirmed by using ELISA techniques. Triggering of Fc $\gamma$ R was achieved by the addition of heat aggregated IgG immunoglobulins (HAGGS) to the culture for 48 hours.

**Results** Stimulation of Fc $\gamma$ R resulted in a significantly decreased expression of DC-CK1 (35%), ELC (50%), IL-8 (640%) and TARC (39%) by DC from RA patients ( $n=6$ ). Although not significant, the same trend was observed for MIP-1a (160%). In contrast, a significant increase was seen for DC-CK1 (300%), ELC (120%), IL-8 (640%), MIP-1a (160%) and TARC (39%) upon triggering of Fc $\gamma$ R on DC from healthy individuals ( $n=5$ ). MDC was the only chemokine that showed a decrease upon Fc $\gamma$ R dependent stimulation of DC in both groups. By using ELISA techniques, we confirmed these data for DC-CK1 on the protein level. Triggering of Fc $\gamma$ R led to a decreased (63%) production of DC-CK1 by DC from RA patients, whereas an increase (137%) was observed by those from controls.

**Conclusion** Our study lends strong support for a skewed Fc $\gamma$ R balance toward the inhibitory subtype in RA, and shows the critical role for Fc $\gamma$ R in the inhibition of chemokine production by DCs. Furthermore, our data show that Fc $\gamma$ R triggering influences Toll-like receptor (LPS) mediated cell responses.



49

### Phenotypic and functional deficiencies of monocyte derived dendritic cells in systemic lupus erythematosus patients

C Scheinecker, M Köller, B Zwölfer, JS Smolen

Department of Rheumatology, Internal Medicine III, University of Vienna, Vienna, Austria

*Arthritis Res Ther* 2004 **6**(Suppl 1):49 (DOI 10.1186/ar1091)

**Background** Systemic lupus erythematosus (SLE) represents an autoimmune disease for which alterations in T cells, B cells as well as various antigen-presenting cell (APC) populations have been described. **Objective** In order to better define APC-associated deficiencies we analyzed morphologic, phenotypic and functional characteristics of dendritic cells (DC) from SLE in patients as compared with healthy controls.

**Methods** Monocyte derived DC (MoDC) were generated by culturing monocytes with GM-CSF+IL-4 for 8 days and with LPS for additional 2 days. MoDC were analyzed at different stages of maturation for morphologic, phenotypic and functional characteristics.

**Results and Conclusion** Analysis of MoDC at different stages of maturation revealed substantial phenotypic and functional defects of MoDC from SLE as compared with healthy controls. In particular, we observed a significantly reduced upregulation of MHC class II molecules on MoDC upon activation, which correlated with disease activity scores and functional deficiencies in mixed lymphocyte reaction experiments. Our data imply a crucial role of APC in the immunologic imbalance in SLE for foreign- and self-antigen reactivity.

50

### Vaccination with TNF- $\alpha$ modulated DCs protects against CIA in an antigen-specific manner

LM van Duivenvoorde<sup>1</sup>, P Louis-Plence<sup>2</sup>, F Apparailly<sup>2</sup>, EIH van der Voort<sup>1</sup>, TJW Huizinga<sup>1</sup>, C Jorgensen<sup>2</sup>, REM Toes<sup>1</sup>

<sup>1</sup>Department of Rheumatology, Leiden University Medical Centre, The Netherlands; <sup>2</sup>Immuno Rheumatology, University Hospital Montpellier, France

*Arthritis Res Ther* 2004 **6**(Suppl 1):50 (DOI 10.1186/ar1092)

**Background and Objective** Dendritic Cells (DCs) play an important role in initiation and regulation of immune responses in arthritis, because these cells are crucial for the initiation of T cell immunity. Full mobilization of effector T cells depends on proper maturation of DCs. Current evidence indicates that the type of T cell response indeed crucially depends on the activation status of DC. For example, antigen recognition on resting DCs can result in immunoregulation. In this study we explored the immunological effects of differentially matured DCs on the development of collagen-induced arthritis (CIA).

**Methods** Bone marrow derived DCs were cultured in the presence of GM-CSF with or without IL-4. Immature, TNF- $\alpha$  or LPS activated, antigen-pulsed DCs were used. At several time points before immunization with bovine CII protein, mice were injected with DCs exposed to these different maturation stimuli. Mice were boosted on day 21 post-CII-immunization and disease course was monitored.

**Results** Although vaccination with immature or LPS activated DCs had no significant influence on disease course, administration of antigen-loaded, TNF- $\alpha$  modulated DCs resulted in a delayed onset of arthritis and a decreased clinical score. The effect was antigen-specific, as also evidenced when antibody titres were measured. A specific increment in the collagen-specific 'Th1-associated' IgG<sub>2a</sub> response was observed. Remarkably, IgG<sub>1</sub> was unaffected by this vaccination.

**Conclusions** CIA can be prevented through vaccination with TNF- $\alpha$  matured DCs in an antigen-specific manner. These findings provide a rationale to employ DCs in treatment or prevention of arthritis.

51

### The effects of NF- $\kappa$ B inhibition by a NEMO binding domain peptide *in vitro* and *in vivo*

SW Tas<sup>1</sup>, EC de Jong<sup>2</sup>, MJ Vervoordeldonk<sup>1</sup>, KA Reedquist<sup>1</sup>, M May<sup>3</sup>, S Ghosh<sup>4</sup>, PP Tak<sup>1</sup>

<sup>1</sup>Division of Clinical Immunology & Rheumatology, AMC/University of Amsterdam, The Netherlands, AMC/University of Amsterdam, The Netherlands; <sup>2</sup>Department of Cell Biology and Histology, AMC/University of Amsterdam, The Netherlands; <sup>3</sup>University of Pennsylvania, Philadelphia, PA, USA; and <sup>4</sup>Yale University Medical School, New Haven, CT, USA

*Arthritis Res Ther* 2004 **6**(Suppl 1):51 (DOI 10.1186/ar1093)

**Objective** Dendritic cells (DC) are thought to play an important role in the pathogenesis of rheumatoid arthritis (RA). In RA, fully matured APC are present in the inflamed synovial tissue clustered around activated T cells. Because DC maturation and cytokine production are NF- $\kappa$ B dependent, we hypothesized that blocking NF- $\kappa$ B activity in DC by selectively targeting IKK $\beta$  with a specific NEMO binding domain (NBD) peptide could inhibit the maturation of DC and thereby modulate the immune response.

**Methods** Immature DC were obtained by culturing freshly isolated monocytes in the presence of GM-CSF and IL-4. On day 6 immature DC were incubated with the NBD peptide (WT versus MUT) in the presence of maturation factors. DC were analyzed for NF- $\kappa$ B activity, surface marker expression, cytokine production and interaction with naive T cells. Furthermore, we investigated the effect of ia injection of the NBD peptide in adjuvant arthritis in rats.

**Results** NF- $\kappa$ B blockade by the NBD peptide resulted in strongly reduced maturation of DC. In addition, IL-6, IL-12 and TNF- $\alpha$  production was dose dependently blocked. Interestingly, NBD peptide treatment resulted in increased CCR7 expression. Coculture with naive T cells resulted in reduced proliferation and differentiation. *In vivo*, injection of the NBD peptide resulted in reduced paw swelling in arthritic rats.

**Conclusions** Inhibiting NF- $\kappa$ B with the NBD peptide in DC results in an immature phenotype with increased CCR7 expression. The enhanced CCR7 expression may promote migration to draining lymph nodes and presentation of antigen in the absence of costimulation. These data strongly suggest that targeting NF- $\kappa$ B in DC could be beneficial in the treatment of arthritis, which is supported by preliminary data in rat adjuvant arthritis.

### Joint destruction/tissue engineering

52

#### CD44 regulates bone erosion and osteoclastogenesis in arthritis

S Hayer<sup>1</sup>, B Goertz<sup>1</sup>, J Zwerina<sup>1</sup>, K Redlich<sup>1</sup>, O Hoffmann<sup>2</sup>, M Amling<sup>3</sup>, F Hilberg<sup>4</sup>, G Kollias<sup>5</sup>, G Steiner<sup>1</sup>, EF Wagner<sup>6</sup>, JS Smolen<sup>1</sup>, G Schett<sup>1</sup>

<sup>1</sup>Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna, Austria; <sup>2</sup>Institute of Pharmacology and Toxicology, University of Vienna, Vienna, Austria; <sup>3</sup>Department of Experimental Trauma Surgery, Hamburg University School of Medicine, Hamburg, Germany; <sup>4</sup>Boehringer Ingelheim, Vienna, Austria; <sup>5</sup>Molecular Genetics Laboratory, Institute of Immunology, Alexander Fleming Biomedical Sciences Research Center, Vari, Greece; <sup>6</sup>Research Institute of Molecular Pathology, University of Vienna, Vienna, Austria

*Arthritis Res Ther* 2004 **6**(Suppl 1):52 (DOI 10.1186/ar1094)

**Background and Objective** CD44 mediates cell-matrix interaction and is thought to play a role in cell adhesion, fusion and migration. Blocking of CD44 is considered as potential target in the therapy of rheumatoid arthritis.

**Methods** To elucidate the role of CD44 in arthritis, human TNF transgenic (hTNFtg) mice were crossed with CD44 knockout mice.

**Results** Clinical evaluation revealed a significantly increased severity of arthritis in CD44<sup>-/-</sup> hTNFg mice than in hTNFg mice. Wild-type mice and CD44<sup>-/-</sup> mice were normal. Histologically, bone destruction was dramatically increased in the arthritic paws of CD44<sup>-/-</sup> hTNFg mice. Changes were based on a significant increase of size and number of osteoclasts in the synovial inflammatory tissue. *Ex vivo* analysis of osteoclastogenesis revealed that osteoclasts differentiated more rapidly and were increased in size and number in CD44<sup>-/-</sup> hTNFg mice compared with hTNFg controls. In addition, bone resorption assay showed increased 'pit' formation by osteoclasts of CD44<sup>-/-</sup> hTNFg mice.

**Conclusion** CD44 deficiency does not block but rather increases the severity of TNF-mediated arthritis. This was due to increased bone damage caused by deregulation of osteoclastogenesis. We conclude that CD44 is of benefit for TNF-mediated arthritis because of its regulatory role on osteoclasts.

### 53

#### Differential gene expression and protein expression levels of MMP and TIMP molecules in response to glucocorticoid treatment in arthritic patients

T Andersson<sup>1,5</sup>, E af Klint<sup>1</sup>, S Strobel<sup>2</sup>, U Andersson<sup>3</sup>, A Stark<sup>4</sup>, R Gelinas<sup>2</sup>, J Lundeborg<sup>5</sup>, L Klareskog<sup>1</sup>, A-K Ulfgren<sup>1</sup>

<sup>1</sup>Rheumatology Unit, Department of Medicine, Karolinska Hospital, Sweden; <sup>2</sup>Celltech Group PLC, Seattle, USA; <sup>3</sup>Department of Woman and Child Health, Karolinska Hospital, Sweden; <sup>4</sup>Department of Orthopedic Surgery, Karolinska Hospital, Sweden; <sup>5</sup>Department of Biotechnology, Royal Institute of Technology (KTH), Stockholm, Sweden  
*Arthritis Res Ther* 2004 **6**(Suppl 1):53 (DOI 10.1186/ar1095)

**Objectives** In this study we attempted to map the molecular events that underlie the clinical effects of glucocorticoid (GC) treatment in patients.

**Methods** DNA arrays and immunohistochemical staining was used for comparison of patient material isolated before and after intra-articular glucocorticoid (GC) treatment. Gene expression data analysis was performed in the GeneSpring™ software.

**Results** Hierarchical clustering of gene expression data could distinguish samples taken before from those taken after treatment to a surprisingly high degree, in spite of anticipated individual and experimental variations. Patterns were further analyzed by identification of genes with both statistically significant differential expression ( $P < 0.05$ ) using the cross gene error model implemented in GeneSpring™, and greater than twofold differential expression. Twelve genes satisfying both of these criteria were found, including matrix metalloproteinase (MMP)-1 and MMP-3, for which mRNA expression was downregulated, and tissue inhibitor of MMP (TIMP)-1 and TIMP-4, for which mRNA expression was upregulated by GC treatment. Immunohistochemical staining for several MMP and TIMP molecules confirmed data for MMP-1 and MMP-3 on a protein level, whereas the result for TIMP-1 and other TIMPs revealed reduced protein expression of these molecules.

**Conclusions** Our data demonstrate that DNA arrays may be used for evaluating the molecular effects of novel as well as established therapies, but also that data should be interpreted with caution concerning their ability to predict therapeutic effects at the protein level.

### 54

#### Local interferon-β gene therapy ameliorates adjuvant arthritis in rats

P Adriaansen<sup>1</sup>, J Van Holten<sup>1</sup>, C Kaynor<sup>2</sup>, MJ Vervoordeldonk<sup>1</sup>, PP Tak<sup>1</sup>

<sup>1</sup>Division of Clinical Immunology & Rheumatology, AMC/University of Amsterdam, The Netherlands; <sup>2</sup>Biogen Inc., Cambridge, MA, USA  
*Arthritis Res Ther* 2004 **6**(Suppl 1):54 (DOI 10.1186/ar1096)

**Objective** Interferon (IFN)-β is thought to inhibit the expression of proinflammatory cytokines and to enhance the production of anti-

inflammatory proteins such as IL-1Ra. More recently it was shown that IFN-β is important in maintaining homeostasis of bone resorption. Because systemic treatment does not appear to be effective in RA patients possibly because of the short half-life of IFN protein, we studied the potential of intra-articular gene therapy using an adenoviral vector to determine whether local constitutive expression of IFN-β in the joint might have a beneficial effect.

**Methods** Three different dosages (109, 1010 and 1011 viral particles) of an adenoviral vector containing the gene for rat IFN-β or LacZ (Ad.IFN-beta and Ad.LacZ) were injected into the right ankle joints of rats with adjuvant arthritis (AA) on day 12 after adjuvant immunization. Joints were harvested 2 weeks later. The effect of IFN-β on paw swelling measured by plethysmometry, bone degradation and histologic joint damage was assessed.

**Results** In the rats treated with the highest dose of Ad.IFN-beta reduced paw swelling was observed ( $P = 0.022$  Ad.IFN-beta versus Ad.LacZ). In addition, a clear reduction in paw swelling was seen in the left uninjected paw. Moreover, the IFN-β-treated animals had significantly less cartilage and bone destruction ( $P = 0.05$ ) in both the right and left paws as compared with control animals.

**Conclusion** We demonstrate that adenoviral *in vivo* gene transfer of IFN-β cDNA into the synovium reduces the severity of inflammation of AA in rats. In addition, an even more potent effect was found on articular cartilage and bone destruction. Furthermore, injection of Ad.IFN-beta into a single paw can suppress inflammation and joint degradation in the contralateral joints. Thus, treatment of a single joint by local delivery of the IFN-β gene could protect multiple joints.

### 55

#### Neutralizing synovial RANKL by local OPG gene therapy in collagen-induced arthritis prevents cartilage erosion through induction of a non-destructive type 2 synovitis

E Lubberts<sup>1</sup>, MI Koenders<sup>1</sup>, B Oppers-Walgreen<sup>1</sup>, M Wagenmans<sup>1</sup>, L van den Bersselaar<sup>1</sup>, LAB Joosten<sup>1</sup>, J Schurr<sup>2</sup>, JK Kolls<sup>2</sup>, WB van den Berg<sup>1</sup>

<sup>1</sup>Department of Rheumatology, Rheumatology and Advanced Therapeutics, University Medical Center St Radboud, Nijmegen, The Netherlands; <sup>2</sup>Department of Medicine, Gene Therapy Program, Louisiana State University Health Sciences Center, New Orleans, LA, USA

*Arthritis Res Ther* 2004 **6**(Suppl 1):55 (DOI 10.1186/ar1097)

Chondrocytes express RANKL and its receptor RANK, implicating the involvement of this pathway in cartilage damage. However, a direct role of RANKL in cartilage destruction has not yet been identified. Here, we used local and systemic osteoprotegerin (OPG) treatment to inactivate RANKL in different arthritis models. We demonstrated that inactivation of RANKL did not suppress cartilage breakdown in a local T-cell IL-17-induced joint pathology, but completely prevented cartilage erosion in collagen-induced arthritis, which is mediated by T cells and immune complexes. Synovial inactivation of RANKL by local OPG gene therapy in collagen-induced arthritis resulted in a chronic type 2 inflammation characterized by abundant expression of IL-4 and protection of cartilage erosion. Microarray analysis revealed abundant expression of YM1 and arginase, which are specific markers of the macrophage M2 phenotype (alternative activated macrophage). Furthermore, protease specific inhibitors and Fc receptor type II are upregulated by OPG. Changes in expression of catabolic mediators and inhibitors in the synovial infiltrate, including the key catabolic cytokine in cartilage destruction IL-1, contribute to the cartilage protective effect of OPG. These data provide evidence that the cartilage protective effect of OPG in collagen arthritis is mediated by induction of a nondestructive type 2 synovitis.

56

### Bone morphogenic protein (BMP-2) enhances expression of type II collagen and aggrecan in human chondrocytes in 3D alginate cultures

WK Aicher<sup>1</sup>, B Thunemann<sup>2</sup>, C Gaissmaier<sup>3</sup>, J Fritz<sup>3</sup>, T Gründer<sup>2</sup>

<sup>1</sup>Department Orthopaedic Surgery, University of Tuebingen Medical Centre, Tuebingen, Germany; <sup>2</sup>TETEC AG, Aspenhastrasse, Reutlingen, Germany; <sup>3</sup>BG Center for Traumatology, Schnarrenberg, Tuebingen, Germany

*Arthritis Res Ther* 2004 **6**(Suppl 1):56 (DOI 10.1186/ar1098)

**Background** The healing capacity of articular cartilage is very limited in the adult. Therefore, tissue engineering techniques were developed to treat cartilage lesions.

**Objective** Because high expression of type II collagen is of importance for the properties of cartilage after transplantation, we investigated whether the growth factor BMP-2 may modulate the chondrogenic phenotype in monolayer cell cultures (2D) and in three-dimensional culture (3D) systems.

**Methods** Chondrocytes from articular knee cartilage of five individuals were isolated and expanded under GMP conditions suitable for clinical purposes. Cells were seeded either in 2D cultures or embedded in alginate beads (3D) in the presence or absence of human recombinant BMP-2 (hr-BMP-2). Then, cells were harvested and analysis of the chondrogenic phenotype was performed using quantitative RT-PCR, immunocytochemistry and ELISA methods.

**Results** Expansion of chondrocytes in primary culture (P0) or in first subculture (P1) did not yield populations enriched for dedifferentiated or hypertrophic cells, because type X collagen encoding mRNA was detectable only at very low copy numbers. Seeding P1 chondrocytes in 3D culture significantly reduced type I collagen, BMP-4 and IL-18, and induced type II collagen and BMP-2 encoding mRNA. Suppression of IL-1 $\beta$  and induction of IL-10 were noted but were not statistically significant. At P2, these changes were still evident. Addition of BMP-2 to 2D chondrocytes had no effect on type II collagen or IL-1 $\beta$  mRNA amounts. In contrast, in 3D chondrocytes BMP-2 induced type II collagen and reduced IL-1 mRNA amounts. This was also seen by ELISA and immunocytochemistry.

**Conclusions** We conclude that chondrocytes during expansion for ACT may benefit from BMP-2 activation only when seeded in an appropriate 3D culture system.

57

### Human bone marrow-derived mesenchymal stem cells: studies on chondrogenic differentiation, chemotaxis and recruitment

J Ringe<sup>1</sup>, S Straßburg<sup>1</sup>, M Endres<sup>1</sup>, M Notter<sup>2</sup>, T Haeupl<sup>1</sup>, R Manz<sup>3</sup>, C Kaps<sup>1</sup>, M Sittlinger<sup>1</sup>

<sup>1</sup>Department of Rheumatology and Clinical Immunology, University Medicine Berlin (CCM), Germany; <sup>2</sup>Department of Medicine III, University Medicine Berlin (CCBF), Germany; <sup>3</sup>Deutsches Rheuma-Forschungszentrum, Berlin, Germany

*Arthritis Res Ther* 2004 **6**(Suppl 1):57 (DOI 10.1186/ar1099)

**Background** We tested the hypothesis that a tissue engineering approach using chemoattractant molecules will allow *in situ* recruitment of human bone marrow mesenchymal stem cells (MSC) to sites of degenerated articular cartilage.

**Objective** The aim of our ongoing study is to characterize molecules that are involved in chondrogenesis and chemotaxis of MSC.

**Methods** Human bone marrow aspirates were used to isolate MSC. The culture homogeneity was verified by FACS analysis (CD14<sup>-</sup>, CD34<sup>-</sup>, CD45<sup>-</sup>, CD105<sup>+</sup>, CD166<sup>+</sup>). For differentiation, MSC were centrifuged to form high-density cultures and different TGFs were added. Chondrogenesis was documented by Alcian blue, type II collagen staining and by real-time PCR of marker genes. Chemotaxis was analyzed by chemokine receptor analyses and transwell chamber assays.

**Results** The histological staining showed BMP-2 promotes differentiation along the chondrogenic lineage. Matrix formation was comparable to MSC stimulated with TGF- $\beta_3$ . The results suggest a synergistic stimulation on chondrogenic differentiation with BMP-2 and TGF- $\beta_3$ . Differentiation was further demonstrated by the induction of type II collagen, aggrecan, SOX-9 and link protein on the gene expression level. Furthermore, for the first time, expression of chemokine receptors of all four chemokine subfamilies was proven by RT-PCR and subsequent sequence analysis, as well as at the protein level using specific antibodies. The chemotactic activity in 24-transwell chemotaxis chambers was demonstrated for, for example, SDF1a.

**Conclusion** These findings demonstrate that chondrogenic development of MSC is inducible by different TGF- $\beta_3$  superfamily growth factors including BMP-2. Additionally, MSC express chemokine receptors relevant for chemotaxis or *in situ* recruitment for cartilage regeneration.

58

### Requirement of local synovial IL-17 receptor signaling in the progression of chronic synovitis and bone erosion in arthritis

E Lubbers<sup>1,2</sup>, W Huang<sup>1</sup>, P Schwarzenberger<sup>1</sup>, J Schurr<sup>1</sup>, J Peschon<sup>3</sup>, WB van den Berg<sup>2</sup>, JK Kolls<sup>1</sup>

<sup>1</sup>LSU Health Sciences Center, Department of Medicine, Gene Therapy Program, New Orleans, LA, USA; <sup>2</sup>University Medical Center St Radboud, Department of Rheumatology, Rheumatology and Advanced Therapeutics, Nijmegen, The Netherlands; <sup>3</sup>Amgen, Seattle, WA, USA

*Arthritis Res Ther* 2004 **6**(Suppl 1):58 (DOI 10.1186/ar1100)

IL-17 is a proinflammatory cytokine that is suspected to be involved in development of rheumatoid arthritis (RA). However, the role of IL-17-IL-17 receptor signaling in the effector phase of arthritis, including requirement of this signaling pathway in synoviocytes, is still not fully elucidated. Here we demonstrate, using IL-17 receptor deficient (IL-17R<sup>-/-</sup>) mice, a requirement for IL-17R signaling in immune reactivity and progression of synovitis and bone erosion in a T cell mediated mBSA arthritis model and chronic streptococcal cell wall arthritis. Of great interest, chimeric mice of host wild-type (wt) and donor IL-17R<sup>-/-</sup> bone marrow (BM) cells developed chronic synovitis similar to that in wt/wt chimeras. In contrast, chimeric mice of host IL-17R<sup>-/-</sup> and donor wt BM cells were protected from progressive synovitis similar to IL-17R<sup>-/-</sup> IL-17R<sup>-/-</sup> chimeras, suggesting a crucial role of resident synovial cells. Weakened mobilization of neutrophils into the joint and downregulation of synovial mRNA expression for leukocyte specific chemokines and selectins, and MMP-1 was found in IL-17R<sup>-/-</sup> mice. These data suggest that, in addition to the role played by IL-17-IL-17R signaling in development of immunity, synovial IL-17-IL-17R signaling plays a critical role in the effector phase of arthritis. Activation of IL-17R on fibroblast-like synoviocytes appears pivotal.

59

### TRAIL-induced rheumatoid arthritis fibroblast-like synoviocyte proliferation is inhibited by OPG

J Morel<sup>1,2</sup>, R Audo<sup>2</sup>, V Deschamps<sup>2</sup>, B Combe<sup>1,2</sup>

<sup>1</sup>Department of Immuno-rheumatology, CHU Lapeyronie, Montpellier, France; <sup>2</sup>Inserm U454, Montpellier, France

*Arthritis Res Ther* 2004 **6**(Suppl 1):59 (DOI 10.1186/ar1101)

TNF- $\alpha$  related apoptosis inducing ligand (TRAIL) is a proapoptotic factor that can also induce cell proliferation. The role of TRAIL in rheumatoid arthritis (RA) is still unclear. We investigated the effect of TRAIL on RA fibroblast-like synoviocyte (FLS) proliferation. TRAIL induces RA FLS proliferation in a dose-dependent manner, with a maximum proliferation at 0.5 nmol/l ( $P < 0.05$ ;  $n = 5$ ). This proliferation could be prevented by the natural TRAIL inhibitor osteoprotegerin (OPG) and a TRAIL antibody. By flow cytometry, we analyzed TRAIL receptors (DR4, DR5 and DcR2). RA FLS constitutively expressed DR5 ( $n = 5$ ) and three out five RA FLS expressed DR4. Interestingly, RA FLS proliferate more after TRAIL stimulation when expressing both

DR4 and DR5, suggesting a cumulative effect of the two receptors. DR5 receptor mediates the signal-inducing cell proliferation because stimulation with an agonistic anti-DR5 antibody induces RA synoviocyte proliferation ( $n = 4$ ;  $P < 0.05$ ). Next, we investigated which cells in the synovium could produce TRAIL and OPG. In RA FLS, TRAIL was detected at the mRNA level after IL-1 $\beta$  and TNF- $\alpha$  stimulation but not at the protein level. OPG was constitutively produced (2 ng/ml) and upregulated by IL-1 $\beta$  (14-fold) and TNF- $\alpha$  (5-fold) but not IL-18. On RA synovial T cells, TRAIL was constitutively expressed. Our results show that TRAIL induces RA FLS proliferation. TRAIL produced on synovial T cells may interact with RA FLS expressing DR4 and DR5 to induce FLS proliferation. OPG inhibits TRAIL induced RA FLS proliferation. This novel propriety of OPG may be another explanation for its bone protective role in RA.

## 60

### Expression of TRAIL-R2 (DR5) on fibroblasts from synovial fluid of rheumatoid arthritis

E Miranda, A Balsa, M Benito, C Pérez de Ayala, E Martín-Mola

Department of Rheumatology, Hospital La Paz, Madrid, Spain

Arthritis Res Ther 2004 6(Suppl 1):60 (DOI 10.1186/ar1102)

Fibroblasts can be isolated from rheumatoid arthritis (RA) synovial fluid (SfId), and these cells may be derived from the synovium. Although normal tissues do not express DR5 protein, most cancerous tissues express high levels of DR5. Synovial fibroblasts from RA synovium share expression of DR5 protein with transformed cells. Our objective was to characterize fibroblasts from RA SfId using an anti-DR5 monoclonal antibody. SfId mononuclear cells were cultured from 50 patients with RA, 20 patients with seronegative arthritis, 20 patients with osteoarthritis (OA), and 15 patients with unclassified monoarthritis or oligoarthritis. Progressive growth of spindle-shaped cells was observed in some cultures. By the third passage 100% of cells were fibroblasts (Thy-1<sup>+</sup>, CD45<sup>-</sup>, CD68<sup>-</sup>). Fibroblasts were stained with a PE-conjugated anti-DR5 antibody and examined by flow cytometry. Fibroblasts grew from 35 of 50 RA SfId samples. Twenty-six of these 35 were DR5<sup>+</sup> (>95% positive cells; MFI relative to isotype control,  $13.97 \pm 2.5$ ). Fibroblasts also grew from SfId in six out of 20 seronegative arthritis, four out of 20 OA, and five out of 15 unclassified monoarthritis or oligoarthritis patients. All these were DR5<sup>-</sup> (MFI relative to isotype control,  $1.2 \pm 0.23$ ). Ten out of 10 fibroblast lines from joint replacement surgery or synovectomy specimens of RA were DR5<sup>+</sup>. All fibroblast lines from the synovium of 10 OA patients were DR5<sup>-</sup>, as were fibroblasts from the skin of five healthy subjects. DR5<sup>+</sup> SfId cultures underwent apoptosis when treated *in vitro* with an anti-DR5 antibody, as determined by propidium iodide and annexin V staining. These results suggest that fibroblast-like cells from SfId of RA are of at least two different lineages. Those expressing DR5 protein share this characteristic with transformed cells and with synovial fibroblasts from RA synovial membrane, and more likely derive from the synovium. The origin of DR5<sup>-</sup> SfId fibroblasts remains to be determined. Because all RA patients with DR5<sup>-</sup> SfId fibroblasts had active disease, we do not believe that DR5<sup>-</sup> cells are derived from 'burnt out' synovial membrane.

## 61

### The active metabolite of leflunomide, A77-1726, increases proliferation of human synovial fibroblasts in presence of IL-1 $\beta$

D Magne, F Mezin, G Palmer, PA Guerne

Department of Pathology, University of Geneva School of Medicine, Geneva, Switzerland

Arthritis Res Ther 2004 6(Suppl 1):61 (DOI 10.1186/ar1103)

**Background** Leflunomide is an immunomodulatory agent used for the treatment of rheumatoid arthritis (RA) and is known to inhibit the proliferation of several cell types, including T lymphocytes.

**Objectives** Because pannus formation due to excessive synoviocyte proliferation is generally associated with the development of RA, we

sought to determine the effects of A77-1726, the active metabolite of leflunomide, on synovial fibroblast proliferation.

**Methods** Cell viability was investigated by measuring at 490 nm the formation of formazan from MTS tetrazolium, and cell proliferation by determination of thymidine incorporation and cell counts.

**Results** Whereas A77-1726 alone had no significant effects on proliferation, it dramatically increased the mitogenic effects of IL-1 $\beta$ . Then we investigated the possible mechanisms of this effect of A77-1726 (i.e. inhibition of DHODH, of tyrosine kinases and COX). The effect was not mediated through inhibition of DHODH because it was not reversed by addition of exogenous uridine. It was not due to inhibition of tyrosine kinases either, because the broad-range inhibitor genistein and the src tyrosine kinase inhibitor PP1 blocked rather than increased IL-1 $\beta$  effects. Finally, although in the absence of IL-1 $\beta$  PGE2 dose-dependently decreased proliferation, it had no effect in the presence of IL-1 $\beta$ , and treatment with indomethacin did not consistently reproduce the effects of A77-1726.

**Conclusions** The mitogenic effects of A77-1726 in presence of IL-1 $\beta$  may thus be independent on DHODH and tyrosine kinase inhibition, whereas the role of COX is more uncertain; identification of involved mechanisms may prove useful for the development of related compounds or new therapeutic strategies.

**Acknowledgement** This work was supported by the Swiss National Science Foundation (grant 3100-064123.00/1 to PAG) and by Aventis Pharma (Frankfurt am Main, Germany).

## 62

### Protection of inflammation-related bone loss by OPG and TNF- $\alpha$ antibodies through distinct mechanisms in collagen-induced arthritis

N Saidenberg-Kermanach<sup>1</sup>, A Corrado<sup>2</sup>, N Bessis<sup>1</sup>, D Lemeiter<sup>1</sup>, MC de Vernejoul<sup>2</sup>, MC Boissier<sup>1</sup>, M Cohen-Solal<sup>2</sup>

<sup>1</sup>Avicenne Hospital (AP-HP) and UPRES EA-3408, Bobigny, France;

<sup>2</sup>INSERM U349, Paris, France

Arthritis Res Ther 2004 6(Suppl 1):62 (DOI 10.1186/ar1104)

**Background** Focal and systemic bone loss in rheumatoid arthritis (RA) involves several cytokines such as RANKL, which is secreted by both osteoblasts and activated lymphocytes, and TNF- $\alpha$ . Anti-TNF- $\alpha$  antibodies decrease articular inflammation and bone erosions, but the effect on bone remains to be elucidated. Osteoprotegerin (OPG) inhibits bone resorption.

**Objective** We conducted the study to evaluate the respective and combined effect of OPG and anti-TNF- $\alpha$  antibodies on inflammation and on bone remodelling.

**Methods** DBA/1 mice were immunized then treated at the onset of arthritis with OPG-Fc or anti-TNF- $\alpha$  antibodies or with both OPG-Fc + anti-TNF- $\alpha$  antibodies or saline; one group of mice remained untreated (naïve). Deoxypyridinoline changes ( $\Delta$ D-Pyr) in urine, bone mineral density gain ( $\Delta$ BMD) at the total body level, and histomorphometric parameters at the femur metaphysis were measured.

**Results** Anti-TNF- $\alpha$  antibodies but not OPG decreased clinical and histological scores ( $P < 0.02$  versus saline).  $\Delta$ BMD was lower in saline-treated CIA mice than in naïve mice ( $P < 0.01$ ), suggesting the effect of inflammation on bone loss. OPG and anti-TNF- $\alpha$  antibodies increased  $\Delta$ BMD compared with saline ( $P < 0.001$  and  $P < 0.05$ , respectively).  $\Delta$ D-Pyr decreased by 65% with OPG and by 7% with saline ( $P < 0.001$ ), but by 13% when mice were treated with TNF- $\alpha$  antibodies (NS). Compared with saline, OPG induced increased trabecular (Tb) bone volume ( $P < 0.02$ ), decreased Tb spacing ( $P < 0.02$ ) and decreased BFR/BS ( $P < 0.01$ ). In contrast, the anti-TNF- $\alpha$  antibody treated group showed no significant changes in Tb bone volume and Tb spacing compared with saline, but Tb thickness was greater ( $P < 0.02$ ), close to that in naïve mice, suggesting a protective effect on bone formation. There was no additive effect of OPG and anti-TNF- $\alpha$  antibodies on any parameter.

**Conclusion** Administration of OPG and anti-TNF- $\alpha$  antibodies prevented bone loss in CIA mice through distinct mechanisms involving

inhibition of bone resorption and formation. Combinations of both treatments must be further investigated.

## 63

### Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-TNF in combination with OPG or PTH in TNF-mediated arthritis

**K Redlich<sup>1</sup>, B Görtz<sup>1</sup>, S Hayer<sup>1</sup>, J Zwerina<sup>1</sup>, N Doerr<sup>2</sup>, P Kostenuik<sup>2</sup>, G Kollias<sup>3</sup>, G Steiner<sup>1</sup>, JS Smolen<sup>1</sup>, G Schett<sup>1</sup>**

<sup>1</sup>Division of Rheumatology, University of Vienna, Austria; <sup>2</sup>Department of Pathology, Amgen, Inc., Thousand Oaks, CA, USA; <sup>3</sup>Molecular Genetics Laboratory, Institute of Immunology, Alexander Fleming Biomedical Sciences Research Center, Vari, Greece

*Arthritis Res Ther* 2004 **6**(Suppl 1):63 (DOI 10.1186/ar1105)

Local bone erosion and systemic bone loss are hallmarks of rheumatoid arthritis and cause progressive disability. Tumour necrosis factor (TNF) is a key mediator of arthritis and acts catabolically on bone by stimulating bone resorption and inhibiting bone formation. We hypothesized that the concerted action of anti-TNF, which reduces inflammation, and of PTH, which stimulates bone formation, or of OPG, which blocks bone resorption, could lead to repair of local bone erosions and reversal of systemic bone loss. To test this, human TNF-transgenic (hTNFtg) mice with established erosive arthritis and systemic bone loss were treated with PTH, OPG and anti-TNF, alone or in combination. Local bone erosions almost fully regressed, upon combined treatment with anti-TNF and PTH and/or OPG, suggesting repair of inflammatory skeletal lesions. In contrast, OPG and anti-TNF alone led to arrest of bone erosions but did not achieve repair. Treatment with PTH alone had no influence on the progression of bone erosions. Local bone erosions showed all signs of new bone formation such as the presence of osteoblasts, osteoid formation and mineralization. Furthermore, systemic bone loss was completely reversed upon combined treatment and this effect was mediated by osteoblast stimulation and osteoclast blockade. In summary, we conclude that local joint destruction and systemic inflammatory bone loss due to TNF can regress, and that repair requires a combined approach by reducing inflammation, blocking bone resorption or stimulating bone formation.

## 64

### Histochemical detection of oxidative stress in synovial tissue: spontaneous reactive oxygen species (ROS) production by rheumatoid arthritis T cells

**PHJ Remans<sup>1</sup>, WM Fredericks<sup>2</sup>, PP Tak<sup>1</sup>, FC Breedveld<sup>3</sup>, JM van Laar<sup>3</sup>, KA Reedquist<sup>1</sup>**

<sup>1</sup>Division of Clinical Immunology and Rheumatology, AMC, Amsterdam, The Netherlands; <sup>2</sup>Department of Cell Biology and Histology, AMC, Amsterdam, The Netherlands; <sup>3</sup>Department of Rheumatology, LUMC, Leiden, The Netherlands

*Arthritis Res Ther* 2004 **6**(Suppl 1):64 (DOI 10.1186/ar1106)

**Background** Oxidative stress is thought to underlie the altered pathogenic behavior of T cells in rheumatoid arthritis (RA). We recently demonstrated that intracellular signaling by Ras family GTPases leads to ROS production in RA synovial fluid (SF) T cells. However, other cellular sources of ROS may cause oxidative stress in RA synovial tissue (ST).

**Objectives** The study was conducted to determine whether T cells or other cells spontaneously produce ROS in RA ST, to determine the specificity of T cell ROS production in long-standing RA versus early RA and osteoarthritis (OA) T cells, and to identify signaling pathways producing ROS in RA ST and SF T cells.

**Methods** ROS production was assessed using ROS-dependent polymerization of diaminobenzidine (DAB) on cryostat sections of ST from patients with long-standing RA, early RA, and OA ( $n=10$  patients in each group),

purified RA patient peripheral blood (PB) and SF mononuclear cells, and purified T cells ( $n=4$ ), and oxidation of the dye DCF by FACS analysis of purified RA PB and SF T cells ( $n=10$ ), in the absence or presence of pharmacological inhibitors. Cryostat sections were double labelled with DAB and cell-specific antibodies to quantify ROS-producing cells.

**Results** ROS production was observed in both longstanding and early RA, but not OA ST. ROS production was observed only in T cells (68%) and neutrophils (15%). In RA ST, ROS producing T cells were observed in the synovial sublining and perivascular tissue. Catalase and BAPTA-AM, but not other ROS inhibitors, blocked ROS production in ST and SF T cells. Intracellular ROS production is detected in ST of patients with RA but not OA. T cells are the major source of intracellular ROS production in RA ST. Conserved signaling pathways regulate ROS production in ST, SF and Jurkat T cells. ROS production is observed in recently extravasated T cells, indicating that oxidative stress is an early event affecting T cell function in the RA synovial joint.

## 65

### Immunization with the glycolytic enzyme glucose-6-phosphate isomerase (GPI) induces peripheral polyarthritis in genetically unaltered mice

**D Schubert<sup>1</sup>, B Maier<sup>1</sup>, L Morawietz<sup>2</sup>, V Krenn<sup>2</sup>, T Kamradt<sup>1</sup>**

<sup>1</sup>German Arthritis Research Centre (DRFZ), Berlin, Germany;

<sup>2</sup>Universitätsklinikum Charité, Institute of Pathology, Berlin, Germany

*Arthritis Res Ther* 2004 **6**(Suppl 1):65 (DOI 10.1186/ar1107)

Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown etiology that primarily affects the joints. Recently, a T cell receptor transgenic murine model yielded novel insights. K/BxN TCR transgenic mice spontaneously develop an autoimmune arthritis that resembles human RA. Arthritis development depends on the recognition of the ubiquitously expressed glycolytic enzyme GPI by both the transgenic T cells and B lymphocytes. Here we show that immunization with heterologous GPI in adjuvant induces a symmetric polyarthritis of the small distal joints in genetically susceptible mice. The course of GPI-induced arthritis is highly predictable: clinically overt arthritis develops 9–10 days after immunization, reaches its maximum at D15 and then slowly resolves. Histologically, the disease is characterized by early synovitis followed by massive cartilage destruction and erosions of the bones and later resolution of the inflammation, fibrosis, and repair processes. Although antibody titers in susceptible and nonsusceptible mouse strains are high, transfer of purified total IgG of sick mice alone do not transfer disease. Anyway, antibodies seem to play a major role since Fc-receptor  $\gamma$ -chain deficient mice develop disease with a much lower frequency and reduced severity than the wild-type mice. Treatment with a depleting monoclonal anti-CD4 antibody completely prevents disease. Depletion of CD4<sup>+</sup> T cells during disease leads to a rapid resolution of arthritis. Therefore, CD4<sup>+</sup> T cells are important for both the induction of the disease and the effector phase. Thus, GPI-induced arthritis in normal mice bridges the gap between the transgenic K/BxN model and the highly complex human situation, thereby providing a model in which both the induction and effector phase of antigen specific arthritis can be dissected, and preventive and therapeutic strategies evaluated.

## 66

### Differential expression and response to infliximab treatment of specific macrophage subsets in inflammatory synovitis

**L De Rycke<sup>1</sup>, D Baeten<sup>1</sup>, D Foell<sup>2</sup>, E Kruithof<sup>1</sup>, EM Veys<sup>1</sup>, J Roth<sup>2</sup>, F De Keyser<sup>1</sup>**

<sup>1</sup>Rheumatology, Gent University Hospital, Belgium; <sup>2</sup>Pediatrics, University of Münster, Germany

*Arthritis Res Ther* 2004 **6**(Suppl 1):66 (DOI 10.1186/ar1108)

**Background** Myeloid related protein (MRP)8 and MRP14 are expressed in early monocytes, whereas CD163 is marker for mature tissue macrophages.

**Objective** To analyse macrophage subsets in RA and SpA, and the effect of infliximab on the synovial infiltration of these subsets.

**Methods** Paired synovium and synovial fluid (SF) were collected in 20 RA and 30 SpA patients. In nine SpA patients, synovium was also obtained after 12 weeks of infliximab treatment. The levels of expression of MRP8, MRP14, CD163 and CD68 were analyzed by immunohistochemistry on frozen sections. Levels of MRP8/MRP14 in SF were determined by ELISA.

**Results** In inflammatory arthritis, MRP8, MRP14, CD163 and CD68 positive cells were abundant in the lining and sublining layer. The expression of CD68 and CD163 exhibited a cellular pattern. The MRP8 and MRP14 expression was characterized by a cellular staining, with in some samples also an extracellular and perivascular pattern. Comparing RA and SpA, CD68-positive macrophages were equally present (lining  $P=0.463$ , sublining  $P=0.235$ ), whereas MRP8 expression was higher in the lining of RA synovium ( $P=0.025$ ) and CD163-positive cells were more prominent in SpA synovium (lining  $P<0.001$ , sublining  $P=0.017$ ). No differences for MRP8, MRP14, CD163 or CD68 were seen between the SpA subgroups. Confirming that these markers identify different macrophage subsets, the expression of MRP8 and MRP14 was more reduced after infliximab than CD163 (MRP8: lining  $P=0.038$ , sublining  $P=0.023$ ; MRP14: lining  $P=0.088$ , sublining  $P=0.036$ ; CD163: lining  $P=0.119$ , sublining  $P=0.125$ ). Local secretion of soluble MRP8/MRP14 was evidenced by high SF levels (RA 24 530 ng/ml, SpA 4152 ng/ml), which were higher than in serum (RA 20-fold, SpA 6-fold).

**Conclusion** MRP8/MRP14 and CD163 identify different macrophage subsets as evidenced by the differential expression in RA versus SpA, and by the differential effect of infliximab on the synovial expression of these markers

## 67

### Involvement of SUMO-1 in the regulation of apoptosis in prosthesis loosening fibroblasts

I Meinecke<sup>1</sup>, A Wille<sup>1</sup>, A Cinski<sup>1</sup>, W Neumann<sup>1</sup>, B Ink<sup>2</sup>, R Hay<sup>3</sup>, S Gay<sup>4</sup>, T Pap<sup>1,4</sup>

<sup>1</sup>University Hospital Magdeburg, Germany; <sup>2</sup>GSK, London, UK;

<sup>3</sup>University of St. Andrews, UK; <sup>4</sup>University Hospital Zurich, Switzerland

*Arthritis Res Ther* 2004 **6**(Suppl 1):67 (DOI 10.1186/ar1109)

**Background** Prosthesis loosening fibroblasts (PLF) contribute significantly to the pathogenesis of aseptic prosthesis loosening (APL) and show similarities to rheumatoid arthritis synovial fibroblasts (RA-SF). Based on data that have linked the increased expression of the small ubiquitin-like modifier SUMO-1 to the resistance of RA-SF against apoptosis, we investigated the expression of SUMO-1 in APL and used gene transfer of the SUMO protease SENP1 to study consequences of SUMOylation in PLF.

**Methods** We used *in situ* hybridization (ISH) to study the expression of SUMO-1 in APL interface tissues. Quantitative PCR and Western blot were applied to measure the expression of SUMO-1 in PLF in comparison with RA-SF. Confocal microscopy of PLF transfected with GFP-labeled wild type (wt) or mutant (mt) gene constructs of SENP1 was performed to investigate the cellular localization of SUMO-1. To study the functional contribution of SUMO-1 to the apoptosis of PLF, SENP1wt-, SENP1mt- and mock-transfected PLF were stimulated with FasL, and apoptosis was determined by a histon fragmentation assay.

**Results** ISH revealed marked expression of SUMO-1 in all tissues, with most prominent staining at sites attached to bone. The expression of SUMO-1 in PLF was comparable with that in RA-SF. Confocal microscopy revealed localization of SUMO-1 mainly in nuclear PML-bodies. After transfection of PLF with SENP1, high levels of SENP1 mRNA were measured (up to 472-fold versus endogenous SENP1). Transfection of PLF with SENP1wt decreased the nuclear staining for SUMO-1, and increased significantly FasL-induced apoptosis (155% versus SENP1mt). Spontaneous cell death remained unaffected.

**Conclusion** The data suggest that SUMO-1 is involved in the activation of PLF and RA-SF by preventing these cells from Fas-induced apoptosis. The modification of nuclear proteins by SUMO-1 appears to contribute to the antiapoptotic effects of SUMO-1. By de-conjugating SUMO-1 from its nuclear substrates, SENP1 can regulate the apoptotic response of PLF.

## Genomics and signal transduction

### 68

#### Monocyte-specific gene signatures in rheumatoid arthritis

A Grützkau<sup>1</sup>, J Grün<sup>1</sup>, M Rudwaleit<sup>3</sup>, L Goldschmidt<sup>3</sup>, G-R Burmester<sup>2</sup>, A Radbruch<sup>1</sup>, T Häupl<sup>2</sup>

<sup>1</sup>DRFZ, Berlin, Germany; <sup>2,3</sup>Departments Rheumatology, Charité 2CCM/3CCBF, Berlin, Germany

*Arthritis Res Ther* 2004 **6**(Suppl 1):68 (DOI 10.1186/ar1110)

**Background** In rheumatoid arthritis (RA), monocytes are of central importance in the chronic inflammatory immune response. These cells may display diagnostic markers and provide insight into pathophysiological pathways in RA.

**Objective** To identify characteristic expression patterns in rheumatoid arthritis (RA), highly purified peripheral blood monocytes were investigated.

**Methods** Monocytes from five normal donors (ND) and six patients with active RA were purified by erythrocyte lysis and CD14-positive selection at constant low temperature (4°C) conditions to minimize *in vitro* induced artefacts. Gene expression was detected by Affymetrix HG U133A hybridization. Bioinformatic analysis included MAS5.0 image analysis, statistical methods (*t*-test; Mann-Whitney) and cluster analysis (genes@work).

**Results** Array analysis revealed about 50% present calls in ND or RA monocytes. MAS5.0 comparison expression analysis revealed 605 genes that were significantly changed in more than 50% of all RA versus ND pair-wise comparisons. Statistical methods revealed that 260 of these genes were significantly different ( $P<0.05$ ). Selection and reduction by fold changes above 1.6 and statistical methods reduced the number of differentially expressed genes to 152. This set of genes is implicated in cellular processes that are involved in cell communication (cytokines, chemokines and their receptors), intracellular signalling, transcription, defense response, apoptosis and heat shock responses. Hierarchical cluster analysis based on these selected genes separated into two branches, one for ND and one for RA patients.

**Conclusion** Gene expression profiling of separated peripheral blood monocytes identified a characteristic gene pattern that is involved in the activation of monocytes, and clearly indicates an inflammatory process in RA. These results will be compared with expression profiles in other inflammatory rheumatic diseases and further analyzed for dominant pathophysiological pathways in a search for new candidates for targeted therapy in RA.

### 69

#### A customized monocyte cDNA microarray for diagnosis of rheumatoid arthritis and prognosis of anti-TNF- $\alpha$ therapy

B Stuhlmüller, N Tandon, C Hultschig, RJ Kuban, M Hernandez, GR Burmester, T Häupl

Charité, Department of Rheumatology, MPI-MG, Berlin, Germany

*Arthritis Res Ther* 2004 **6**(Suppl 1):69 (DOI 10.1186/ar1111)

**Background** In rheumatoid arthritis (RA) macrophages (M $\phi$ ) play a pivotal role. They become highly activated in synovitis and at the carti-

lage–pannus junction. Furthermore, therapeutic neutralization of molecules produced by activated Mf lead to clinical improvement in RA, and circulating monocytes (MO) of the peripheral blood in patients with RA spontaneously express proinflammatory genes (IL-1 $\beta$ , IL-6, TNF).

**Methods** A custom RA-MO cDNA microarray was generated using differentially expressed genes obtained from gene subtraction and from comparative whole genome wide U133A analysis in normal donors, active and anti-TNF- $\alpha$  treated RA patients. Genes were selected using MAS 5.0, multtest and PAM. The custom microarray consists of 313 genes including guide dots, and positive (housekeeping genes and spike controls) and negative controls for image and statistical analysis. Each probe was spotted in 16 replicates.

**Results** The RA-MO chipset-II was validated using the following: non-stimulated and LPS, PMA, Vit.D3+LPS, PMA+LPS stimulated U937 cells; nonstimulated and LPS stimulated healthy donor MO; MO from normal donors ( $n=3$ ) and RA patients before and during anti-TNF- $\alpha$  treatment ( $n=5$  each); and synovial tissue from normal individuals ( $n=2$ ) and RA patients ( $n=2$ ). Not only LPS/PMA regulated genes but also RA specific and anti-TNF- $\alpha$  regulated genes were validated. In addition, we could clarify whether these genes are differentially transcribed only in MO or whether they can also be found in RA tissue Mf. Our data indicate a high degree of reproducibility that is sufficient for diagnostic applications and therapy monitoring.

**Conclusion** The RA-MO chipset-II microarray is competitive and flexible for enlargement of the number of genes. The current gene selection will contribute to validating the role of monocytes in disease activity, to therapeutic interventions, and may improve the knowledge on the regulation of pathways in activated monocytes in chronic inflammation.

## 70

### Reporter cell lines for real-time imaging of NF- $\kappa$ B activation in the arthritic joint

**RL Smeets, LAB Joosten, WB van den Berg, FAJ van de Loo**

*Department of Rheumatology, University Medical Center Nijmegen, The Netherlands*

*Arthritis Res Ther 2004 6(Suppl 1):70 (DOI 10.1186/ar1112)*

**Background** Inadequate functioning of NF- $\kappa$ B is implicated in many diseases, such as rheumatoid arthritis (RA), and increased activation of NF- $\kappa$ B in synovial tissue precedes the clinical manifestation of experimental arthritis.

**Objective** The aim of the study was to develop NF- $\kappa$ B reporter cell-lines that can be used for real-time evaluation of NF- $\kappa$ B activation in knee joints during experimental arthritis in living animals.

**Methods** For determination of NF- $\kappa$ B transcription activity, an eukaryotic expression vector was created containing five tandemly arranged NF- $\kappa$ B binding sites (5'-GGGACTTCC-3') regulating luciferase expression. Cell lines were selected on stable incorporation of 5  $\times$  NF- $\kappa$ B luciferase and responsiveness was tested toward NF- $\kappa$ B inducing stimuli.

**Results** These cell-lines, derived from fibroblasts, chondrocytes and thymocytes, showed good cytokine responsiveness toward IL-1, IL-17, IL-18, and TNF. We showed that these cells could also be used in *in vitro* inhibition assays using cytokine protein antagonist (e.g. IL-1Ra and IL-18BPc) or RNA interference. By transplanting these cells into HLA matched recipients we were able to image in real time NF- $\kappa$ B activation in knee joints of mice with IL-1- or SCW-induced inflammation using a cooled-charge-coupled device (CCCD) camera. Interestingly, NF- $\kappa$ B activation was also activated at sites remote from the monokine or SCW injection sites. Synovial mRNA revealed a striking upregulation of IL-1 in both SCW challenged and contralateral knee joint. This effect was confirmed by pretreatment of mice with neutralizing anti-IL-1 Abs, which markedly prevented the NF- $\kappa$ B activation in the contralateral naive joints.

**Conclusion** These reporter cell-lines can be a valuable tool to study the role of NF- $\kappa$ B activation in arthritis and to evaluate cytokine/NF- $\kappa$ B based inhibition therapies. Furthermore, we show that local induction of experimental arthritis results in contralateral NF- $\kappa$ B activation, which is dependent on IL-1.

## 71

### Differential regulation of mitogenic activated protein kinases by thymosin $\beta$ 4 sulphoxide (Tb4SO)

**M Junghee, JD Young, JA Gracie, IB McInnes**

*CRD, University of Glasgow, UK*

*Arthritis Res Ther 2004 6(Suppl 1):71 (DOI 10.1186/ar1113)*

**Background** Thymosin  $\beta$ 4 (Tb4) is a 4.9 kDa ubiquitously expressed intracellular peptide known to sequester G-actin, with a growing number of extracellular biological functions. We have shown that oxidation of its single methionine residue at position 6 (Tb4 sulphoxide [Tb4SO]) gives the peptide potent anti-inflammatory properties. In addition, Tb4 promotes wound healing in various *in vitro* and *in vivo* models. The mechanism by which Tb4SO exerts its extracellular biological functions is unknown. Its cell receptor remains unidentified and intracellular signalling consequences of Tb4SO require elucidation.

**Objective** The study was conducted to investigate the intracellular signalling consequences of the addition of Tb4SO to various cell types, specifically MAP kinase activation.

**Methods** Cell types used were treated with Tb4SO and lysed using RIPA buffer. Lysates were run on SDS PAGE, transferred to PVDF membrane and probed with antiphospho ERK1/2, p38, JNK1/2 or AKT antibodies. Membranes were then stripped and reprobed with pan-antibodies to allow normalization of samples.

**Results** Tb4SO induced the phosphorylation of ERK1/2 in peripheral blood-derived monocytes in dose-dependent manner. This was inhibited by addition of U0126, an inhibitor of the upstream activator of ERK1/2, implicating ERK1/2 in Tb4SO-mediated functions in monocytes. Neither p38 MAPK nor JNK1/2 were activated in peripheral blood monocytes. In peripheral blood-derived macrophages, Tb4SO induced rapid and marked activation p38 MAPK, pAkt and ERK1/2, but not of JNK (p-JNK1/2). Interestingly, only JNK1 was activated by Tb4SO in HeLa cells, and this occurred in a delayed (after 15 min) and transient manner. Short-term activation of JNKs has previously been shown to be involved in the upregulation of apoptosis. Preliminary studies have shown an acceleration in neutrophil but not monocyte/macrophage apoptosis in response to Tb4SO.

**Conclusions** These observations suggest that Tb4SO activates MAPKs and that activation is dependent on cell type, which may in turn regulate differential functions in these different cell types.

## 72

### Polymorphism at the position -308 of TNF- $\alpha$ gene influences outcome of infliximab therapy in rheumatoid arthritis

**B Mugnier<sup>1</sup>, D Reviron<sup>1</sup>, A Darque<sup>2</sup>, N Balandraud<sup>1</sup>, C Roudier<sup>1</sup>, J Roudier<sup>1</sup>**

*<sup>1</sup>Immuno-Rhumatologie, INSERM EMI 9940, Marseille, France;*

*<sup>2</sup>Pharmacologie, Hôpital de la Conception, Marseille, France*

*Arthritis Res Ther 2004 6(Suppl 1):72 (DOI 10.1186/ar1114)*

**Background** Not all rheumatoid arthritis (RA) patients respond well to the standard infliximab regimen. No clinical or biological factor that would allow one to predict response has yet been identified.

**Objective** The aim of the study was to test whether the -308 G/A polymorphism in the promoter of the TNF- $\alpha$  gene and the -1082 G/A polymorphism in the promoter of the IL-10 gene influence response to infliximab therapy in patients with RA.

**Methods** We genotyped 85 RA patients for -308TNF $\alpha$  polymorphism by PCR and subdivided them into group A (A/A or A/G genotypes) and group B (G/G genotypes). We compared clinical response to infliximab treatment between the two groups after four infusions, using the DAS28 index.

**Results** We found that 47.4% of patients in group A and 79.3% of patients in group B had DAS28 index improvement greater than 1.2 ( $P=0.0075$ ) and that the average DAS28 improvement was 1.12 in

group A and 2.08 in group B ( $P=0.05$ ). IL-10 polymorphism did not allow us to discriminate between good and poor responders.

**Conclusion** These data suggest that the -308 A/G and the -308 A/A TNF- $\alpha$  genotypes predict poor response to infliximab therapy in RA. -308TNF $\alpha$  genotyping might represent an easy tool with which to predict response to infliximab treatment. Conversely, the IL-10 polymorphism did not appear to be useful.

### 73

#### Unraveling complexity of rheumatoid synovial gene expression by comparison with purified leukocyte profiles

T Häupl<sup>1</sup>, A Grützkau<sup>3</sup>, J Grün<sup>3</sup>, R Baumgrass<sup>3</sup>, M Janitz<sup>4</sup>, B Stuhlmüller<sup>1</sup>, T Rohrlach<sup>1</sup>, C Kaps<sup>5</sup>, M Rudwaleit<sup>2</sup>, L Morawietz<sup>6</sup>, J Zacher<sup>7</sup>, V Krenn<sup>6</sup>, G-R Burmester<sup>1</sup>, A Radbruch<sup>3</sup>

Department of Rheumatology, Charité<sup>1</sup>CCM<sup>2</sup>CCBF, Berlin, Germany; <sup>3</sup>DRFZ, Berlin, Germany; <sup>4</sup>MPI-MG, Berlin, Germany; <sup>5</sup>Oligene GmbH, Berlin, Germany; <sup>6</sup>Institute of Pathology, Charité, Berlin, Germany; <sup>7</sup>Department of Orthopedics, Helios-Klinik, Berlin-Buch, Germany

Arthritis Res Ther 2004 6(Suppl 1):73 (DOI 10.1186/ar1115)

**Background** Gene array analyses reflect the molecular complexity in rheumatoid synovitis. Insufficient knowledge about the majority of differentially regulated genes hampers adequate interpretation.

**Objective** To unravel this complexity, cell type specific expression profiles were applied as baseline information for comparison.

**Methods** Gene expression profiles were determined by Affymetrix HG-U133A array hybridization of synovial tissues, sorted blood monocytes, granulocytes, CD4 and CD8 T cells from up to 10 patients with rheumatoid arthritis (RA) and 10 normal donors (ND). Primary analysis was performed using MAS5.0. Tissues were scored according to histological standards (Krenn, *Pathol Res Pract* 2002).

**Results** Compared with ND synovium, 145 genes were differentially regulated in all, and up to 2681 genes in at least 50% of RA-ND pairwise comparisons. Marker genes of isolated cell populations were defined by absence in more than 70% of other populations and normal synovial tissue, defining 59, 25 or 110 genes for granulocytes, monocytes or T cells, respectively. Of these markers, 1, 6 or 22 were identified in more than 50% of RA-ND comparisons for each cell type, respectively. This reflects the altered cellular composition in synovitis. Excluding all genes present in normal tissue or any of the purified populations revealed immunoglobulins as markers of B-cell infiltration.

**Conclusion** This initial analysis of our approach substantially improved the quality of array interpretation and allows identification of tissue associated gene regulation. It helps to identify markers shared between blood and tissue and may provide candidates for disease classification and activity scoring.

### 74

#### B lymphocytes infiltrating Wegener's granuloma: the immunoglobulin VH gene repertoire from granulomatous tissues displays an antigen-driven maturation and suggests a microbial trigger

J Voswinkel, J Krämer, A Müller, K Herlyn, P Lamprecht, WL Gross, A Gause


Department of Rheumatology, University of Luebeck and Rheumaklinik Bad Bramstedt, Germany

Arthritis Res Ther 2004 6(Suppl 1):74 (DOI 10.1186/ar1116)

**Background** In Wegener's granulomatosis (WG) the development of a generalized vasculitis is based on strong expression of proteinase 3 (PR3) on the surface of neutrophil granulocytes and the appearance of circulating high-affinity anti-PR3 autoantibodies (PR3-ANCAs) suggesting an antigen-driven B lymphocyte maturation.

**Objective** In order to analyze mechanisms relevant to the induction of ANCA, we compared the immunoglobulin heavy chain (VH) gene

Figure 1



CD20 staining of a cryosection from an endonasal Wegener granuloma.

repertoire in biopsy specimen of granulomas from two cases of ANCA-negative localized WG and from two cases of ANCA-positive generalized WG with a healthy control.

**Methods** Frozen tissue samples were stained for B lymphocytes by anti-CD20 APAAP. DNA was prepared, purified and subjected to a PCR with individual VH primers matching to the families VH1-VH6 and a JH consensus primer. After bacterial subcloning PCR products were sequenced and characterized for gene usage and mutational pattern.

**Results** Immunohistology revealed lymphoid infiltrates within typical WG granulomas containing more than 30% B cells, which is suggestive of germinal center formation (Fig. 1). One hundred and fifty differently rearranged VH genes from WG tissues were characterized and compared with 84 VH genes from peripheral blood of a healthy donor. The mutation frequency as well as the ratio of amino acid replacement to silent mutations indicate an antigen-driven selection of antibodies within such germinal center-like regions of the granuloma in WG and differ significantly from the healthy control. The VH genes in WG revealed both striking similarities to published PR3-ANCA-encoding genes as well as to VH genes from *Staphylococcus aureus* superantigen-affine B cells. Furthermore, 50% of mutations within the binding-site coding regions led to negatively charged amino acids that favour affinity to the positively charged PR3.

**Conclusion** In WG a subset of autoreactive PR3-producing B cells may be induced to produce PR3-ANCA within granulomatous lesions after *Staphylococcus aureus* B-cell superantigen stimulation. Selected B cells undergo affinity maturation and differentiate into plasma cells that produce high levels of circulating ANCAs, which are involved in the pathogenesis of the systemic vasculitis.

**Acknowledgement** This work is supported by the Deutsche Forschungsgemeinschaft (Sonderforschungsbereich 367, A11) and by the University of Luebeck (FUL N20-2001).

### 75

#### Toll-like receptor 4 polymorphism influences susceptibility to but not severity and outcome of rheumatoid arthritis

TRDJ Radstake<sup>1</sup>, B Franke<sup>2</sup>, S Hanssen<sup>2</sup>, P Welsing<sup>1</sup>, LAB Joosten<sup>1</sup>, PLCM van Riel<sup>1</sup>, P Barrera<sup>1</sup>, WB van den Berg<sup>1</sup>

<sup>1</sup>Department of Rheumatology, University Medical Center Nijmegen, The Netherlands; <sup>2</sup>Department of Genetics, University Medical Center Nijmegen, The Netherlands

Arthritis Res Ther 2004 6(Suppl 1):75 (DOI 10.1186/ar1117)

**Introduction** Toll-like receptors (TLRs) play an important role in the innate and adaptive immune response. TLR4 is the most thoroughly studied member of this receptor family and interacts with endogenous



ligands, which are abundantly present in the synovial joint during rheumatoid arthritis (RA).

**Objective** The aim of the present study was to analyze the relationship between the TLR4 Asp299Gly (896A>G) polymorphism and RA susceptibility, disease phenotype and outcome over a 6-year period of the disease.

**Methods** Genotyping was performed on RA patients from an early RA inception cohort. Healthy controls consisted of healthy blood donors. To assess the influence of the TLR4 variant on disease phenotype, course and outcome, we compared prospectively collected disease activity and outcome parameters of patients with and without the variant TLR4 allele. TLR4 genotyping of the A>G polymorphism at position 896 of the TLR4 gene was performed using RFLP.

**Results** in 282 RA patients and 314 healthy individuals we found that the frequency of the TLR4 Asp299Gly polymorphism was significantly lower among RA patients (10.6%) than among controls (17.2%;  $P=0.02$ ). To analyze potential differences in disease phenotype, severity and outcome 30 RA patients heterozygous for the TLR4 variant were compared with 252 RA patients possessing two wild-type alleles. Apart from the higher DAS at baseline (6.1 versus 5.4;  $P=0.01$ ), no other differences in phenotype, severity or outcome of RA were detected between both groups.

**Discussion** Here we demonstrate a link between RA disease susceptibility and the TLR4 polymorphism in a large set of RA patients and healthy individuals. Furthermore, we show that the TLR4 polymorphism might be important in the onset of disease but does not seem to play a role in disease outcome.

## 76

### Radiological sacroiliitis is linked with CARD15 gene polymorphisms in patients with Crohn's disease

**B Vander Cruyssen<sup>1</sup>, H Peeters<sup>2</sup>, D Laukens<sup>3</sup>, P Coucke<sup>4</sup>, H Mielants<sup>1</sup>, M De Vos<sup>2</sup>, F De Keyser<sup>1</sup>**

<sup>1</sup>Department of Rheumatology, Ghent University Hospital, Belgium;

<sup>2</sup>Department of Gastroenterology, Ghent University Hospital, Belgium;

<sup>3</sup>Department of Molecular Biomedical Research, Ghent University Hospital, Belgium; <sup>4</sup>Department of Medical Genetics, Ghent University Hospital, Belgium

*Arthritis Res Ther* 2004 **6**(Suppl 1):76 (DOI 10.1186/ar1118)

**Background** Sacroiliitis (SI) is a common extraintestinal manifestation of Crohn's disease (CD). In contrast to idiopathic ankylosing spondylitis (AS), its association with HLA-B27 is less evident. Mutations in the CARD15 gene are recently identified as susceptibility genes for CD. The CARD15 gene encodes the intracellular NOD2 receptor and should play an important role in innate immunity. Studies on associated disease phenotypes revealed a predisposition for ileal localization, early onset of disease, familial cases and fibrostenosing disease. We recently described a higher prevalence of CARD15 variants in a subgroup of spondyloarthropathy patients with chronic gut inflammation, which are prone to evolution to CD.

**Background** The present study evaluated whether CARD15 polymorphisms are associated with sacroiliitis in patients with CD.

**Methods** One hundred and two consecutive CD patients were clinically evaluated by a rheumatologist. Radiographs of sacroiliac joints were performed and blindly scored by two investigators. RFLP-PCR technique was used to genotype all patients for three single nucleotide polymorphisms in the CARD15 gene. Every SNP was verified by direct sequencing. HLA-B27 phenotype was determined.

**Results** Radiological evidence of SI with or without AS was present in 23 patients (23%). Of patients with SI 78% carried a CARD15 variant, versus 48% of patients without SI ( $P=0.011$ ; OR 3.8, 95% CI 1.3–11.5). A logistic regression analysis with SI as dependent variable and CARD15, HLA-B27, familial cases, need for resection surgery, age of diagnosis and ileal disease as covariates showed that only carriage of CARD15 variants was a significant predictor of SI ( $P=0.035$ ).

**Conclusion** This result suggests that carriage of CARD15 variants is a genetic marker for CD related SI, independent of HLA-B27 or other CARD15 related phenotypes.

## 77

### Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence for the existence of distinctive pathways relevant to disease

**PV Kasperkovitz<sup>1</sup>, NL Verbeet<sup>1</sup>, T Smeets<sup>2</sup>, PP Tak<sup>2</sup>, TWJ Huizinga<sup>3</sup>, B Baltus<sup>1</sup>, T Timmer<sup>1</sup>, E Pieterman<sup>3</sup>, M Fero<sup>4</sup>, GS Firestein<sup>5</sup>, AA Alizadeh<sup>4</sup>, TCTM van der Pouw Kraan<sup>1</sup>, CL Verweij<sup>1</sup>**

<sup>1</sup>Department of Molecular Cell Biology & Immunology, VUMC,

Amsterdam, The Netherlands; <sup>2</sup>Department of Clinical Immunology

and Rheumatology, Academic Medical Center, Amsterdam, The

Netherlands; <sup>3</sup>Department of Rheumatology, LUMC, Leiden, The

Netherlands; <sup>4</sup>Department of Biochemistry, Stanford University,

Stanford, CA, USA; <sup>5</sup>University of California, San Diego, CA, USA

*Arthritis Res Ther* 2004 **6**(Suppl 1):77 (DOI 10.1186/ar1119)

The molecular pathogenesis of rheumatoid arthritis (RA) is still poorly understood and its clinical course can vary widely. In a recent report we noted heterogeneity in global gene expression signatures between synovial tissue specimens from different patients with RA. The results of the present study support the view that clinically diagnosed RA is a heterogeneous disease that is featured not only at the whole synovial tissue level but also at the level of FLS cultured from those tissues. One of the most impressive features of our 24k cDNA microarray profiling studies is the clear correlation of the FLS phenotype with that of paired synovial tissue from which the cells were derived. One class of FLS is tightly related to the presence of lymphocytes in the lesions whereas the other class of FLS suggests that synoviocyte-mediated invasion appears to be less dependent on infiltrating immune cells. Clearly, the list of genes that are differentially expressed between the FLS subgroups facilitates our understanding of the pathophysiology of the distinct groups of rheumatoid FLS. These data reveal features of fibrosis as the hallmark of FLS derived from a high inflammatory lesion, whereas FLS that are characterized by deregulated growth appear to constitute a characteristic feature of low inflammatory tissues. These data support the notion that heterogeneity between synovial tissues is reflected in the FLS as a stable trait and provide a molecular basis for the well recognized but as yet poorly understood heterogeneity in RA.

## Gene therapy

### 78

#### Host immune responses to salivary gland administration of recombinant adeno-associated virus serotype 2 vectors

**MR Kok<sup>1,2</sup>, A Voutetakis<sup>1</sup>, S Yamano<sup>1</sup>, J Wang<sup>1</sup>, A Cotrim<sup>1</sup>, H Katano<sup>1</sup>, I Bossis<sup>1</sup>, JA Chiorini<sup>1</sup>, PP Tak<sup>2</sup>, BJ Baum<sup>1</sup>**

<sup>1</sup>Gene Therapy and Therapeutics Branch, NIDCR, NIH, DHHS,

Bethesda, MD, USA; <sup>2</sup>Division of Clinical Immunology and

Rheumatology, AMC, University of Amsterdam, Amsterdam, The Netherlands

*Arthritis Res Ther* 2004 **6**(Suppl 1):78 (DOI 10.1186/ar1120)

**Background** Salivary glands (SGs) provide a novel target site at which gene transfer can be accomplished in a minimally invasive manner [1]. SGs are also capable of producing large amounts of proteins, and human SGs are well encapsulated, a circumstance likely to minimize the undesirable access of administered vectors and transgenes to other tissues [2]. Previous studies have indicated that intravenous, intramuscular and intranasal administration of rAAV2 vectors induce relatively mild host immune responses.

**Objective** The aim of the study was to examine the effects on immune responsiveness of rAAV2 vector delivery into SGs.

**Methods** The main excretory ducts of the submandibular glands of Balb/c mice were cannulated and vectors administered by retrograde

infusion [1]. On day 0 we delivered a rAAV2 encoding  $\beta$ -galactosidase or saline (control) to adult mice. On day 28, we administered a second rAAV2 vector encoding either human erythropoietin (Epo) or human growth hormone to one-third of each group. Immune activities were evaluated in saliva, serum, SGs and spleens collected at different times.

**Results** Vector delivery had little effect on salivary flow rates at all time points studied. Histological examination of SGs on day 1 did not indicate any significant inflammatory cell infiltration due to rAAV2 vectors. *Ex vivo* stimulation, with rAAV2, of splenocytes on days 28 and 56 resulted in elevated interferon- $\gamma$  levels in culture media from rAAV2-administered mice, but not from control mice. Significant titers of neutralizing antibodies to rAAV2 were detected in serum, with generally lower levels found in saliva. We were unable to observe transduction of SG cells by rAAV2Epo in mice previously infected with rAAV2LacZ (i.e. no elevations in hematocrit [Hct] and serum Epo levels were seen in the virus re-administration group). Conversely, we found significant elevations in Hct and serum Epo levels in mice previously administered saline.

**Conclusion** We conclude that after a single administration of rAAV2 to murine SGs there is no significant innate immune response. However, we observe a modest adaptive immune response that abrogates the efficacy of additional rAAV2 administration.

**Acknowledgement** MRK and PPT are supported by the Dutch Arthritis Foundation NR 02-1-302.

**References**

1. Baum BJ, Wellner RB, Zheng C: **Gene transfer to salivary glands.** *Int Rev Cytol* 2002, **213**:93-146.
2. Kok MR, Yamano S, Lodde BM, Wang J, Couwenhoven RI, Yakar S, Voutetakis A, Leroith D, Schmidt M, Afione S, Pillemer SR, Tsutsui MT, Tak PP, Chiorini JA, Baum BJ: **Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjogren's syndrome.** *Hum Gene Ther* 2003, **14**:1605-1618.

**79**

**Switching of serotype can improve local AAV-mediated gene therapy in RA**

**J Adriaansen<sup>1</sup>, M Vervoordeldonk<sup>1</sup>, P Plence<sup>2</sup>, A Bakker<sup>3</sup>, E Gicquel<sup>4</sup>, C Jorgensen<sup>2</sup>, PP Tak<sup>1</sup>, F Apparilly<sup>2</sup>**

<sup>1</sup>Academic Medical Center, Amsterdam, The Netherlands; <sup>2</sup>INSERM U475, Montpellier, France; <sup>3</sup>Amsterdam Molecular Therapeutics, Amsterdam, The Netherlands; <sup>4</sup>Genethon, Evry, France

*Arthritis Res Ther* 2004 **6(Suppl 1)**:79 (DOI 10.1186/ar1121)

**Objective** Adeno-associated virus (AAV) is a very promising vector for gene therapy in RA. Although an increasing number of AAV serotypes have been identified, all studies so far have been performed with serotype 2. The aim of this study was to compare the transduction efficiency of five different AAV serotypes (AAV1–AAV5) encoding reporter genes, the murine secreted alkaline phosphatase (mSEAP) or the *E. coli*  $\beta$ -galactosidase (beta-Gal), in two different animal models of arthritis.

**Methods** AAV1–AAV5 containing the gene for beta-Gal were injected into the right ankle joints of rats with adjuvant arthritis (AA) on day 12 after adjuvant immunization. Joints were collected 2 weeks after injection. The number of viral genomic copies in the joint was determined by qPCR. For detection of LacZ transcription in joints and organs, RT-PCR was used. Beta-Gal expression was analyzed by direct *in situ* staining of frozen sections, quantified by digital image analysis. In mice with collagen-induced arthritis (CIA), AAV1, 2 and 5 constructs encoding the mSEAP gene were injected into the left knee joint 32 days following arthritis induction. Transgene expression was analyzed by chemiluminescence in sera and culture medium conditioned by the joint tissues at different time points.

**Results** The greatest number of viral genomic copies was detected using AAV5. This was confirmed by *in situ* beta-Gal staining. RT-PCR proved the presence of LacZ mRNA in injected joints, but not in any of the organs tested. In the CIA mice model AAV5 also had the best transduction efficiency. Transgene expression was detectable in sera

and patellae 1 week after joint injection, increased over time, and remained at plateau levels for at least 1 month.

**Conclusion** *In vivo* gene transfer with AAV5 is far more efficient than with other serotypes. Local AAV-mediated gene therapy in RA could be improved by using AAV5.

**80**

**Suppressor of cytokine signaling (SOCS)-3 gene transfer protects against collagen-induced arthritis**

**FAJ van de Loo, RL Smeets, LAB Joosten, WB van den Berg**

Department of Rheumatology, University Medical Center Nijmegen, Nijmegen, The Netherlands

*Arthritis Res Ther* 2004 **6(Suppl 1)**:80 (DOI 10.1186/ar1122)

**Background** Rheumatoid arthritis is characterized by an acute phase response of the liver. IL-6 is produced in the inflamed joint and high levels are found in the circulation. IL-6 is a potent inducer of acute-phase proteins (APP) in hepatocytes via its signal transducer gp130 by the activation of the signal transducer and activator of transcription (STAT)-3.

**Objective** The aim of the study was to determine the effect of adenoviral gene transfer of SOCS-3, the inhibitor of STAT3 activation, on collagen-induced arthritis (CIA).

**Methods** Livers were dissected, and activation of STATs was analyzed by Western blot and gene expression by RT-PCR. A replication incompetent adenovirus containing the gene of murine SOCS-3 was constructed. Mice received  $3 \times 10^8$  ffu of Ad5.CMV.mSOCS3 or control viruses intravenously before onset of arthritis. The effect of SOCS gene transfer on liver function was studied in zymosan-induced gonarthrosis (ZIA) and the therapeutic effect in CIA.

**Results** Induction of ZIA in the knee joints of mice caused a rapid (within 5 hours) activation of STAT3 but not STAT1 in the liver. The activation of STAT3 was IL-6 dependent, as shown using IL-6 gene knockout mice. Intravenous injection of Ad5.CMV.mSOCS3 24 hours before induction of ZIA prevented STAT3 activation and markedly reduced serum amyloid A (SAA)-1 gene expression in the liver. Control virus treatment did not inhibit STAT3 activation in the liver. Overexpression of SOCS-3 did not affect Erk activation, confirming selectivity for the STAT signaling pathway. Treatment of DBA1/j mice with Ad5.CMV.mSOCS3 virus after immunization ameliorated CIA, and reduced serum TNF- $\alpha$  levels accompanied this effect. SOCS-3 treatment had no effect on the circulating levels of total IgG, IgG<sub>2a</sub> and IgG<sub>1</sub> anti-collagen type II antibodies.

**Conclusion** Inhibition of STAT-mediated signaling via SOCS-3 adenoviral gene transfer in the liver markedly ameliorated CIA. This suggests that the IL-6 mediated liver response modulates the development of arthritis.

**81**

**IL-22 gene transfer in collagen-induced arthritis**

**F Apparilly<sup>1</sup>, J Dudler<sup>2</sup>, J-C Renaud<sup>3</sup>, P Plence<sup>1</sup>, L Dumoutier<sup>3</sup>, F Djouad<sup>1</sup>, D Noel<sup>1</sup>, AK So<sup>2</sup>, J Sany<sup>1,2,3,4</sup>, C Jorgensen<sup>1,2,3,4</sup>**

<sup>1</sup>Unité de Recherches d'Immunopathologie des Maladies Tumorales et Auto-immunes, INSERM U475, Montpellier, France; <sup>2</sup>Service de Rhumatologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; <sup>3</sup>Ludwig Institute for Cancer Research, Experimental Medicine Unit, Université Catholique de Louvain, UCL 74.59, Brussels, Belgium; <sup>4</sup>Service d'Immuno-rhumatologie, CHU Lapeyronie, Montpellier, France

*Arthritis Res Ther* 2004 **6(Suppl 1)**:81 (DOI 10.1186/ar1123)

**Background and Objective** Novel cytokines have been identified by structural homology to IL-10. Among them, IL-22 showed a 25% amino acid identity with IL-10 and shared a common receptor  $\beta$ -subunit. The expression profile suggested involvement in the immune response *in vivo*. The present work evaluates the role of IL-22 in arthritis, examining the effects of systemic murine IL-22 adenoviral-mediated overexpression (Ad-mIL-22) in the collagen-induced arthritis (CIA) DBA1 mouse model.

**Method** Human rheumatoid arthritis (RA) synovial fibroblast (SF) were infected *in vitro* with increasing doses of Ad-mIL-22 (0-25 MOI). Cytokine secretion was assessed in supernatant using a specific ELISA. Therapeutic efficiency of mIL-22 overexpression achieved by intravenous injection of Ad-mIL22 ( $5 \times 10^9$  pfu) after the onset of CIA was assessed. A group injected with a nonrelevant adenoviral vector (Ad-LacZ) was used as a control. Radiological and histological analyses were performed at day 47. Systemic expression of mIL-22 was assessed by ELISA.

**Results** After confirmation that human RA-SF infected with increasing doses of Ad-mIL-22 expressed high levels of mIL-22 transgene, we demonstrated that the intravenous injection of Ad-mIL-22 in DBA1 mice significantly reduced clinical, radiological and histological scores. By the end of the experiment, the number of arthritic paws was decreased by 70% in the Ad-mIL-22-treated group as compared with controls ( $P < 0.0001$ ). Ad-mIL-22 resulted in the complete protection as compared with control vector up to 20 days after treatment. Maximal paw widths reached during the course of the disease were, respectively,  $1.95 \times 0.08$  versus  $2.76 \times 0.60$  mm ( $P = 0.024$ ). Both radiological and histological scores were found to correlate well with clinical observations. Systemic levels of mIL-22 reached  $14.2 \pm 9.5$  ng/ml 4 days after gene transfer, then decreased to  $2.4 \pm 0.9$  ng/ml by day 8 and remained stable until day 21.

**Conclusion** Our data support that IL-22 may have antiarthritic properties. The molecular mechanisms responsible for this observation are under investigation.

## 82

### Nonviral gene therapy by electrotransfer of hTNF- $\alpha$ soluble receptor variants: application to the treatment of collagen arthritis

C Bloquel<sup>1</sup>, P Bigey<sup>2</sup>, D Scherman<sup>2</sup>, MC Boissier<sup>1</sup>, N Bessis<sup>1</sup>

<sup>1</sup>UPRES EA-3408 and Rheumatology Department, University Paris 13 and Avicenne Hospital (AP-HP), Bobigny, France; <sup>2</sup>U266 INSERM FRE 2463 CNRS, Faculté de Pharmacie, Paris, France

*Arthritis Res Ther* 2004 **6**(Suppl 1):82 (DOI 10.1186/ar1124)

**Objectives** Electrotransfer (ET) was used to administer transgenes encoding three hTNF- $\alpha$  soluble receptor-I variants. Electrotransfer parameters and therapeutic effect in collagen-induced arthritis (CIA) in mice were studied.

**Methods** Plasmids pCOR(hTNFR1s)1, pCORhTNFR1s/mlgG1, pCOR(hTNFR1s)2, encoding a monomeric, a chimeric or a dimeric form of hTNFR1, respectively, were used. Electrotransfer was performed by plasmids injection and electric pulses in muscle. hTNFR1s concentrations were determined by ELISA. PCR was performed on genomic DNA from various mouse organs to detect the plasmid. CIA was induced by immunization of DBA/1 mice with collagen II in adjuvant.

**Results** ET of the three plasmids (1–15  $\mu$ g) allowed hTNFR1 production in sera and muscle after 10 days. This expression was dependent on the dose of plasmid. Local expression in the muscle lasted for at least 6 months. Systemic expression in the serum was detectable right from 1  $\mu$ g for the hTNFR1s/mlgG1 form. It lasted for at least 6 months for the hTNFR1s/mlgG1 form, whereas expression was shorter for the two other forms (3 weeks). No plasmid DNA was found in the organs distant from the injected muscle (liver, spleen, kidney, gonads, heart, lung brain and distant muscle). ET of 50  $\mu$ g pCOR/sTNFR1/IgG1 plasmid at the onset of clinical disease induced a clear-cut decrease in clinical signs of arthritis. The dimeric form was also efficient ( $P = 0.0378$ ) although the effect was weaker than with the fusion protein. The monomeric form had no effect on arthritides.

**Conclusion** Intramuscular ET of plasmids encoding the three forms of hTNFR1s leads to a long-term secretion of hTNFR1s *in vivo*. CIA is efficiently inhibited when ET of plasmids encoding either the chimera or the dimeric hTNFR1s was performed at the onset of the disease.

## 83

### Application of regulatable vectors in gene therapy of experimental arthritis

DJ Gould, Y Chernajovsky

Bone and Joint Research Unit, Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London, UK

*Arthritis Res Ther* 2004 **6**(Suppl 1):83 (DOI 10.1186/ar1125)


**Background** Gene therapy studies in experimental models of arthritis have demonstrated effective treatment with a variety of immunosuppressive and proapoptotic genes using *in vivo* and *ex vivo* strategies. Regardless of which approaches are developed for clinical application of gene therapy, we believe that it is imperative that expression of a therapeutic gene is regulated so that levels of expression are controlled and can be downregulated in the event of adverse effects.

**Objective** We previously constructed an autoregulatory self-contained plasmid vector pGTRTL in which gene expression is induced with doxycycline (Dox). Expression kinetics of luciferase from this vector have been characterized *in vitro*. In this investigation we examined the dynamics of luciferase expression from pGTRTL delivered *in vivo* to DBA/1 mice. Therapeutic effect of a small dimeric TNFR2 molecule (dTNFR) expressed constitutively from the vector pcdTNFR and regulated from the vector pGTRTT was compared in DBA/1 mice with established collagen-induced arthritis (CIA).

**Methods** Plasmid DNA was administered to naïve or arthritic mice by intramuscular injection combined with electroporation. Gene expression from regulated vectors was induced with Dox administered in drinking water. The degree of arthritis was scored every 2–3 days, and at the end of the experiment serum immunoglobulin levels and cytokine release from lymph node cells was measured.

**Results** The results show efficient regulation of luciferase expression from pGTRTL *in vivo*. Expression of dTNFR from constitutive or regulated expression vectors in mice with established CIA was therapeutic (Fig. 1), but was dependent upon the level of disease activity when treatment was initiated.

**Figure 1**



Progression of CIA in mice treated with dTNFR expressed constitutively from pcdTNFR (a) and induced from pGTRTT (b).

**Conclusion** Improved pharmacologically regulated vectors could be developed for clinical application. There is also scope to utilize disease-responsive vectors that contain DNA binding motifs that respond to transcription factors upregulated in arthritic joints.

**Acknowledgement** Funded by the Arthritis Research Campaign UK.

## Novel therapies

84

**Long-term immune reconstitution in patients treated with autologous stem cell transplantation for refractory autoimmune diseases****T Alexander<sup>1</sup>, G Massenkeil<sup>2</sup>, GR Burmester<sup>1</sup>, A Radbruch<sup>3</sup>, R Arnold<sup>2</sup>, F Hiepe<sup>1</sup>, A Thiel<sup>2</sup>**<sup>1</sup>Department of Hematology and Oncology, Charité; <sup>2</sup>German Arthritis Research Centre; <sup>3</sup>Department of Rheumatology and Clinical Immunology, Charité, Germany*Arthritis Res Ther* 2004 **6**(Suppl 1):84 (DOI 10.1186/ar1126)**Objectives** We performed here a detailed analysis of the newly developing immune systems in patients treated with immune ablation and subsequent autologous stem cell transplantation (ASCT) for severe autoimmune diseases.**Methods** Peripheral blood lymphocytes were analyzed using flow cytometry, including assessment of TCR-V $\beta$  repertoire of Th cells. Thymic activity was determined by measuring T-cell receptor excision circles (TRECs) in distinct peripheral blood Th cell subsets by quantitative RT-PCR analysis.**Results** Twelve patients, with median follow up of 40 months, were included in the trial thus far: polychondritis ( $n=1$ ), systemic lupus erythematosus (SLE;  $n=6$ ), systemic sclerosis (SSc;  $n=3$ ), panniculitis ( $n=1$ ) and MS ( $n=1$ ). Clinical remission has been achieved in seven patients: polychondritis ( $n=1$ ), SLE ( $n=5$ ) and MS ( $n=1$ ). We observed progress of disease in patients with SSc and panniculitis. In one patient SLE reactivated 17 months after ASCT. In all responding patients no autoreactive Th cells could be detected, and serological remission has been achieved. Lymphocyte compartments reconstituted functionally in all patients as shown by the reappearance and persistence of naive T cells with high levels of TRECs and restored diversity of the T cell receptor repertoire. Reconstituting B cells were found to be of naive phenotype. Although we observed similar kinetics of lymphocyte repopulation in the nonresponding SSc patients, autoantibody titres (ANA, SCL70) were not affected by conditioning.**Conclusion** The newly generated immune system in responding patients is tolerant to rheumatic autoantigens and able to react to pathogens. We conclude that in successfully treated patients autoreactive memory and effector lymphocytes have been eliminated efficiently. Our data demonstrate that ASCT can induce stable long-term clinical and serological remission in patients with severe, standard-therapy refractory autoimmune diseases.


85

**Zoledronic acid protects from local and systemic bone loss in TNF-mediated arthritis****J Zwerina<sup>1</sup>, P Herrak<sup>1</sup>, B Goertz<sup>1</sup>, S Hayer<sup>1</sup>, K Redlich<sup>1</sup>, E Reiter<sup>1</sup>, J Gasser<sup>2</sup>, H Bergmeister<sup>3</sup>, G Kollias<sup>4</sup>, JS Smolen<sup>1</sup>, G Schett<sup>1</sup>**<sup>1</sup>Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria; <sup>2</sup>Novartis, Basel, Switzerland; <sup>3</sup>Institute of Biological Sciences, University of Vienna, Austria; <sup>4</sup>Alexander Fleming Biomedical Sciences Research Center, Vari, Greece*Arthritis Res Ther* 2004 **6**(Suppl 1):85 (DOI 10.1186/ar1127)**Objective** Increased osteoclast activity is a key factor for bone loss in rheumatoid arthritis (RA). This suggests that osteoclast-targeted therapies could effectively prevent skeletal damage in RA. Zoledronic acid (ZA) is one of the most potent agents to block osteoclast function. We therefore investigated whether ZA can inhibit inflammatory bone loss.**Methods** Human TNF transgenic (hTNFtg) mice, which develop severe destructive arthritis as well as osteoporosis, were treated with phosphate-buffered saline, single or repeated doses of ZA, calcitonin or anti-TNF at the onset of arthritis.**Results** Synovial inflammation was not affected by ZA. In contrast, bone erosion was retarded by single administration ( $-60\%$ ) and almostcompletely blocked by repeated administration ( $-95\%$ ) of ZA. Cartilage damage was partly inhibited ( $-40\%$ ), and synovial osteoclast counts were significantly reduced upon ZA treatment. Systemic bone mass dramatically increased in hTNFtg mice upon ZA administration, which was due to an increase of trabecular number and connectivity. In addition, bone resorption parameters were significantly lowered after ZA. Calcitonin had no effect on synovial inflammation, bone erosions, cartilage damage, or systemic bone mass. Anti-TNF entirely blocked synovial inflammation, bone erosion, synovial osteoclast formation and cartilage damage, but had only minor effects on systemic bone mass.**Conclusion** ZA appears an effective tool with which to protect bone from arthritic damage. In addition to anti-inflammatory drug therapy, modern bisphosphonates are promising candidates to maintain joint integrity and to reverse systemic bone loss in arthritis.

86

**Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment****R Westhovens<sup>1</sup>, P van Riel<sup>2</sup>, J Sibilia<sup>3</sup>, G Vratsanos<sup>4</sup>, I Nuamah<sup>4</sup>, JC Becker<sup>4</sup>**<sup>1</sup>Department of Rheumatology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium; <sup>2</sup>Department of Rheumatology, University Medical Center Nijmegen, Nijmegen, The Netherlands; <sup>3</sup>Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France; <sup>4</sup>Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA*Arthritis Res Ther* 2004 **6**(Suppl 1):86 (DOI 10.1186/ar1128)**Background** Effective amelioration of symptoms and induction of remission are goals in treatment of rheumatoid arthritis (RA).**Objectives** Data from a Phase II study for RA treatment with abatacept, a selective co-stimulation modulator, showing induction of remission (DAS-28 score  $<2.6$ ) are presented.**Methods** Patients on background methotrexate (MTX) who met ACR criteria for active RA with  $\geq 10$  swollen joints (66 joint count) and  $\geq 12$  tender joints (68 joint count) were randomly assigned to receive 10 mg/kg abatacept ( $n=115$ ) or placebo ( $n=119$ ) treatment for 1 year. DAS-28 scores and serum cytokine levels were assessed at days 1, 90, 180 and 360.**Results** Abatacept-treated patients showed a progressive increase in remission rates up to 1 year (analysis not prespecified) compared with placebo ( $P<0.001$ ; Fig. 1). Abatacept treatment also decreased serum levels of proinflammatory cytokines. In particular, levels of serum IL-6, a multifunctional cytokine that contributes both to acute phase response and to pathological B cell activation, were reduced by 67% at 180 days and by 73% at 360 days ( $P<0.05$ ). Placebo-treated patients showed no reduction. Abatacept was generally safe and well tolerated.

Figure 1



Abatacept increases the remission rate in RA patients refractory to MTX treatment. Means and 95% confidence intervals are shown.

**Conclusions** In patients with active RA who were receiving MTX, abatacept treatment significantly improved RA symptoms and produced a progressive increase in remission rates for over one-third of the treatment group, which was sustained at 1 year. In addition, abatacept decreased serum IL-6 levels. The results of this phase II study suggest that abatacept may have potential as therapy for patients with active RA despite MTX treatment.

**Acknowledgement** Study supported by Bristol-Myers Squibb.

## 87

### Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis

G Jansen<sup>1</sup>, R Oerlemans<sup>1</sup>, J van der Heijden<sup>1</sup>, WF Lems<sup>1</sup>, GL Scheffer<sup>2</sup>, RJ Scheper<sup>2</sup>, BAC Dijkmans<sup>1</sup>

<sup>1</sup>Department of Rheumatology, VU Medical Center, Amsterdam, The Netherlands; <sup>2</sup>Department of Pathology, VU Medical Center, Amsterdam, The Netherlands

*Arthritis Res Ther* 2004 **6**(Suppl 1):87 (DOI 10.1186/ar1129)

**Background** Upregulation of drug efflux pumps belonging to the family of ATP-binding cassette (ABC) transporters can confer loss of efficacy/resistance to multiple cytostatic drugs, a phenotype referred to as multidrug resistance (MDR). In clinical rheumatology practice, loss of efficacy of disease-modifying antirheumatic drugs (DMARDs) is observed following long-term treatment of rheumatoid arthritis (RA) patients. Whether loss of efficacy/resistance to DMARDs and cytostatic drugs share common molecular mechanisms is not known.

**Objective** The aim of this study was to delineate the potential role of MDR proteins in the loss of efficacy/resistance to DMARDs.

**Methods** *In vitro* model systems of human T cells and monocytic/macrophage cell lines were used to provoke resistance to the DMARD sulfasalazine (SSZ). SSZ-resistant cell lines, as well as macrophages from RA patients and healthy controls, were characterized for expression of MDR proteins.

**Results** Development of SSZ resistance in T cells and monocytic/macrophage cell lines was accompanied by a marked induction of the MDR protein ABCG2. Of note, SSZ-resistant cells displayed cross-resistance to methotrexate, but showed enhanced sensitivity to glucocorticoids (prednisone, dexamethasone). Immunohistochemical studies revealed increased expression of MDR proteins in macrophages from RA patients as compared with controls.

**Conclusion** These results suggest that MDR proteins, originally identified for their role in resistance to cytostatic drugs, could also be involved in DMARD resistance [1]. Beyond this, resistance to one particular DMARD can influence the sensitivity to other antirheumatic drugs.

**Acknowledgement** Supported by a grant (NRF 03-40I) from the Dutch Arthritis Association.

#### Reference

- Jansen G, Scheper RJ, Dijkmans BAC: **Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview.** *Scand J Rheumatol* 2003, **32**:in press.

## 88

### Impact of cellular therapies on autoreactive, long-lived plasma cells in autoimmune diseases (AID)

F Hiepe, R Manz, B Hoyer, A Thiel, T Alexander, G-R Burmester, G Massenkeil, R Arnold, A Radbruch

Charité University Hospital, and German Rheumatology Research Center, Berlin, Germany

*Arthritis Res Ther* 2004 **6**(Suppl 1):88 (DOI 10.1186/ar1130)

According to the current view, chronic AID are driven by the continuous activation of autoreactive B and T lymphocytes. However, despite the use of potent immunosuppressive drugs, these patients exhibit continued autoantibody production, which often contributes to progression

of the AID. To elucidate this problem, we analyzed the lifespan of cells secreting (auto)antibodies (Ab) in NZB/W mice. The number of Ab-secreting cells in splenic tissue increased from ages 1 to 5 months and became stable thereafter. Later, some 60% of the total Ab-secreting cell compartment consisted of dividing, short-lived plasmablasts (SLPB), whereas 40% consisted of nondividing, long-lived plasma cells (LLPC) with a half-life of more than 6 months. Although high-dose cyclophosphamide eliminated SLPB, LLPC survived and continued to produce (auto)Ab. This explains why treatment with cyclophosphamide (CY) does not result in the complete disappearance of antinuclear Ab. Pathogenic anti-dsDNA Ab usually vanish after this treatment, indicating that they are generated by proliferating SLPB. However, anti-dsDNA Ab can be resistant to CY in refractory SLE.

We treated six refractory SLE patients by autologous stem cell transplantation (ASCT) using CY and ATG as the mobilization regimen. ASCT was performed using purified CD34<sup>+</sup> stem cells. The patients have now been followed for 5–70 months. Initially, persistent anti-dsDNA disappeared within 3 months. Likewise, the ANA became negative except in one case. That patient continued to exhibit anti-Ro/SSA and anti-La/SSB, the titers of which decreased continuously and were undetectable after 17 months. This emphasizes the enormous lifespan of residual plasma cells after interrupting the supply of new cells from the dividing SLPB compartment.

In conclusion, the aforementioned ASCT protocol can lead to depletion of autoreactive LLPC. Since ASCT may not always be able to eliminate autoreactive LLPC, these cells are potential targets for autoimmune disease therapy.

## 89

### Addition of cyclosporine-A (Neoral®) in patients on anti-TNF and methotrexate therapy improves disease activity: an open-label, pilot study

P Sidiropoulos, P Siakka, M Mamoulaki, H Kouroumalis, H Kritikos, DT Boumpas

University of Crete, Heraklion, Greece

*Arthritis Res Ther* 2004 **6**(Suppl 1):89 (DOI 10.1186/ar1131)

**Background** Combining anticytokine treatment with a T-cell directed agent such as cyclosporine A (CsA) may rescue patients refractory to anti-TNF treatment. We performed an open label, pilot study to explore the safety and initial efficacy of a triple therapeutic regimen with anti-TNF, methotrexate (MTX) and CsA.

**Methods** Nineteen patients with treatment-resistant RA have been enrolled. Patients had considerable residual disease activity (mean DAS-28 6.8, 4.5–8.6), although they had received a mean of 16.8 infliximab infusions (range 6–23) and adequate dose adjustments of both infliximab (mean dose 4.2 mg/kg q6w) and MTX (mean dose 17.1 mg/week). CsA (mean dose of 2.7 mg/kg per day, range 1.6–3.2) was added to a stable therapeutic regimen. Clinical evaluation of disease activity and treatment side effects was performed before each infliximab infusion. Disease activity was evaluated according to DAS-28 index. Primary end-points were treatment safety profile and efficacy according to the EULAR response criteria. Peripheral blood monocytes (PBMCs) were collected from five patients at baseline and after 12 weeks, and were assessed for markers of activation (CD25 expression) by FACS analysis, with or without activation with PHA.

**Results** Sixteen patients completed 12 weeks of triple therapy. Three patients discontinued treatment because of adverse events: one for pneumonia, one for lymph node tuberculosis and one for gastrointestinal discomfort. Seven out of 16 patients (43.7%) achieved moderate response according to the EULAR response criteria. Statistically significant improvements in the mean values of tender joints (from 18.5 to 13.1;  $P=0.04$ ), swollen joints (from 18.6 to 12.1;  $P=0.004$ ), HAQ (from 1.2 to 0.7;  $P=0.01$ ), patients' global assessment (from 67 to 46;  $P=0.02$ ) and pain (from 64 to 42;  $P=0.04$ ) were identified in those 16 patients. CD25 expression both in unstimulated and in PHA stimulated PBMCs was reduced ( $37 \pm 34\%$  to  $15 \pm 10\%$ , and  $50 \pm 15\%$  to  $29 \pm 20\%$ , respectively).

**Conclusion** In this preliminary report, addition of CsA to a maximum combination therapy of anti-TNF and MTX was well tolerated. Infectious complications that occurred underscore the importance of close follow up of patients on combined immunosuppressive therapy. Longer follow up is required to investigate further the safety and initial efficacy of this regimen.

90

### Effects of anti-TNF therapy on endothelial function and intima-media thickness of common carotid artery in patients with rheumatoid arthritis

P Siakka<sup>1</sup>, A Kalikaki<sup>2</sup>, K Pagonidis<sup>3</sup>, P Sidiropoulos<sup>1</sup>, H Kritikos<sup>1</sup>, E Ganotakis<sup>2</sup>, D Tsetis<sup>3</sup>, DT Boumpas<sup>1</sup>

<sup>1</sup>Department of Rheumatology, University of Crete, Heraklion, Greece; <sup>2</sup>Department of Internal Medicine, University of Crete, Heraklion, Greece; <sup>3</sup>Department of Radiology, University of Crete, Heraklion, Greece

*Arthritis Res Ther* 2004 **6**(Suppl 1):90 (DOI 10.1186/ar1132)

**Background** TNF has been reported to decrease endothelium dependent vasodilatation and promote atherosclerosis. However, recent data suggest that TNF may also increase the production of nitric oxide (NOx) by blood vessels, suggesting a more complex effect of this cytokine. To explore this further, we examined the effect of anti-TNF agents on flow-mediated vasodilatation (FMD) as well as common carotid intima-media thickness (IMT) in RA patients.

**Methods** Two groups of rheumatoid arthritis (RA) patients were studied. In the first, six patients were treated for the first time with a triple DMARD combination (methotrexate, hydroxychloroquine and sulphasalazine) because of highly active disease (mean DAS-28 6.1). In the second group 12 patients with active disease (mean DAS-28 6.1), despite treatment with DMARDs (methotrexate or leflunomide with or without corticosteroids), were started on anti-TNF agents. Patients were assessed by high-resolution ultrasound for CC-IMT, FMD (percentage of increase in flow-mediated vasodilatation) of the brachial artery at baseline and after 12 weeks of treatment. RA disease activity was assessed using the DAS-28, ESR and CRP at the same time points. Based on the DAS-28, patients were classified as good, moderate or nonresponders. Plasma NOx levels will be measured by the modified Griess reaction.

**Results** Two patients in the first group (33%) and six in the second (50%) had a moderate EULAR response. In both groups moderate improvements in the mean ESR (from 60 ± 39 to 50 ± 27 and from 38 ± 19 to 34 ± 24, respectively) and CRP (from 1.3 ± 1.3 to 1 ± 0.3 and from 3.7 ± 3.7 to 2.3 ± 2.8, respectively) were found, which were not significant. Although FMD tended to improve in patients in the first group (from 9.2 ± 6.4% to 12.3 ± 4.9%;  $P=0.11$ ) between baseline and week 12, patients in the second group remained stable (from 9.5 ± 7.2 to 7.9 ± 5.4;  $P=0.49$ ). CC-IMT increased by 6.4% (0.76 mm to 0.80 mm) in the first group whereas it decreased by 3% (from 0.65 mm to 0.63 mm) in patients on anti-TNF agents. The effect on CC-IMT was even greater (from 0.61 mm to 0.53 mm;  $P=0.08$ ) in patients on anti-TNF agents and absence of other risk factors for atherosclerosis (e.g. obesity, hypertension or hyperlipidemia). Measurement of plasma NOx levels is in progress.

**Conclusions** In this pilot study in patients with highly active RA, moderate improvement in disease activity after anti-TNF therapy did not uniformly improve FMD. This may reflect suboptimal control of disease activity or decrease in TNF-dependent NO production.

#### References

- Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Bechir M, Spieker LE, Neidhart M, Michel BA, Gay RE, Luscher TF, Gay S, Ruschitzka F: **Anti-tumor necrosis factor treatment improves endothelial function in patients with rheumatoid arthritis.** *Circulation* 2002, **106**:2184-2187.
- Cambien B, Bergmeier W, Saffaripour S, Mitchell HA, Wagner DD: **Antithrombotic activity of TNF- $\alpha$ .** *J Clin Invest* 2003, **112**: 1589-1596.

91

### Epstein-Barr virus load follow up in rheumatoid arthritis patients treated with TNF- $\alpha$ inhibitors

N Balandraud<sup>1,2</sup>, JB Meynard<sup>3</sup>, I Auger<sup>1</sup>, H Sovran<sup>1</sup>, B Mugnier<sup>1,2</sup>, D Reviron<sup>1,4</sup>, J Roudier<sup>1,2</sup>, C Roudier<sup>1,2</sup>

<sup>1</sup>INSERM EMI 9940, Faculté de Médecine, Marseille, France; <sup>2</sup>Rheumatology, la Conception, Marseille, France; <sup>3</sup>IMTSSA, Marseille, France; <sup>4</sup>Etablissement Français du Sang, Marseille, France

*Arthritis Res Ther* 2004 **6**(Suppl 1):91 (DOI 10.1186/ar1133)

**Background** In patients with rheumatoid arthritis (RA), inflammation, dysregulated Epstein-Barr virus (EBV) infection and immunosuppressive therapy may contribute to increased risk for developing lymphoma. We have shown that EBV load in peripheral blood mononuclear cells (PBLs) is 10-fold higher in RA patients (16 copies/500 ng DNA) than in normal controls (1.9 copies/500 ng DNA). EBV load in RA patients is similar to that in healthy transplant recipients and much lower than in symptomatic EBV-infected transplant recipients with lymphoproliferative disease (>500 copies/500 ng DNA).

**Objectives** We monitored EBV load in RA patients' PBLs to evaluate how it was influenced by methotrexate and infliximab, and to detect lymphoma development.

**Methods** A total of 221 patients fulfilling the 1987 ACR criteria for RA and 100 healthy controls were studied. Of these 221 patients, 88 were followed for 1-4 years: 19 received only methotrexate (eight were included in the study before introduction of methotrexate), eight received only infliximab, and 61 received both methotrexate and infliximab. A 214 base-pair fragment from the EBV genome first internal repeat (IR1) was amplified by quantitative real-time PCR to evaluate EBV DNA load.

**Results** EBV load decreased dramatically in most patients right after introduction of methotrexate and kept decreasing thereafter. In patients receiving infliximab and methotrexate, three patterns of EBV load evolution were observed: stable, decreasing and variable. Patients with only infliximab had either stable or decreasing EBV loads. Although an increase in EBV load was observed in a few patients, none of them reached the 500 copies/500 ng level and no patient developed lymphoma.

**Conclusions** Methotrexate and infliximab do not seem to increase EBV load in patients with RA.

**Acknowledgements** Supported by PHRC 2003 and SFR.

92

### Prediagnosis radiological progression in rheumatoid arthritis: a novel tool to study the effects of early DMARD therapy

MC Wick<sup>1</sup>, RJ Weiss<sup>2</sup>, L Klareskog<sup>1</sup>, RF van Vollenhoven<sup>1</sup>

<sup>1</sup>Rheumatology Unit, Department of Medicine, Karolinska Hospital, Stockholm, Sweden; <sup>2</sup>Department of Orthopaedic Surgery, Karolinska Hospital, Stockholm, Sweden

*Arthritis Res Ther* 2004 **6**(Suppl 1):92 (DOI 10.1186/ar1134)

**Objective** The aim of the study was to determine whether a new method, based on intrapatient comparisons between estimated rates of prediagnosis radiological progression and subsequent progression, can be used to assess the efficacy of commonly used disease-modifying antirheumatic drugs (DMARDs) in a longitudinal early rheumatoid arthritis (RA) inception cohort.

**Methods** We analyzed clinical data and radiographs from 149 newly diagnosed RA patients. Four groups were chosen: patients treated with methotrexate (MTX,  $n=56$ ), sulfasalazine (SSZ,  $n=55$ ) and auranofin (AUR,  $n=19$ ), and a control group of patients who had changed therapy twice during the first 2 years after diagnosis and whom we previously presented as a group of poor responders with persistent clinical activity (control,  $n=19$ ). Radiographs were quantified by an experienced reader using Larsen Erosion Score and the 'X-RayRheumaCoach' software. The rate of prediagnosis radiological progression per time was estimated by taking the first onset of RA symptoms as the starting date for radiographic damage.

**Results** The mean disease duration from onset of symptoms until diagnosis and DMARD institution was  $6.7 \pm 3.6$  months. The mean baseline Larsen Score was  $13.2 \pm 9.3$ , resulting in an estimated prediagnosis progression rate of  $23.6 \pm 16.7$  Larsen Score units/year. In the control group and in the patients receiving AUR, radiological progression after diagnosis was similar to the predicted progression based on the estimated prediagnosis progression rates. In patients for whom MTX or SSZ was the first-line therapy, a marked ( $P < 0.001$ ) reduction in radiographic progression in the first year after treatment initiation was seen compared with prediagnosis progression.

**Conclusions** Prediagnosis rates of radiological progression can be used quantitatively to obtain important information on the potential efficacy of DMARDs, and indicate that MTX and SSZ, but not AUR, significantly retard radiographic damage in the first year after diagnosis.

## 93

### The effect of infliximab on skin lesions in a patient with scleroderma (CREST)

L De Rycke, D Baeten, F Van den Bosch, H Mielants, F De Keyser, EM Veys

*Rheumatology, Ghent University Hospital, Belgium*

*Arthritis Res Ther* 2004 **6**(Suppl 1):93 (DOI 10.1186/ar1135)

**Background** Skin lesions refractory to treatment are a source of morbidity in patients with scleroderma (CREST) and may result in amputation. No established DMARD is available for this disorder.

**Objective** The aim was to report the effect of infliximab in combination with methotrexate (MTX) on refractory skin lesions in a 46-year-old woman with scleroderma (CREST).

**Case report** In 1991, the patient was diagnosed with scleroderma (CREST). Despite several treatments (initially D-penicillamine and colchicine, subsequently MTX, colchicine and misoprostol), she developed severe digital ulcerations, resulting in multiple amputations with difficult wound healing afterward. Since 1999, she was treated with MTX, colchicine and alprostadil. In August 2002 she developed necrosis at the fingertip of digit IV right. Despite hyperbaric oxygen treatment and pulse therapy with corticosteroids, the necrosis worsened. Therefore, infliximab (3 mg/kg iv at weeks 0, 2 and 6, and every 8 weeks thereafter) combined with MTX (10 mg/w im) was started. The patient also had ulcerations at digit II left and at the knees, and suffered from severe Raynaud's attacks. After the second infusion, the ulcerations started to heal. Although an amputation of distal phalanx of digit IV could not be avoided, infliximab was continued. The amputation wound healed quickly, the ulcerations became considerably smaller, and she developed no new skin lesions. The inflammatory parameters remained stable and her general condition improved; she gained weight (6 kg), had less pain in the fingers and fewer Raynaud's attacks, and her skin became more supple. Infliximab was stopped after eight infusions. Now, 4 months later, the previous ulcerations remain healed, no new digital lesions occurred and the inflammatory parameters are stable.

**Conclusion** We present a patient with scleroderma (CREST) and refractory skin lesions. Infliximab combined with MTX was well tolerated and effective in the healing of ulcerative lesions.

## 94

### Anti-TNF- $\alpha$ antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor (VEGF) levels in patients with rheumatoid arthritis: a pilot study

J Strunk, E Heinemann, U Lange

*Department of Rheumatology, Kerckhoff-Clinic/University of Giessen, Bad Nauheim, Germany*

*Arthritis Res Ther* 2004 **6**(Suppl 1):94 (DOI 10.1186/ar1136)

**Background** Pannus growth in rheumatoid arthritis (RA) is critically dependent upon accompanying neovascularization. Vascular endothelial

growth factor (VEGF) is a potent angiogenic promoter, which is thought to play a crucial role in synovial angiogenesis in rheumatoid arthritis (RA). Serum VEGF levels are elevated in RA patients, and therapy with the anti-TNF- $\alpha$  antibody infliximab reduces serum VEGF levels in these patients.

**Objective** The study was conducted to compare the early effect of oral glucocorticoids (GC) with anti-TNF- $\alpha$  therapy (infliximab) on serum VEGF levels in patients with RA.

**Methods** Five RA patients (5/8) who had no prior treatment with DMARDs or glucocorticoids (GC) were administered 20 mg/day prednisolone. Three patients who failed more than one disease-modifying antirheumatic drug (DMARD) therapy received infusion with infliximab (200 mg). VEGF serum levels were measured using ELISA before treatment and at day 10 or 13 during prednisolone therapy or 14 days after the first infliximab infusion.

**Results** Serum VEGF levels in therapy naïve RA patients (GC group) were higher than those in pretreated patients who received infliximab (median serum VEGF level: 1106 pg/ml versus 320 pg/ml;  $P = 0.09$ ). Treatment with infliximab as well as glucocorticoids significantly decreased serum VEGF levels after 10–14 days in RA patients (median serum VEGF level after treatment: GC group 559 pg/ml, infliximab group 92 pg/ml;  $P = 0.01$  versus without treatment or preinfusion).

**Conclusions** Treatment with oral glucocorticoids leads to an early and drastic reduction in serum VEGF levels in therapy naïve RA patients. TNF- $\alpha$  inhibition by infliximab could reduce low serum VEGF levels in pretreated RA patients independent of the initial serum VEGF concentration. This is the first report comparing the effect of both therapies on serum VEGF levels, indicating a possible therapeutic inhibition of angiogenesis in RA.

## 95

### Allogeneic bone marrow transplantation can suppress established and otherwise chronic collagen-induced arthritis after a nonmyeloablative conditioning regimen employing anti-CD40 ligand monoclonal antibody

R Flierman<sup>1</sup>, L Morgan<sup>2</sup>, L van Duivenvoorde<sup>1</sup>, RRP de Vries<sup>2</sup>, WE Fibbe<sup>3</sup>, TJW Huizinga<sup>1</sup>, REM Toes<sup>1</sup>, JM van Laar<sup>1</sup>

<sup>1</sup>*Department of Rheumatology, LUMC, Leiden, The Netherlands;*

<sup>2</sup>*Department of Immunohematology and Bloodbank, LUMC, Leiden, The Netherlands;*

<sup>3</sup>*Department of Hematology, LUMC, Leiden, The Netherlands*


*Arthritis Res Ther* 2004 **6**(Suppl 1):95 (DOI 10.1186/ar1137)

**Objective** Allogeneic bone marrow transplantation (BMT) may be more effective than autologous BMT as a treatment for patients with severe autoimmune diseases, such as rheumatoid arthritis (RA). However, the application of allogeneic BMT for treatment of RA is not yet feasible because of the high-dose immunosuppression that is used before and after BMT. Therefore, in this study collagen-induced arthritis (CIA) – the classic mouse model for RA – was used to compare the effects of allogeneic and syngeneic BMT after less toxic, nonlethal (i.e. nonmyeloablative) conditioning regimens on established disease in DBA/1 (H-2<sup>q</sup>) mice.

**Methods** We induced arthritis in normal DBA/1 (H-2<sup>q</sup>) mice by immunization with type II collagen (CII) in complete Freund's adjuvans (CFA). To allow engraftment, we made use of anti-CD40 ligand monoclonal antibody (one injection of 0.5 mg ip) and nonlethal total body irradiation (TBI) of 6.0 Gy before BMT with  $1.0 \times 10^7$  total BM cells from syngeneic DBA/1 (H-2<sup>q</sup>) mice or from fully MHC-mismatched allogeneic BALB/c (H-2<sup>d</sup>) mice. After treatment, mice were scored for clinical arthritis, and serum was taken to measure the amounts of CII-specific antibodies.

**Results** We were able to induce stable and long-term (>300 days) donor chimerism (>95%) after transplantation with fully MHC-mismatched total BM cells from allogeneic BALB/c (H-2<sup>d</sup>) mice using a nonmyeloablative conditioning regimen. After initial exacerbation of arthritis shortly after allogeneic BMT, due to a graft-versus-host (GvH)/host-versus-graft (HvG) response, mice receiving allogeneic BM cells showed a significant suppression of arthritis and CII-specific anti-

Figure



Allogeneic BMT can suppress both clinical disease and pathogenic antibodies. (a) Clinical disease over time. (b) Anti-type II collagen antibodies are decreased after treatment.

bodies. Syngeneic BMT was also effective in suppressing clinical disease, although no effects on CII-specific antibodies could be observed.

**Conclusion** These data indicate that nonmyeloablative conditioning using low-dose TBI and anti-CD40 ligand monoclonal antibody followed by MHC mismatched allogeneic BMT results in donor chimerism, disappearance of pathogenic autoantibodies and improvement in disease activity.

## Miscellaneous

### 96

#### Cross-reaction between the major epitope of Ro60 protein (pep216-232) and a homologous peptide of Coxsackievirus 3C protease

EA Stathopoulou, JG Routsias, HA Stea, HM Moutsopoulos, AG Tzioufas

Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece

Arthritis Res Ther 2004 6(Suppl 1):96 (DOI 10.1186/ar1138)

**Background** Coxsackievirus RNA has recently been detected in biopsy specimens of minor salivary glands from patients with Sjögren's syndrome (SS). A peptide of 3C protease of Coxsackievirus (pepCoxs) has 87% homology with a major linear B-cell epitope of Ro60 protein spanning the sequence 216–232aa.

**Objective** To investigate a possible cross-reaction between Coxsackievirus 3C protease and Ro60 autoantigen.

**Methods** PepCoxs MVTSTITEKLLKLVKI and pep216-232 of Ro60 KALSVETEKLLKYLEAV were prepared. Sera from 27 patients with SS and 28 patients with systemic lupus erythematosus (SLE) were tested against the two homologous peptides. Twenty-eight samples were a-Ro (+), and 26 samples were a-Ro/a-La (+). Sera from 27 healthy individuals were used as normal controls. Antibodies against Ro60 peptide were purified and tested for antipeptide reactivity.

**Results** Of SLE sera 25%, and 33.3% of SS sera reacted against pep216-232, whereas 28% of SLE sera and 37% of SS sera reacted against pepCoxs. The reactivity of normal sera against pep216-232 and pepCoxs was 17.4% and 3.7%, respectively. Pep216-232 was recognized by 17% of the a-Ro (+) sera and by 42% of the a-Ro/La (+) sera, whereas pepCoxs was recognized by 28.5% and 38% of the a-Ro (+) and a-Ro/La (+) sera, respectively. Both peptides reacted more prominently with a-Ro/La (+) sera from SS patients. Purified a-Ro60 antibodies reacted with both peptides and inhibition experiments revealed the specificity of this reaction.

**Conclusion** These results revealed a possible cross-reaction between the major linear B-cell epitope of Ro60 protein (216–232aa) and the homologous peptide of Coxsackievirus 3C-protease in SS patients. This cross-reaction might potentially play a role on autoantibody formation and pathogenesis of SS.

### 97

#### Aberrant expression of the co-chaperone HDJ2 in rheumatoid arthritis

A Zgaga-Griesz, S Haak, K Retzlaff, C Schick, R Rzepka, I Melchers

Clinical Research Unit for Rheumatology, University Medical Center, Freiburg, Germany

Arthritis Res Ther 2004 6(Suppl 1):97 (DOI 10.1186/ar1139)

**Background** HDJ2 is among approximately 98 human DnaJ homologues listed in protein databases. DnaJ homologues cooperate with HSP70 chaperones, which regulate protein conformation under stress as well as normal physiological conditions. Functions of the HSP70 chaperone machinery include destruction and repair of misfolded proteins. We previously observed that several DnaJ homologs are differentially expressed in synovial tissue of patients with rheumatoid arthritis (RA).

**Objective** HDJ2 is one of the few DnaJ homologues that can be detected specifically as protein and mRNA. We therefore wished to evaluate its expression on both levels in material derived from RA patients or healthy donors (HD).

**Methods** Synovial tissue (ST) from RA patients and appropriate controls was stained with a specific monoclonal antibody (immunohistochemistry). The expression of HDJ2 was characterized in peripheral blood (PB) mononuclear cells (MNC) from HD; PBMNC from RA patients; and MNC from synovial fluid (SFMNC) and ST from RA patients. PB and SF leukocytes isolated by density gradient centrifugation were separated in monocytes (MC), remaining mononuclear cells (nonMC) and granulocytes. Cell populations were analyzed for HDJ2 expression by FACS and RT-PCR.

**Results** HDJ2 mRNA was expressed in PBMNC of HD. Separation of PBMNC in MC and nonMC showed HDJ2 mRNA in both populations. HDJ2 protein was detected intracellularly in PBMNC of HD by FACS analysis, with stronger signals in MC than in nonMC. PBMNC derived from HD and RA patients did not show any surface expression of HDJ2. PB and SF leukocytes from RA patients varied in their HDJ2 mRNA expression between presence and absence. HDJ2 protein was overexpressed in RA ST and detected on the cell surface of RA SFMNC.

**Conclusions** HDJ2 mRNA and protein expression are regulated differentially. More patients must be analyzed to describe possible correlations between expression patterns and other parameters and to understand the function of synovial HDJ2 expression.

**Acknowledgement** Supported by DFG grant Me 604/6.

### 98

#### Effects of anti-rheumatic treatments on expression of microsomal prostaglandin E synthase-1 in rheumatoid arthritis synovium

M Korotkova<sup>1</sup>, M Westman<sup>1</sup>, E af Klint<sup>1</sup>, A-K Ulfgren<sup>1</sup>, L Klareskog<sup>1</sup>, P-J Jakobsson<sup>2</sup>

<sup>1</sup>Rheumatology Unit, Department of Medicine, Karolinska Hospital, Stockholm, Sweden; <sup>2</sup>Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

Arthritis Res Ther 2004 6(Suppl 1):98 (DOI 10.1186/ar1140)

**Background** mPGES-1 catalyzes the formation of PGE2 from COX-derived PGH2. mPGES-1 is induced by proinflammatory cytokines and linked to conditions with high PGE2 biosynthesis. Recent studies in animals suggest that mPGES-1 upregulation is involved in the pathogenesis of inflammatory arthritis, and thus has important clinical relevance for a better understanding and treatment of rheumatoid arthritis (RA).



**Objective** Our aim was to study the effects of different antirheumatic therapies on expression of mPGES-1 in RA synovial tissue.

**Methods** Synovial biopsies were taken by arthroscopy in patients with RA before and after TNF-blocking therapy with either etanercept (eight patients) or infliximab (10 patients), and in patients with chronic inflammatory arthritis before and after intra-articular injection of steroids (16 patients). Immunohistological analysis was performed using antibody against mPGES-1 and COX-2. Double immunofluorescence (DIF) was performed with antibodies to CD3, CD20, CD68, CD163 and prolyne-4-hydroxylase.

**Results** mPGES-1 staining was detected in synovial lining cells, in sublining scattered cells in all patients, and in endothelial cells in few patients. DIF showed that mPGES-1 is produced in synovial macrophages and fibroblasts, whereas in lymphocytes mPGES-1 expression was not observed. TNF-blocking therapy has heterogeneous effects on the expression of mPGES-1, as well as COX-2 in synovial tissues. Intra-articular steroid treatment significantly reduced both mPGES-1 and COX-2 expression in synovial tissues ( $P < 0.05$ ); however, the downregulation of mPGES-1 appears to be more prominent than that of COX-2.

**Conclusion** The results demonstrate that corticosteroids but not TNF blockade downregulate mPGES-1. These data might be of importance for interpretation of effects of various therapies and provide support to the use of combination of TNF-blockade, corticosteroids, and nonsteroidal anti-inflammatory drugs.

99

### Salivary gland epithelial cells (SGEC) express a novel alternate transcript of the B7.2 costimulatory molecule that lacks the CD28/CTLA4-binding IgV-like domain

**EK Kapsogeorgou, HM Moutsopoulos, MN Manoussakis**

*Department of Pathophysiology, National University of Athens, Greece*  
*Arthritis Res Ther 2004 6(Suppl 1):99 (DOI 10.1186/ar1141)*

**Background** Epithelial cells appear to have a central role in the pathogenesis of Sjögren's syndrome (SS), by acting as antigen-presenting cells. SGEC lines established from minor SG biopsies of SS patients express MHC and B7 costimulatory molecules. We previously showed that B7.2 molecules expressed by SGEC display distinctive binding properties denoted by the functional interaction with CD28 receptor and reduced binding to the negative immune regulator CTLA4.

**Objective and Methods** To delineate the role of RNA modifications in the SGEC-B7.2 protein binding properties, we applied a RT-PCR protocol that amplifies the entire coding region of the B7.2 mRNA. The amplified PCR products were sequenced and characterized.

**Results** SGEC were found to express three distinct alternate transcripts of the B7.2 molecule. These included the two previously described transcripts (encoding the full-length and the soluble form, respectively), as well as a third novel form (designated as B7.2C). B7.2C is characterized by exon 4 deletion, which encodes the IgV-like binding domain of the B7.2 protein to the CD28 and CTLA4 receptors. The conservation of the signaling peptide and the transmembrane region in the B7.2C transcript suggests the membranous expression of the encoded protein. The cell surface expression of the B7.2C protein was verified in CHO cell lines transfected with this transcript. B7.2C mRNA analysis of peripheral blood cell subpopulations (monocytes, T and B cells) revealed exclusive expression by monocytes.

**Conclusion** The role of B7.2C transcript remains to be determined. The clustering of B7.2 molecules and the development of a network has been considered necessary for their effective interaction with CD28/CTLA4 receptors. Thus, the co-expression of the full length B7.2 with the truncated B7.2C protein (that lacks the CD28/CTLA4-binding sites) may lead to negative regulation of T cell activation by interference of B7.2C in the formation of B7.2 clusters.

100

### Statins have no effect on collagen-induced arthritis in mice

**G Palmer<sup>1</sup>, V Chobaz<sup>2</sup>, D Talabot<sup>1</sup>, S Taylor<sup>3</sup>, A So<sup>2</sup>, C Gabay<sup>1</sup>, N Busso<sup>2</sup>**

*<sup>1</sup>Division of Rheumatology, University Hospital, and Department of Pathology, University of Geneva, School of Medicine, Geneva, Switzerland; <sup>2</sup>Division of Rheumatology, University Hospital, Lausanne, Switzerland; <sup>3</sup>Division of Clinical Pathology, University Hospital, Geneva, Switzerland*

*Arthritis Res Ther 2004 6(Suppl 1):100 (DOI 10.1186/ar1142)*

**Background** HMG-Co A reductase inhibitors (statins) are widely used lipid-lowering agents. It has recently been shown that, in addition to their well known effect on cholesterol levels, statins display anti-inflammatory activities both *in vitro* and *in vivo*. In this context, *in vivo* prophylactic and therapeutic effects of simvastatin were recently described in mouse collagen-induced arthritis, a well-described experimental model for human rheumatoid arthritis (RA).

**Objective and Methods** The aim of this study was to investigate further the *in vivo* effects of three different statins – atorvastatin, rosuvastatin and simvastatin – using the same experimental model. Different doses and routes of administration were used for the various statins in an attempt to elicit antiarthritic activity in preventive and curative treatment protocols.

**Results** Atorvastatin and rosuvastatin had no *in vivo* efficacy, as indicated by clinical, histological (synovial hyperplasia, exudate and cartilage damage), immunological (anti-type II collagen IgG production and T lymphocyte proliferation) and biochemical (IL-6, serum amyloid A and glucocorticoid production) parameters of inflammation and autoimmunity. The previously described antiarthritic effects of intraperitoneal simvastatin administration were reproduced in our experiments, but could be accounted for by very severe side effects of the treatment leading to increased glucocorticoid levels.

**Conclusions** This work shows that statins do not have any effect in a murine model of arthritis; this is an unexpected observation, given the previously described therapeutic effect of statins in immune-mediated inflammatory diseases. It is still unclear whether statins might have a benefit in rheumatic diseases.

101

### Serum MRP8/MRP14 as a biomarker for inflammation in autoimmune arthritis

**L De Rycke<sup>1</sup>, D Baeten<sup>1</sup>, D Foell<sup>2</sup>, E Kruihof<sup>1</sup>, EM Veys<sup>1</sup>, J Roth<sup>2</sup>, F De Keyser<sup>1</sup>**

*<sup>1</sup>Rheumatology, Gent University Hospital, Belgium; <sup>2</sup>Pediatrics, University of Münster, Germany*

*Arthritis Res Ther 2004 6(Suppl 1):101 (DOI 10.1186/ar1143)*

**Background** Myeloid related protein (MRP)8 and MRP14 are released by early monocytes upon contact with activated endothelium and correlate with inflammation in rheumatoid arthritis (RA) and juvenile arthritis.

**Objective** The aim of the study was to investigate serum MRP8/MRP14 as biomarker for inflammation in chronic arthritis.

**Methods** The study included 40 RA patients with active joint involvement (SJC = 14, CRP = 2.4 mg/dl, ESR = 28 mm/hour); 30 SpA patients with peripheral synovitis (SJC = 2, CRP = 2.2 mg/dl, ESR = 21 mm/hour); 10 AS patients with exclusive axial involvement (SJC = 0, CRP = 3.1 mg/dl, ESR = 19 mm/hour); and 20 healthy controls (HC). In 20 RA, 10 peripheral SpA and 10 axial AS patients, sera were also obtained after 6 weeks of infliximab therapy. Serum MRP8/MRP14 was measured by ELISA.

**Results** MRP8/MRP14 was increased in RA (1075 ng/ml;  $P < 0.001$ ), peripheral SpA (815 ng/ml;  $P < 0.001$ ) and axial AS (710 ng/ml;  $P < 0.001$ ), as compared with HC (280 ng/ml). In patients with peripheral synovitis, MRP8/MRP14 correlated with CRP (RA,  $r = 0.77$ ,  $P < 0.001$ ; peripheral SpA,  $r = 0.69$ ,  $P < 0.001$ ) and ESR (RA,  $r = 0.70$ ,  $P < 0.001$ ; peripheral SpA,  $r = 0.62$ ,  $P = 0.001$ ). MRP8/MRP14 decreased after infliximab in RA ( $P < 0.001$ ), peripheral SpA

( $P=0.009$ ) and axial AS ( $P=0.012$ ). Of 9/40 RA, 6/30 peripheral SpA and 1/10 axial AS patients with CRP < 1 mg/dl, only one peripheral SpA patient had increased MRP8/MRP14 (> mean MRP8/MRP14 in HC + 2SD). Of 17/40 RA, 12/30 peripheral SpA and 6 axial AS patients with ESR < 20 mm/hour, 3/17 RA, 6/12 peripheral SpA and 3/6 axial AS patients had raised MRP8/MRP14. Finally, we assessed the sensitivity to change after infliximab. In RA and peripheral SpA, changes in MRP8/MRP14 were not different from changes in CRP and ESR, whereas in axial AS changes in MRP8/MRP14 were less pronounced than changes in ESR ( $P=0.005$ ).

**Conclusion** Raised MRP8/MRP14 levels, correlations with CRP and ESR, and decrease after infliximab confirm that serum MRP8/MRP14 reflect inflammation. Further research is warranted to assess the added value of MRP8/MRP14 as compared with CRP and ESR.

## 102

### Three-dimensional power Doppler sonographic visualization of synovial vasculature: an 'in vivo' model to study angiogenesis in rheumatoid arthritis

J Strunk, K Strube, P Klingenberg, U Lange

Department of Rheumatology, Kerckhoff-Clinic/University of Giessen, Bad Nauheim, Germany

Arthritis Res Ther 2004 6(Suppl 1):102 (DOI 10.1186/ar1144)

**Background** Joint damage in rheumatoid arthritis (RA) is caused by a tumor-like proliferation of synovial cells, which is accompanied by an increase in vasculature (angiogenesis) to support the metabolic requirements. Technological improvements such as three-dimensional (3D) power Doppler sonography have made possible the assessment of a whole blood vessel tree in a region of interest (ROI).

**Objective** Because 3D power Doppler sonography plays an important role in obstetrics and oncology for assessing the vascular system, we used it to visualize intra-articular synovial new blood vessel formation in painful and swollen joints of patients with RA.

**Methods** Inflamed wrist, knee or finger joints in 21 patients with active RA were investigated by ultrasound. Vascularity near and inside the joint capsule was visualized by power Doppler mode. The online 3D power Doppler function, provided by the ATL/HDI 5000 vascular software, was used to generate a 3D image of the periarticular and intra-articular blood vessels.

**Results** In 21 patients with RA who showed power Doppler signals in 2D mode, the 3D function revealed a blood vessel tree branching out from periarticular small blood vessels into the joint capsule. Until now it was possible to obtain good 3D imaging of synovial vasculature in the wrist (15 patients), knee (three patients), and finger joints (MCP II and PIP III) (three patients).

**Conclusion** This is the first report on 3D power Doppler imaging of synovial angiogenesis. In comparison with 2D power Doppler, 3D mode reveals more and very small blood vessels in connection with the whole blood vessel tree, and provides a new opportunity to study the architecture and morphological structure of synovial vasculature in various joint disorders and under different conditions. Thus 3D power Doppler sonography may be used as an 'in vivo' model to study the mechanisms between inflammation and angiogenesis in rheumatoid joint damage.

## 103

### A new approach to study angiogenesis in rheumatoid arthritis by power Doppler sonography and serum vascular endothelial growth factor level measurement

J Strunk, E Heinemann, U Lange

Department of Rheumatology, Kerckhoff-Clinic/University of Giessen, Bad Nauheim, Germany

Arthritis Res Ther 2004 6(Suppl 1):103 (DOI 10.1186/ar1145)

**Background** Joint destruction in rheumatoid arthritis (RA) is caused by hypervascularized pannus which invades cartilage and bone. Angio-

genesis is recognized as a key event in the formation and maintenance of the pannus, which is regulated by a delicate balance of angiogenesis inducers, including vascular endothelial growth factor (VEGF), and different angiostatic agents. Technological improvements such as high-resolution ultrasound and power Doppler mode make the discrimination between periarticular and intra-articular blood flow possible.

**Objective** We used power Doppler sonography to visualize intra-articular new blood vessel formation as a result of angiogenesis to evaluate a possible correlation with serum VEGF levels.

**Methods** Vascularity near and inside the wrist of 23 RA patients and 12 healthy controls was visualized by power Doppler sonography. Microvascular doppler flow was localized to either inside or outside the joint capsule, and estimated according to a grading from 1 to 4. Serum levels of VEGF were measured using a standard quantitative sandwich ELISA.

**Results** Power Doppler mode identified increased synovial microvascular blood flow inside the joint capsule in 20 RA patients (87%), in comparison with in none of the healthy controls ( $P<0.0001$ ). Although the median serum VEGF level in RA patients (853 pg/ml) was higher than in healthy controls (638 pg/ml), qualitative Doppler sonographic estimation of the intensity of intra-articular synovial blood flow did not correlate with the actual serum VEGF level of the same patient.

**Conclusion** Power Doppler sonography is a reliable imaging modality to detect increased intra-articular synovial microvascular blood flow as a result of vasodilatation and new blood vessel formation (angiogenesis) in acute arthritis of RA patients. A correlation with elevated serum VEGF levels indicates this method as a helpful tool to study the role of blood vessels in the rheumatoid inflammatory process.

## 104

### The role of a defective clearance in the pathogenesis of systemic lupus erythematosus

S Franz, US Gaipi, U Appelt, P Heyder, RE Voll, JR Kalden, M Herrmann

Institute for Clinical Immunology and Rheumatology, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany

Arthritis Res Ther 2004 6(Suppl 1):104 (DOI 10.1186/ar1146)

Impaired clearance of apoptotic cell material has been implicated in the pathogenesis of systemic lupus erythematosus (SLE). We analyzed the phagocytotic potency of macrophages differentiated from CD34-positive stem cells derived from the peripheral blood from SLE patients and normal healthy donors (NHD), respectively. Furthermore, we examined the uptake of beads and dying cells by granulocytes of SLE patients and NHD.

We found that, in a subgroup of SLE patients, the proliferation and differentiation patterns of the stem cells were different in comparison with NHD. Furthermore, in SLE patients a significantly reduced number of macrophages differentiated out of the stem cells. Additionally, the uptake capacity of some macrophages of SLE patients was reduced in comparison with NHD. Regarding the phagocytosis of albumin beads, polyglobuline beads, apoptotic and necrotic cells as well as degraded chromatin, we found that macrophages and/or granulocytes of some SLE patients showed a strongly reduced uptake of the prey.

The defective clearance of dying cells in a subgroup of SLE patients seems to be an intrinsic defect because fewer macrophages differentiated out of stem cells, and some of the generated phagocytes also showed reduced uptake efficiency. Furthermore, the impaired clearance capacities of granulocytes from some SLE patients could play an important role in the development of autoimmunity.

## 105

### Clinical and serological study of 26 patients with anti-SL (Ki) autoantibodies

I Cavazzana, F Franceschini, C Vassalini, M Quinzanini, L Andreoli, R Cattaneo

Rheumatology Unit and Chair, Spedali Civili, Brescia, Italy

Arthritis Res Ther 2004 6(Suppl 1):105 (DOI 10.1186/ar1147)

**Background** Anti-SL (Ki) antibody was described in 1981 in patients affected by systemic lupus erythematosus (SLE) and sicca symptoms.

**Objective** To evaluate clinical and serological profile associated with anti-SL antibodies

**Methods** Twenty-six consecutive sera with anti-SI antibodies, selected from our laboratory routine ENA detection, were studied. All sera were analyzed by counter immunoelectrophoresis (CIE) for anti-ENA detection, using rabbit thymus and human spleen extract as substrates. ANA (by IFI assay on HEp-2 cells), anti-dsDNA (by Farr assay), anti-ENA, anticardiolipin (aCL) and anti-beta2GPI (by ELISA) were detected at disease onset and during follow up. The patients (20 female and 6 male) had a mean age at onset of 39.4 years (SD: 18.3 years) and a mean follow-up of 10.7 years (SD: 7.3 years).

**Results** All the patients were affected by autoimmune rheumatic diseases, but one with HCV-related cryoglobulinemia. SLE and primary Sjögren Syndrome (pSS) were the most frequent diagnoses achieved (in 13 and in 6 cases, respectively). Main clinical features were represented by skin involvement (65%), Raynaud's phenomenon (38%), xerophthalmia (54%), xerostomia (34%) and serositis (15%). Nevertheless, severe manifestations of disease were frequently observed: CNS involvement in three (11.5%) and renal disease in four cases (15%), while one patient with SLE had primary pulmonary hypertension. No cases of hemolytic anemia or severe cytopenia were recorded. ANA positivity was observed in all the sera. Anti-SL antibodies were detected as isolated antibody specificity in only five patients, while nine sera showed reactivity to anti-SL plus one antinuclear specificity (5 anti-dsDNA, 2 anti-Ro, one anti-RNP, one anti-Sm). Ten patients had anti-SL antibodies associated with two other ANA specificities: in five cases, anti-Ro and anti-dsDNA; in three, anti-Ro and anti-La; in two cases, anti-Sm and anti-dsDNA. Two patients showed multiple antinuclear specificities (anti-SL with anti-Ro, anti-La and anti-dsDNA in one case and anti-SL with anti-Ro, anti-Ku and anti-dsDNA in another). Anticardiolipin and anti-beta2GPI were detected in seven and four patients, respectively.

**Conclusion** Anti-SL antibodies identify a group of patients mainly affected by SLE and pSS, presenting in approximately one third of patients a severe disease with pulmonary, CNS or kidney involvement. Twenty-one patients with anti-SL (81%) have multiple antinuclear specificities.

## 106

### Drug induced differential gene expression in normal and RA synovial fibroblasts cell lines

M Yahyawi<sup>1</sup>, C Kaps<sup>2</sup>, C Lübke<sup>3</sup>, J Ringe<sup>1</sup>, T Rohrlach<sup>1</sup>, H Augst<sup>4</sup>, G-R Burmester<sup>1</sup>, T Häupl<sup>1</sup>, M Sittinger<sup>1</sup>

<sup>1</sup>Department of Rheumatology, Charite, Berlin, Germany; <sup>2</sup>Oligene GmbH, Berlin, Germany; <sup>3</sup>Vasotissue GmbH Berlin, Germany;

<sup>4</sup>Transtissue Technologies GmbH Berlin, Germany

*Arthritis Res Ther* 2004 **6**(Suppl 1):106 (DOI 10.1186/ar1148)

**Background** Rheumatoid arthritis (RA) synovial fibroblasts destructively invade into joint cartilage. We could demonstrate in our pannus model of interactive three-dimensional tissue culture that the immortalized synovial fibroblast cells from a normal donor (K4IM) and a patient with RA (HSE) provide an *in vitro* system for differential invasiveness into artificial cartilage.

**Objective** In this study, we investigated the molecular differences between these two cell lines and the influence of antirheumatic drugs on their expression profiles to gain insight into molecular pathways of joint destruction.

**Methods** HSE and K4IM cells were characterized by immunostaining with Fibroblast-AK, CD3, CD31, CD68 and MAC3 antibodies. MTS-assay provided information for kinetics and effective concentration of MTX, decortin and diclofenac. Gene expression profiles were generated with HG-U133A Affymetrix GeneChips, analyzed by RMA, dCHIP and MAS5.0 software, and validated by RT-PCR, ELISA.

**Results** Positive fibroblast-AK staining confirmed the fibroblastoid phenotype of both cell lines. RA fibroblasts reacted more sensitively towards MTX-mediated cytotoxicity compared to K4IM fibroblasts. Gene expression profiling revealed 1303 differentially expressed genes

between HSE and K4IM. MTX affected 191/1365, Decortin 84/172 and Diclofenac 19/0 genes in HSE/K4IM, respectively, as identified by all three softwares in common. Only 41, 26, or 8 genes were influenced in HSE towards the K4IM profile by MTX, Decortin or Diclofenac, respectively. Regulation of ten selected genes was confirmed by RT-PCR. Proteins in the supernatant from three of four genes revealed similar ratios by ELISA compared to transcription levels.

**Conclusion** Only a minority of differentially regulated genes in the RA fibroblasts was positively influenced by current therapeutics. Those genes, which were not influenced, may be new potential candidates for therapeutic intervention.